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“It is not the strongest of the species that survive,  
nor the most intelligent, 
but the ones most responsive to change” 
Charles Darwin 
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Summary 
 
Retinal pigment epithelium (RPE) and choroid are components of the mammalian 
retina, of which the central region is called macula. The most common form of retinal 
degeneration, age-related macular degeneration (AMD), involves primarily deregulation of 
growth factors secretion by the RPE. Very little is known about the molecular mechanisms 
that lead to impairment of RPE’s homeostatic intracellular processes, namely the secretion 
of vascular endothelial growth factor (VEGF). Rab GTPases’ family regulates membrane 
targeting and traffic, being essential in the transduction of signal pathways. Given Rab 
proteins’ role in intracellular trafficking, we propose to identify key regulatory Rab proteins 
involved in either the secretory or the recycling pathways of VEGF in RPE. Understanding 
how Rab proteins’ function disruption could lead to retinal and choroidal pathology would 
ultimately contribute to find new therapeutic agents. Here, we characterized two mouse RPE 
in vitro cell models, primary cells and B6-RPE07 cell line, and concluded that both display 
important epithelial features as the RPE presents in vivo. Considering unlimited cell number 
and results reproducibility, we chose B6-RPE07 cells to further study Rab proteins’ function. 
To scrutinize the consequences of Rab proteins’ absence or diminished levels, we have 
developed novel molecular tools to achieve silencing of these key proteins using miRNA 
technology. We further addressed the effect of Rab proteins’ absence on VEGF secretion by 
performing an extensive screening where different Rab proteins were silenced, both 
individually and in multiple combinations considering their cellular/compartment location. 
We conclude that Rab GTPases are important intervenients in VEGF secretion by RPE cells, 
confirming endocytic Rab proteins’ role in regulation of VEGF biology. We also propose a 
novel model for Rab proteins’ interaction in RPE. Our results suggest that Rab10 and Rab14 
might influence Rab8 in a negative feedback mechanism, important for controlling VEGF 
secretion. Our achievements’ unravel Rab proteins’ role in VEGF secretion by RPE cells and 
are the basis for future studies to better understand RPE molecular secretory machinery.  
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Resumo 
A retina é composta, entre outras estruturas, pelo epitélio pigmentar da retina (EPR) 
e pela coróide. A região central da retina denomina-se mácula, e é a zona mais afetada na 
degenerescência macular relacionada com a idade, a forma mais comum de 
degenerescência da retina. Nesta doença, a secreção de fatores de crescimento pelo EPR é 
afetada, nomeadamente a do fator de crescimento vascular endotelial (VEGF), e pouco se 
sabe ainda sobre os mecanismos moleculares conducentes a esta condição. A família de 
proteínas Rab GTPases está envolvida nas vias intracelulares de sinalização e tráfego 
membranares, essenciais na transdução de sinais extracelulares em respostas biológicas. A 
sua crucial importância nestes mecanismos levou-nos a considerar o seu potencial 
envolvimento nas vias de secreção do VEGF, e a questionar-nos se teriam algum papel 
regulador sobre as mesmas. O principal objetivo deste trabalho é identificar Rab GTPases 
importantes para as vias de secreção e endocitose do VEGF no EPR. Essa identificação 
ajudará a esclarecer a patogénese da degenerescência macular da retina, e poderá servir 
para uma procura mais direcionada de novos agentes terapêuticos. A caracterização de dois 
modelos in vitro do EPR, células primárias isoladas de murganho e a linha celular B6-RPE07, 
levou-nos a concluir que são ambos semelhantes. Contudo, a linha celular foi escolhida 
como protótipo do EPR por permitir o acesso a um número ilimitado de células. No decurso 
deste trabalho, desenvolvemos e caracterizámos uma biblioteca de ferramentas moleculares 
que nos permitiram reduzir os níveis proteicos das proteínas Rab GTPases, com base na 
tecnologia de ácido ribonucleico (ARN) de interferência. O papel das proteínas Rab GTPases 
na secreção do VEGF no EPR foi estudado com base no silenciamento de apenas uma 
proteína, ou combinando várias, segundo a sua localização e funções intracelulares 
descritas. Este trabalho permitiu-nos concluir que as proteínas Rab GTPases são importantes 
intervenientes no processo de secreção de VEGF pelo EPR, e confirmar dados anteriores que 
relatam o envolvimento de algumas Rab GTPases endocíticas no processo. Propomos ainda 
um novo modelo para a interação destas proteínas no EPR, e sugerimos que a Rab10 e a 
Rab14 atuam negativamente sobre a Rab8, controlando o seu funcionamento. Os nossos 
resultados evidenciam a importância das proteínas Rab GTPases na secreção do VEGF pelas 
células do EPR, e servem de base a futuros estudos que melhor procurem compreender este 
mecanismo e de que modo a sua alteração se relaciona com a degenerescência da retina.   
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NSF – N-ethyl-maleimide-sensitive fusion protein 
NT – Non-transduced  
NuRD – Nucleosome remodelling and histone deacetylase  
OD – Optical density 
OIR – Oxygen-induced retinopathy  
ONL – Outer nuclear layer 
OPL – Outer plexiform layer 
Otx2 – Orthodenticle homeobox 2  
PAK-2 – p21-activated protein kinase-2  
PAS – Preautophagosomal structure  
PBS – Phosphate buffer saline  
PCR – Polymerase chain reaction 
PDGF – Platelet-derived growth factor 
PDK – Phosphoinositide-dependent kinases  
PDR – Proliferative diabetic retinopathy  
PEDF – Pigment-derived growth factor 
PFA – Paraformaldehyde  
PGl – Prostanglandins  
PI3K – Phosphoinositide 3’ kinase  
PIP2 – Phosphatidylinositol (4,5)-biphosphate  
PIP3 – Phosphatidylinositol (3,4,5)-triphosphate 
PI3P – Phosphatidylinositol 3-phosphate  
piRNA – Piwi-interacting RNA  
  
PIs – Phosphoinositides  
PKB – Protein kinase B   
PKC – Protein kinase C  
PKD – Protein kinase D   
PLCγ – Phospholipase C gamma  
PlGF – Placenta growth factor  
PMA – Phorbol 12-myristate 13-acetate 
POS – Photoreceptor outer segments 
pri-miRNA – Primary miRNA  
pRPE – primary RPE  
PTP – Phosphotyrosine phosphatase 
PVDF – Polyvinylidene fluoride  
PVR – Proliferative vitreoretinopathy  
qRT-PCR – Quantitative reverse transcriptase PCR 
Rab – Ras-related proteins in brain  
RAB11FIP2 – RAB11 family-interacting protein 2  
RabF – Rab family   
RabGDI – GDP dissociation inhibitor  
RabSF – Rab subfamily regions  
RAGE – Receptor for AGE 
RDS – Retinal outer segment membrane protein 1  
RE – Recycling endosome  
REP – Rab escort protein  
RGGT – Rab geranylgeranyl transferase  
RGR – RPE-retinal G protein-coupled receptor 
RILP – Rab-interacting lysosomal protein  
RNA – Ribonucleic acid  
RNAi – RNA interference 
RN-tre – N-terminus of tre   
ROP – Retinopathy of prematurity  
ROS – Reactive oxygen species  
RPE – Retinal pigment epithelium  
RPE65 – Retinal pigment epitheliumspecific protein 65 KDa 
Rpm – Revolutions per minute   
RPMI-1640 – Roswell Park Memorial Institute-1640 
RQ – Relative quantification  
RT – Room temperature 
RTK – Receptor tyrosine kinases 
Sc – Single-chain  
SD – Standard deviation 
SDS-PAGE – Sodium dodecyl sulfate – polyacrylamide gel electrophoresis  
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Shh – Sonic hedgehog   
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siRNA – Small interfering RNA  
SLP – Synaptotagmin-like protein 
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VPF – Vascular permeability factor  
VPS45 – Vacuolar protein sorting-associated protein 45  
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XPO5 – Exportin 5  
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1.1. The retinal pigment epithelium in the vertebrate retina
The eye is the visual sense organ that 
first element of the visual system. The vertebrate retina has an orderly laminated structure 
and it is composed by the neural retina
choroid.  (Figure 1.1) (Sung & Chuang, 2010)
Figure 1.1 – Schematic diagram of the eye (
transverse histological section of human retina (
the eye cup (an enlarged diagram of the fovea is shown in the box)
formed by rod (R) and cone (C) 
cells (A), ganglion cells (G) and Müller cells (M)
the basal to apical portion) 
photoreceptor inner segments (IS), outer nuclear layer (ONL), outer plexiform layer (OPL), 
inner nuclear layer (INL), inner plexiform layer (IPL) and ganglion cell layer (GCL). 
Sung & Chuang, 2010. 
 
 The neural retina is composed of outer nuclear layer (ONL), inner nuclear layer (INL) 
and ganglion cell layer (GCL). The ONL comprises the photoreceptors, where outer segment 
(OS) region is localized. The bipolar cells, horizontal cells and amacrine cells are l
mainly in the INL, while GCL comprises the ganglion cells and Müller cells. The neural retina 
is responsible for receiving light and 
 
detect and transmits light into the retina, the 
, the retinal pigment epithelium (RPE)
.   
A) and the neural retina (
C). The retina lays in the posterior part of 
 (A), and its layers are 
photoreceptors, bipolar cells (B), horizontal cells (H), amacrine 
 (B). The laminated layers of the retina
are sclera, choroid, RPE, photoreceptor outer segments (OS),
compiles the relevant information to be transmitted 
3 
 and the 
B), and a 
 (C) (from 
 
Adapted from 
ocalized 
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through the optic nerve to the midbrain and thalamus
perception. Light passes through the inner cell layers and is captured by the visual pigment 
of OS of the photoreceptor cell, thereby initiating a signal transduction cascade that 
culminates in one’s visual experiment. In the fovea
resolution is higher (each cone photoreceptor is connected to only one bipolar cell and one 
ganglion cell) and shifting of retinal neurons to the side enables 
photoreceptors with minimal distortion
The RPE consists of a polarized monolayer of hexagonal cells containing pigment 
granules, the melanosomes. 
outer segments, and a hyaluronan
(IPM) fills the narrow subretinal space between both. The basolateral membrane of RPE lies 
in the Bruch’s membrane, which separates the RPE from fenestrated endothelium of the 
choriocapillaries (Figure 1.2) (Strauss, 2005)
 
 
 
 
 
 
 
 
Figure 1.2 – Schematic diagram 
close contact with photoreceptor outer segments
communicate with the fenestrated endothelium of the choriocapillaries. 
et al., 2009. 
, where it is processed for visual 
 the visual acuity is 
 (Sung & Chuang, 2010). 
Its apical surface with long microvilli faces 
-rich extracellular matrix; the interphotoreceptor matrix 
. 
of the outer retina. The apical microvilli of RPE cells are in 
 (POS), and RPE’s 
Adapted from 
privileged as cone 
light to reach 
the photoreceptor 
basal infoldings 
Sonoda 
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Since the photoreceptors lack a direct blood supply, the RPE regulates the traffic of 
both nutrients and metabolic waste needed to maintain visual function between the 
choriocapillaries and the photoreceptors. The management of the bi-direccional flow of 
molecules and ions includes supplying of nutrients to the photoreceptors, removal of debris 
from the photoreceptors metabolism, and maintaining the ionic gradients needed for 
occurrence of phototransduction. This delicate and specific transport system constitutes the 
blood-retinal barrier, an immune barrier responsible for the homeostasis of the ionic 
environment in and around the RPE (Bhutto & Lutty, 2012; Marmorstein, 2001; Strauss, 
2005).  
 The Bruch’s membrane is a 1-4 µm-thick pentalaminar structure of connective tissue 
combining the basement membranes of the RPE and the choriocapillaries. From the RPE 
towards the choriocapillaries, five layers can be histologically distinguished: the basement 
membrane of the RPE, the inner collagenous layer, the elastin layer, the outer collagenous 
layer and the basement membrane of the choriocapillaries. The main components of Bruch’s 
membrane are collagens type I, III, IV, V and VI, fibronectin, laminin, heparin sulphate 
proteoglycans (HSPG) and chondroitin/dermatan. Since the Bruch’s membrane is an acellular 
structure these substances are mainly produced by the adjacent RPE and choroid cells. As 
part of the blood-retinal barrier, the Bruch’s membrane primary functions include regulating 
the reciprocal molecular diffusion between RPE and the choroid, providing physical support 
for RPE cell adhesion and migration, and acting as a restriction barrier of retinal and 
choroidal cell migration (Bhutto & Lutty, 2012; Booij, Baas, Beisekeeva, Gorgels, & Bergen, 
2010).  
 The choroidal vasculature relies adjacent and posterior to the Bruch’s membrane. 
The network of feeding arterioles and draining venules that compose the choriocapillaries 
allows the provision of all metabolic needs from serum, with fenestrated cells characteristic 
of secretion and/or filtration-involved tissues playing an important role (Bhutto & Lutty, 
2012).  
 Besides its role in epithelial transport, RPE cells also participate in light absorption 
and the visual cycle of retinal, act as glial cells in spatial ion buffering, actively phagocytose 
shed photoreceptor outer segments (POS) and are able to secrete a variety of growth 
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factors, crucial for the structural integrity of the retina. For all that reasons, the RPE is 
essential for visual function, and a failure of any of these functions can lead to retinal 
degeneration culminating in blindness (Strauss, 2005).  
 
1.1.1. Embryonic origin of the mouse RPE 
The vertebrate eye is formed through coordinated interactions between the 
neuroepithelium, the surface ectoderm and the extraocular mesenchyme (Figure 1.3). The 
mouse eye development starts at around embryonic day (E) 7.5 from an “eye field” of cells 
that evaginate laterally in a distal-ventral direction. The neuroepithelium then gives rise to 
the optic stalk and the optic vesicle, visible by E9.5. The optic stalk will form the optic nerve, 
and the optic vesicle will bring about the neuroretina, RPE, ciliary body and iris. By the time 
the optic vesicle contacts the surface ectoderm its distal-most part becomes indented to 
form the optic cup, and an optic fissure is generated as indentation extends to the ventral 
part of the optic stalk. The optic cup is now a highly polarized structure (E12.5). The neural 
retina develops from the inner layer of the optic cup and the RPE is derived from the outer 
layer, and both are separated by a thin remnant of lumen, which will become the IPM. At 
this stage, both layers are equipotent, and a controlled balance between extracellular 
factors and intrinsic signals is required for precise cell differentiation. The fissure 
progressively seals and it is usually closed by E13.5. By then the cup’s outer wall is entirely 
composed of RPE (Bharti, Nguyen, Skuntz, Bertuzzi, & Arnheiter, 2006; Fuhrmann, 2010; 
Strauss, 2005).  
 
Figure 1.3 – Schematic diagram of 
vesicle is visible (a). The distal portion of the vesicle makes contact with the surface ectoderm 
and invaginates, giving rise to a bilayered optic cup. The optic stalk narrows to become the 
optic fissure (b). At day E14.5 
RPE (c). The ventral optic stalk epithelium c
the astrocytes of the optic nerve. 
 
 The RPE is specified at the early optic vesicle stage, long before pigmentation 
becomes obvious, being microphtalmia
that is specifically expressed by primordial RPE 
specification is the orthodenticle homeobox 2
transactivation of pigment genes with 
extrinsic regulators ensure that 
optic vesicle (Fuhrmann, 2010)
 The maturation and differentiation of RPE begin with the activation of
promoter, the onset of melanogenesis, resulting in dramatic morphological, structural and 
functional changes of the cells. 
expansion of apical microvilli and invagination of the basal mem
sorting mechanisms cooperate to distribute intracellular and membranar proteins 
accordingly. The formation of tight junctions follows, and terminates with cytoskeleton’s 
maturation. RPE cells are now ready to closely i
melanin content of pigment granules
recycling machinery also contributes for a more efficient light absorption 
Strauss, 2005).  
mouse eye development. By E9.5 the evaginated optic 
the inner layer becomes the neural retina and the outer l
omes to lie inside the stalk, where it will generate 
Adapted from Bharti et al., 2006. 
-associated transcription factor (
cells. Another key regulator in RPE 
 (Otx2) whose expression is required for 
Mitf cooperation. Several other intrinsic and 
Mitf is sufficiently expressed to promote RPE ce
. 
At first, the establishment of polarity involves the 
brane. Then, protein 
nteract with the photoreceptors. 
 is higher at this time, and the presence of retinoid 
7 
ayer, 
Mitf) the first gene 
ll fate in the 
 the tyrosinase 
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(Fuhrmann, 2010; 
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1.1.2. Functions of RPE in retinal homeostasis 
At a first glance, light absorption is the most obvious function of the RPE. Light enters 
the eye via the pupil and is concentrated in the retina by the lens, improving the optical 
system. For a long time, this was the only known function of RPE. Nowadays, however, it is 
well established that RPE has a multitude of functions and it plays a critical role in 
maintaining retinal homeostasis. 
Besides the photo-oxidative energy from light absorption, the RPE is also exposed to 
an oxygen-rich environment via its basal side due to the perfusion of the choriocapillaries.  
There is also low oxygen extraction by the retina. The process of photoreceptors’ renewal 
involves an extra load of reactive oxygen species (ROS) as POS are phagocytosed by RPE. As 
consequence, RPE cells have three lines of defense against this photo-oxidative damage. 
First, it contains melanosomes with various pigment granules that are specialized to detect 
different wavelengths, contributing for photon absorption. Photoreceptors also contain 
pigments as lutein and zeaxanthin, important for blue light absorption, but, still only 
approximately 60% of total light energy is absorbed. The second line of defense existing in 
the RPE is made of non-enzimatic and enzymatic antioxidants, as carotenoids and 
superoxide dismutase, respectively. Thirdly, RPE cells can physiologically repair damages in 
proteins, lipids and DNA (Strauss, 2005).  
The tight junction epithelium that forms the blood-retinal barrier controls a highly 
selective transport between the blood and the subretinal space. This blood-retinal barrier 
supplies nutrients to the photoreceptors, controls ion homeostasis in the subretinal space 
and eliminates water and metabolites from the retinal tissue. Glucose, retinal and fatty acids 
are supplied to the photoreceptors from the blood to fulfill their metabolic demands. On the 
opposite direction, RPE actively transports metabolic water from the subretinal space where 
it accumulates using a Cl
-
 and K
+
-driven transport. The apically localized Na
+
/K
+
 ATPase 
provides the energy needed for this transport by establishing an ionic gradient. Moreover, 
the main metabolic end product from photoreceptors, the lactic acid, is removed by an 
efficient regulation of intracellular pH by secondary active transport mechanisms (Strauss, 
2005).  
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The spatial buffering of ions in the subretinal space done by the RPE maintains 
photoreceptors’ excitability. Müller glia cells are responsible for the major buffering task, but 
the RPE is able to rapidly compensate for fast changes due to activity of voltage-dependent 
ion channels at the apical membrane that regulate K
+
 currents (Strauss, 2005).  
 The RPE and the photoreceptors constitute a functional unit which fundamental role 
is the visual cycle of retinal (Figure 1.4). Light absorption by rhodopsin is the first step of light 
transduction. Rhodopsin is composed by the opsin protein and the chromophore 11-cis-
retinal, which changes its conformation into all-trans-retinal when a photon comes. The 
active form of rhodopsin then activates transducin in the next step in the phototransduction 
pathway. Rhodopsin’s activity is terminated by phosphorylation and inactivated rhodopsin 
releases all-trans-retinal, becoming free to bind another photon. All-trans-retinal is then 
reduced to all-trans-retinol by a retinol dehydrogenase. As photoreceptors are unable to re-
isomerize all-trans-retinal to 11-cis-retinal, this step takes place in the RPE. So all-trans-
retinol is translocated to RPE bounded to interstitial retinal binding protein (IRBP) and 
transferred to a complex of several enzymes, including retinal pigment epithelium specific 
protein 65 KDa (RPE65) and cellular retinylaldehyde-binding protein (CRALBP), that will 
promote the 3-step re-isomerization. The all-cis-retinal is released back to IRBP and 
transported back to the photoreceptors where it reenters the visual cycle. There is also an 
alternative pathway for retinal regeneration involving RPE-retinal G protein-coupled 
receptor (RGR) activity. RGR uses an inverted light-induced rhodopsin isomerization reaction 
to convert all-trans-retinal into all-cis-retinal. Moreover, in order to fulfill eye’s adaption to 
different visual needs, as darkness and lightness, there are several retinal pools of retinal 
binding proteins which are connect to each other by the transportation and reaction steps of 
the visual cycle (Strauss, 2005).   
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Figure 1.4 – Visual cycle between RPE and photoreceptors
a photon absorption by rhodopsin and the stereochemical 
retinal into all-trans-retinal. All
back to the RPE, where it 
photoreceptors. Adapted from 
 
 The constant photo-oxidative damage inflicted to photoreceptors requires a daily 
renewal process of POS. The tips of the POS that contain the highest concentration of 
radicals and photo-damaged proteins and lipids are shed from the photoreceptors and 
phagocytosed by the RPE. Therefore, 
phagocytosis, a process also regulated by the circadian rhythm. The initial step of 
phagocytosis is the specific binding of POS to the apical membrane of RPE. Then a second 
messenger cascade is activated and the bound POS is ingested. Three receptors have been 
described to interplay in this process. 
tyrosinase kinase c-mer) and 
phagocytosis (Strauss, 2005). 
 The RPE not only communicate
longer distance by secreting a variety of factors and si
adenosine triphosphate (ATP), different types of tissue inhibitor
(TIMPs), fas-ligand (fas-L), fibroblast growth factors (FGF
growth factor β (TGF-β), insulin
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), lens 
epithelium-derived growth factor (LEDGF)
. Light transduction starts with 
configuration 
-trans-retinal is reduced into all-trans-retinol and transported 
is metabolized into 11-cis-retinal and redelivered back to the 
http://lpi.oregonstate.edu/infocenter/. 
the RPE is an important coordinator in shed POS 
Cluster of differentiation 36 (CD36
αVβ5 integrin ensure regulated and coordinated POS 
s with adjacent cells but is also able to interact over a 
gnaling molecules. It secretes 
s of matrix metalloprotease
-1, FGF-2 and FGF
-like growth factor-1 (IGF-1), ciliary neutrophic factor (CNTF), 
, pigment-derived growth factor (PEDF) and 
change of all-cis-
), MerTK (receptor 
s 
-5), transforming 
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several members of the interleukin family. In the healthy eye some of these factors are 
constantly released and contribute to the maintenance of structural integrity of neighboring 
tissues. PEDF, for example, is a neurotrophic factor apically secreted, where it prevents 
neuroretinal apoptosis. VEGF and TIMPs are secreted by the basolateral side where they 
stabilized the fenestrated structure of the choroidal endothelium. Overall, the secretory 
activity of RPE is finely regulated by the expression of a large number of ion channels and 
transporters involved in Ca
2+
-dependent regulatory mechanisms (Strauss, 2005).  
As in other secretory tissues, RPE expresses voltage-dependent Ca
2+
 channels of the 
neuroendocrine subtype, and intracellular free Ca
2+
 is responsible for almost every referred 
RPE function, once signals spread between cells within the epithelial monolayer via gap 
junction channels. The dark adaptation of the photoreceptor activity occurs by Ca
2+
-
dependent mechanisms inside POS. Also the transepithelial transport of ions and water 
involves intracellular Ca
2+
 modulation. Lastly, the inositol triphosphate (IP3) second 
messenger and intracellular Ca
2+
 systems cooperate in the initiation of the phagocytosis’ 
process (Wimmers, Karl, & Strauss, 2007).  
The immune privilege of the eye is the ultimate function involving RPE. The 
epithelium separates the inner space of the eye from the blood stream by a mechanical and 
tight barrier, and it is able to communicate with the immune system either for activating or 
silencing an immune reaction. RPE can secrete immune modulatory factors such as 
interleukin-8 (IL-8), complement factor H (CFH) and monocyte chemotactic protein-1 (MCP-
1). On the other hand, RPE interacts with the immune system by expressing receptors for 
different factors of the immune signaling cascade, like major histocompatibility complex 
(MHC) and toll-like receptors (TLR) (Strauss, 2005).  
 
1.1.3. RPE dysfunction in eye diseases 
The central region of the retina, the macula, in particular its central 2-3 square 
millimeters the fovea, is the only region that transmits visual information of high spatial 
resolution. If lost, it can deprive patients of the most value aspect of their vision. Macular 
degeneration is quite diverse in its manifestations and pathogenesis, with symptoms ranging 
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from subtle distortions in the perception of fine details to a complete loss of central vision 
resulting in legal blindness. Age-related forms of macular degeneration (AMD) are 
collectively the most common cause of severe vision loss in the developed world, affecting 
more than 60 million people worldwide, specially the elderly (Rattner & Nathans, 2006; 
Stone, 2007). AMD causes and consequences will be further analyzed in more detail.  
Other existing eye pathologies, mainly intraocular neovascular syndromes, involve 
RPE indirectly. Abnormal growth of blood vessels into the retina impairs RPE functions, as in 
retinopathy of prematurity (ROP) and diabetic retinopathy (DR). In the case of proliferative 
vitreoretinopathy (PVR), the most sight-threatening complication in patients recovering from 
surgery to repair retinal detachment, RPE proliferate and invade the vitreous in response to 
growth factors and cytokines’ secretion. Cell migration due to modification of retinal 
homeostasis generates traction and can open treated retinal breaks and/or create new ones, 
thereby compromising vision (Pennock, Rheaume, Mukai, & Kazlauskas, 2011). 
Clinical manifestations of ciliopathies include some forms of retinal degeneration. 
Photoreceptor cilia are crucial for retinal function, and mutations in ciliary proteins can 
cause a variety of phenotypes ranging from isolated retinal degeneration to more systemic 
and pleiotropic phenotypes. The concept of “retinal ciliopathies” brings to attention the 
importance of retina and specifically RPE for human well-being (Adams, Awadein, & Toma, 
2007). 
 
1.1.3.1. Age-related macular degeneration 
1.1.3.1.1. Etiology and pathology  
AMD is a multifactorial disease attributed to a complex interaction of genetic and 
environmental factors and it was first described in the medical literature in 1875 as 
“symmetrical central choroidoretinal disease occurring in senile persons”. It is characterized 
by degeneration involving the RPE, the photoreceptors and the Bruch’s membrane, as well 
as alterations in the choriocapillaries-choroid complex. The most established contributing 
factors for AMD are advanced age, cigarette smoking, diet and race. Additionally, cellular 
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pathogenic mechanisms involving the immune system, the extracellular matrix, oxidative 
stress and lipid metabolism also play a role in AMD’s etiology. However, many of these 
mechanisms are not exclusive of the others and there is no specific order in which they must 
operate or influence one another (X. Ding, Patel, & Chan, 2009; Stone, 2007).  
The most characteristic ophthalmoscopic features of AMD are subretinal, 
extracellular and dumbbell-shaped deposits called drusen (from the German word meaning 
cavities in rocks). These are formed by a complex aggregate of lipids, proteins and cellular 
elements that lie between the RPE and the Bruch’s membrane. Their morphological 
classification in hard and soft drusen helps to define the evolution of the disease. Hard 
drusen are yellow-white punctuated lesions, typically <63 µm in diameter, whereas soft 
drusen are more diffuse, paler and larger. If the presence of some small hard drusen in the 
peripheral retina is part of the aging process, the presence of large and many drusen in the 
macula indicates early AMD. With time, drusen often give rise to other common clinical 
features of AMD: geographic atrophy of the RPE (late AMD) and choroidal 
neovascularization (CNV), which is the growth of choroidal vessels into the macula (Bhutto & 
Lutty, 2012; X. Ding et al., 2009; Kinnunen, Petrovski, Moe, Berta, & Kaarniranta, 2012; 
Stone, 2007).  
Clinically, AMD is classified in early- or late-atrophic AMD (dry AMD) and exudative 
(wet AMD) (Figure 1.5). Most patients with AMD have the early form of the disease; they will 
not lose central vision, but have fluctuating vision, difficulty in reading and limited vision at 
night or under conditions of reduced illumination. The earliest pathological changes are the 
appearance of basal laminar and basal linear deposits. Basal laminar deposits are 
membranogranular material and foci of wide spaced collagen between the plasma 
membrane and the basal lamina of the RPE, while basal linear deposits are made of vesicular 
material located in the inner collagenous zone of Bruch’s membrane. Early AMD is then 
characterized by thickening and loss of normal Bruch’s membrane architecture, lipofucsin 
accumulation in the RPE and drusen formation beneath the RPE and the Bruch’s membrane. 
Lipofucsin are granular yellow-brown pigment granules composed of lipid-containing 
residues of lysosomal digestion. Also hypo- and hyperpigmented regions of RPE indicate 
underlying RPE abnormalities (Bhutto & Lutty, 2012; X. Ding et al., 2009; Kinnunen et al., 
2012; Stone, 2007).  
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Figure 1.5 – Color fundus photographs and schematic illustration of the RPE and 
Bruch’s membrane histopathology associated with various macular degenerative 
processes. Normal appearance of the eye fundus 
Lipofucsin accumulation in the RPE 
(CH) (C, thick arrows in B) are the first signs of an early AMD fundus 
characterized by a window defect 
photoreceptors (d). In neovascular AMD there is CNV 
growing into neuroretina (e)
photoreceptor inner segments. 
& Nathans, 2006; Vinci, Fossarello, & Peiretti, 2011
 
The late stage of atrophic AMD is known as geographic atrophy. In this case RPE cells 
are lost by apoptosis and roughly 
gradual degeneration of nearby photoreceptors resu
progressive visual impairment. CNV is a clinical hallmark of exudative AMD (also
neovascular AMD). New vessels can sprout from the choroid vessels, penetrate the Bruch’s 
membrane and grow into the subretinal space, leaking blood into the retina and causing 
distortion and even loss of vision.
outward into the subretinal space, sometimes anastomosing with the choroid
vessels (Bhutto & Lutty, 2012; X. Ding et al., 2009; Kinnunen et al., 2012; Stone, 2007)
(A), with layered normal retina 
(b) and drusen deposits between the RPE and the choroid 
(B). Atrophic AMD is 
(C, thin arrows) with loss of RPE and overlying 
(D, thin arrows), with choroidal vessels 
. BM, Bruch’s membrane. OS, photoreceptor outer segments. IS,
Adapted from Mettu, Wielgus, Ong, & Cousins, 2012; Rattner 
.   
oval areas of hypopigmentation are detectable. The 
lts in thinning of the retina and 
 Rarely, new vessels can develop from the ne
(a). 
 
 known as 
uroretina 
-derived 
.  
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1.1.3.1.2. Genetics  
A small number of monogenic diseases cause early-onset macular degeneration, and 
they were the starting point in the search for individual genes relevant to AMD. 
Unfortunately, AMD linkage analysis has generally pooled data from large number of small 
pedigrees due to the late onset of disease. As consequence these analysis have little 
statistical power. However, in recent years, with the improved DNA sequencing and mapping 
technologies, genetic studies were performed in an attempt to identify single nucleotide 
polymorphisms (SNP) that confer increased or decreased risk of AMD. The discovering of 
SNP associated with inflammation, oxidative stress, angiogenesis, among others, and their 
investigation has led to a deeper understanding of the pathological mechanisms underlying 
AMD (X. Ding et al., 2009; Rattner & Nathans, 2006; Stone, 2007). 
Vitelliform macular dystrophy (VMD) is an example of a disease causing macular 
degeneration. It is also known as Best macular dystrophy, an autossomal dominant disorder 
caused by missense mutations in VMD2 gene. This gene codes for bestrophin, an integral 
membrane protein located in basolateral membrane of RPE with an anion channel’s 
function. Best disease is most prominently characterized by accumulation of yellow and 
insoluble material within the subretinal and sub-RPE spaces of the macula. TIMP-3 is 
responsible for the matrix turnover, and point mutations affecting this gene cause impaired 
diffusion of small molecules between the choroid and the retina. Affected patients have 
Sorsby fundus dystrophy and display dramatic thickening of Bruch’s membrane and night 
blindness. In the case of Mallatia Leventinese, a single point mutation affects the fibulin 3 
gene (EFEMP1), involved in binding basement membranes of epithelia and blood vessels. 
This autossomal dominant disease has sub-RPE drusen as hallmarks. The retinal outer 
segment membrane protein 1 (RDS) gene encodes a transmembrane protein involved in 
maintaining the flattened shape of POS’ disks. Diverse phenotypes arise when variations in 
this gene are present, as impairment of phagocytosis accumulates lipofucsin granules within 
and beneath the RPE, including retinitis pigmentosa and pattern dystrophy. In dominant 
Stargardt-like macular dystrophy large yellow inclusions are present, as mutations in ELOVL 
fatty acid elongase 4 gene (ELOVL4) in photoreceptors affect the biosynthesis of very-long-
chain of fatty acids. Finally, ATP-binding cassette transporter (ABCA4) gene is responsible for 
the correct transportation of an intermediate of visual cycle across the photoreceptor disk 
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membrane by an ATP-binding cassette transporter. Failure in this step eventually leads to a 
slowing of the visual cycle, delayed dark adaptation and a slow and progressive 
accumulation of A2E (bis-retinal/ethanolamine adduct) in the RPE, an insoluble amphipathic 
substance that generates free radicals in the presence of oxygen and light. This phenotype is 
seen in the autossomal recessive Stargardt macular dystrophy and in retinitis pigmentosa 
(Rattner & Nathans, 2006; Stone, 2007).   
Recent genetic studies identified inflammation-associated SNP that modulate AMD 
risk and the genetic loci 1q26-32 came up showing tight association with AMD-related genes. 
CFH is now widely accepted as an AMD susceptibility gene. CFH is a negative regulator of the 
complement system in the RPE and the choroid, and its dysfunction may lead to excessive 
inflammation and tissue damage. Two additional complement regulatory genes, factor B (BF) 
and component 2 (C2) have been identified in the production of proinflammatory peptides. 
Among chemokines, IL8, IL-1β and IL6 polymorphisms are reported to be associated to AMD. 
Chemokine (C-X3-C motif) receptor 1 (CX3CR1) gene is the only example of a chemokine 
receptor so far where SNP confer an increased risk of AMD. On the other hand, diverse TLR 
have been implicated in AMD pathogenesis, but more studies are needed to clarify their 
exact role. Also the VEGF gene polymorphisms within the 5’-untranslated region (UTR) have 
been correlated with the occurrence of AMD  (X. Ding et al., 2009; Penn et al., 2008; Rattner 
& Nathans, 2006). 
Other susceptibility locus is 10q26, where age-related maculopathy susceptibility 2 
(LOC387715/ARMS2) and high temperature required factor A-1 (HtrA1) genes reside. ARMS2 
is reported to be expressed in the mitochondria of photoreceptors, an organelle that plays a 
central role in aging and in the pathogenesis of AMD when damaged. HtrA1 is a stress-
inducible member of a family of heat-shock serine proteases that, in case of chronic 
inflammation, enhances degradation of extracellular proteins, and binds to TGF-β, an 
angiogenic factor linked to CNV (X. Ding et al., 2009; Rattner & Nathans, 2006). 
Apolipoprotein E (ApoE) is a structural component of plasma chylomicrons and 
regulates the uptake of cholesterol required by cells, and its active biosynthesis supports the 
high rate of photoreceptors renewal in the macular region. ApoE gene polymorphisms may 
17 
 
result in the accumulation of lipoproteins between the RPE and the Bruch’s membrane, 
consistent with lipid deposits in drusen observed in AMD patients (X. Ding et al., 2009). 
The development of animal models that substantially reproduce the natural history 
of AMD has been of a great help in understanding the basic molecular mechanisms and in 
the searching for potential treatments. Although murine retina has no macula, murine 
retinal diseases can still provide valuable information. Moreover, the mouse is a genetically 
well-defined species, with a considerably shorter lifespan. There are some genetic-
engineered mouse AMD models that have been linked to a corresponding human retinal 
disease, regarding chemokines [chemokine (C-C motif) ligand 2 (Ccl2
-/-
), C-C chemokine 
receptor 2 (Ccr2
-/-
) and Cx3Cr1
-/-
], complement system (Cfh
-/-
), oxidative stress (Abcr
-/-
) and 
lipid metabolism [superoxide dismutase (Sod1)
-/-
 and ApoE2 and ApoE4 transgenic mice] (X. 
Ding et al., 2009; Rattner & Nathans, 2006).   
 
1.1.3.1.3. Molecular mechanisms of RPE damage 
With aging homeostatic intracellular processes are disturbed and RPE cells are no 
exception. Most of these mechanisms are also impaired in macular degeneration, being 
responsible for the features of this disease.  
Oxidative stress is the main process triggering detrimental effects on RPE. The 
phagocytic function of POS by these cells generates ROS, and high oxygen consumption and 
long periods of light exposure also contribute for their increment. With time, lipofucsin 
progressively accumulates in lysosomes and the cellular ability to degrade POS material and 
cytoplasmic proteins decreases. Lipofucsin contains vitamin A-derived fluorophores that 
inhibit mitochondrial respiration and promote protein misfolding. Furthermore, drusen 
deposits contain advanced glycation end-products (AGE), high levels of oxidized low-density 
lipoproteins (LDL) and oxysterols. The receptor for AGE (RAGE) is known to be highly 
accumulated in RPE cells and photoreceptors in advanced stages of AMD, and the fact that 
its activation induces expression and secretion of VEGF by RPE could explain its role in CNV. 
Basal laminar and basal linear deposits are also a consequence of incomplete degradation of 
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metabolic end products from photoreceptors and RPE (Bhutto & Lutty, 2012; Kinnunen et 
al., 2012). 
As it happens in other cell types, harmful misfolded protein aggregates in RPE can be 
either destroyed by heat-shock proteins (HSP), or tagged with a small polypeptide ubiquitin 
that directs the complex to the ubiquitin/proteasomal protein degradation pathway, or 
cleared by autophagy. During the aging process, cellular capacity of HSP response is 
impaired, as increased accumulation of Hsp90 and Hsp27 in drusen shows. If the HSP-linked 
protein folding fails, the proteins are tagged with ubiquitin and transferred for proteasomes 
for selective degradation. Here, aging can either reduce proteasomal activity or favor 
tagged-proteins production which will block or overwhelm the system. Lastly, autophagy can 
be activated for protein clearance, but there is evidence that this activity is weakened in 
AMD patients. Thus preservation of the autophagic activity is associated with better 
handling of protein damage and improved RPE cell function (Kinnunen et al., 2012). 
The natural environment of the eye is designed to downregulate immune response, a 
role played by the RPE. Usually the immune system can act by evoking phagocytosis and get 
disposed of the target structure, or it can trigger signaling pathways that induce the 
expression of inflammatory mediators. Cellular insults in aged RPE prompt danger signals 
and RPE-immune system interactions are established, in a two way system: RPE potentiates 
inflammation, which further worsens RPE degeneration. Both macrophages, choroidal 
dendritic cells and microglia proliferate and migrate to the injured areas, either helping 
repair the lesion, and secreting pro-inflammatory chemokines and neurotoxins (X. Ding et 
al., 2009; Kinnunen et al., 2012). 
 
1.1.3.1.4. Treatment strategies 
The AMD treatment modalities are usually divided in those which aim is to delay or 
prevent the onset of vision-impairing complications, and those aimed to arrest or reverse 
CNV. Until recently, the only approved treatment for any form of AMD was laser ablation of 
new choroid vessels, with minimal damage to surrounding retinal tissue, later facilitated by 
the photodynamic therapy. Photosensitizing agents are injected intravenously and 
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irradiation of abnormal blood vessels with a low-powered laser follows. This combination 
spares the outlying retina and it is associated with better visual outcome. However, it only 
targets the end-stage of the disease and do not alter its underlying progression (Rattner & 
Nathans, 2006; Stone, 2007). 
The fact that VEGF is crucial for the growth of new blood vessels has led to a variety 
of therapeutic strategies to inhibit VEGF and treat AMD. The first drug to be approved for 
this purpose was pegaptaninib, a nucleic acid aptamer that specifically inhibits VEGF. 
Nowadays, intravitreal injections of a VEGF-inhibiting monoclonal antibody (bevacizumab) or 
fragment (ranibizumab) are currently used in CNV treatment. There is a worldwide-spread 
search for molecules involved in VEGF biology in RPE that could be used as novel therapeutic 
agents (Rattner & Nathans, 2006; Stone, 2007). 
The prophylactic strategies rely on decreasing the complement system activation, as 
well as the number of all-trans-retinal molecules produced by POS, and in immune 
modulators that might be able to delay the disease (Rattner & Nathans, 2006).  
 
1.2. VEGF role in eye homeostasis 
The cardiovascular system is the first organ system to develop and reach a functional 
state in the embryo. VEGFs are crucial regulators in either vasculogenesis, the formation of 
the embryonic vascular system, and angiogenesis processes, the formation of new blood 
vessels from already established vasculature. Besides its physiological functions in wound 
healing and reproduction, angiogenesis is also implicated in the pathogenesis of variety of 
diseases. Tumors are the main example but others follow such as atherosclerosis, amyloid 
lateral sclerosis (ALS), psoriasis, rheumatoid arthritis, sepsis, diabetic retinopathy, 
retinopathy and AMD (Ferrara, 2004; Olsson, Dimberg, Kreuger, & Claesson-Welsh, 2006).  
Prior to VEGF identification as we know it nowadays, several groups reported the 
presence of angiogenic molecules and mitogens in tumors and retinal disorders during the 
20
th
 century. In 1983 tumor vascular permeability factor (VPF) was proposed to mediate the 
permeability of tumor blood vessels. In 1989 a diffusible endothelial cell-specific mitogen 
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was isolated and named as VEGF due its restricted target cell specificity. This finding led to 
the hypothesis that this molecule could play a role in the regulation of physiological and 
pathological growth of blood vessels, and keeps fueling worldwide research (Ferrara, 2004).   
 
1.2.1. VEGF gene isoforms and regulation 
The mammalian VEGF family is composed of 5 structurally related factors: VEGF-A 
(the prototype), VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF). All members 
are secreted, heparin-binding homodimeric glycoproteins of approximately 40 KDa. 
Additionally 2 structurally related proteins have been described in parapoxvirus (VEGF-E) 
and in snake venom (VEGF-F) (Olsson et al., 2006).    
The human VEGFA gene (also VEGF) contains 8 exons, separated by 7 introns, and is 
Iocalized in chromosome 6p21.3. The alternative splicing of the gene is the basis for its 
heterogenenity. After cleavage of the signal sequence, four isoforms are generated having 
121, 165, 189 and 206 amino acids, respectively (VEGF121, VEGF165, VEGF189 and VEGF206). 
Other less frequent isoforms have also been reported: VEGF145, VEGF162 and VEGF183. 
VEGF165 is the predominant isoform and lacks the residues encoded by exon 6. 
Unconventional spliced variants were denoted VEGF(xxx)b and reported to have an 
antiangiogenic effect. The corresponding murine gene has a similar organization, encoding 
only three isoforms, each one amino acid shorter than human VEGF (VEGF120, VEGF164 and 
VEGF188) (Ferrara, 1997, 2004).  
Native VEGF properties closely correspond to those of VEGF165. VEGF121 is an acid 
polypeptide freely diffusible that fails to bind heparin. In contrast, VEGF189 and VEGF206 are 
highly basic, bind heparin with greater affinity and are almost completely sequestered in the 
extracellular matrix (ECM). VEGF165 has intermediate properties: it is a weakly acidic peptide 
that is secreted although a significant fraction remains bound to the cell surface and to the 
ECM, and it does not bind heparin. The VEGF ECM-bound isoforms can be proteolytically 
processed by a heparinase or by plasmin cleavage at the carboxyl-terminus, generating 
different bioactive forms of VEGF. However, this loss of heparin-binding domain results in a 
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significant loss of the mitogenic activity of VEGF, suggesting that VEGF165 has optimal 
features of bioavailability (Ferrara, 1997, 2004).  
The regulation of VEGF gene expression is modulated by diverse factors, with oxygen 
tension playing a key role. VEGF mRNA is rapidly and reversibly induced by exposure to low 
partial pressure of oxygen during tissue growth, both in health (wound healing and 
embryonic development) and in disease (cancer). The hypoxia-inducible factor-1 (HIF-1) is a 
heterodimeric transcription factor composed of 2 subunits: HIF-1β, the constitutively 
produced subunit, and HIF-1α, the inducible component. Under normoxic conditions, HIF-1α 
is inactivated by hydroxylation at a proline residue, a requirement for association with VHL 
(von Hippel-Lindau). This protein is the product of VHL tumor suppressor gene and it is part 
of an ubiquitin-ligase complex that targets HIF-1α for proteasomal degradation after 
covalent attachment of a polyubiquitin chain. Under hypoxic conditions, however, the 
hydroxylases are inhibited and HIF-1α is rescued from degradation. HIF-1α complexes with 
HIF-1β and translocates into the nucleus, binding to the hypoxia responsive element (HRE), a 
specific sequence in the 5’ flanking region of the VEGF gene. Two additional isoforms of HIF, 
HIF-2α and HIF-3α, appear to exert different biological functions. HIF-2α is closely related to 
HIF-1α and can also promote HRE-dependent gene transcription, whereas HIF-3α 
antagonizes this mechanism, suggesting a negative influence on hypoxia-induced gene 
expression (Ferrara, Gerber, & LeCouter, 2003; Penn et al., 2008).  
Post-translational events are also important in the regulation of VEGF production as 
3’-UTR and 5’-UTR are crucial for controlling mRNA stability and the rate of translation 
through an internal ribosomal entry site (IRES). VEGF mRNA has a half-life of less than one 
hour in normoxic conditions, while the average half-life of eukaryotic mRNA is 10-12 hours. 
During hypoxia, its half-life increases by 2-3-fold due to stabilization effect of 3’-UTR, 
protecting it from endonucleases degradation. Moreover, the IRES at the 5’UTR provide 
alternative sites for translational control  (Penn et al., 2008). 
The paracrine and autocrine release of cellular growth factors and hormones 
cooperates with local hypoxia in regulating VEGF release in the microenvironment. 
Epidermal growth factors (EGF), TGF-α, TGF-β, keratinocyte growth factor (KGF or FGF7), 
IGF-1, FGF and PDGF upregulate VEGF expression, in addition to some inflammatory 
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cytokines such as IL-1α and IL-6. Hormones like tyroid-stimulating hormone (TSH), 
adrenocorticotropic hormone (ACTH) and gonadotropins have been also described to induce 
VEGF transcription. Furthermore, specific transforming events such as oncogenic mutations 
or amplification of some genes such as v-Raf and v-Src led to VEGF upregulation. Physical 
forces also stimulate VEGF expression, including stretch. Vascular development and 
remodeling are then influenced by blood flow and shear stress through a mechanosensory 
complex involving VEGF receptors (Ferrara, 1997; Maharaj & D’Amore, 2007; Olsson et al., 
2006).   
 
1.2.2. VEGF receptors  
The VEGFs act through 3 structurally related receptor tyrosine kinases (RTKs), known 
as VEGF receptor 1 (VEGFR1), VEGFR2 and VEGFR3, and co-receptors such as HSPGs and 
neuropilins (Nrp1 and Nrp2) (Figure 1.6). As members of the RTK superfamily, VEGF 
receptors contain a 750-amino-acid-residue extracellular domain, which is organized into 7 
immunoglobulin (Ig)-like folds. In VEGFR3 the fifth domain is replaced by a disulfide bridge. 
Adjacent to the extracellular domain is a single transmembrane region, followed by a 
juxtamembrane domain, a split tyrosine kinase domain that is interrupted by a 70-amino-
acid kinase insert and a carboxyl-terminal tail. The Ig domain-2 constitutes the ligand-binding 
site on the receptor. Moreover, the Ig domain-3 in VEGFR2 is important for the 
determination of ligand-binding specificity. The neuropilins are 120-130 KDa cell-surface 
glycoproteins that lack intrinsic catalytic activity and operate as non-tyrosine kinase 
receptors. They were first identified as receptors for the collapsing/semaphorin family of 
axonal guidance proteins (Koch & Claesson-Welsh, 2012; Olsson et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 – VEGF receptor
ligands binds to 3 VEGFRs, inducing the formation of 
Proteolytic process of VEGFC and VEGFD allows binding to VEGFR2. The binding to co
receptors as HSPGs and neuropilins also modulates VEG
represents an extracellular Ig
cylinders represent the intracellular domains of VEGFRs. 
 
VEGFR1 (alternatively named Fms
expressed, has all the conserved motifs required for kinase activity, and binds
VEGF-B and PlGF, which have quite distinct functions. However, the level of phosphor
of VEGFR1 in response to VEGF
responsible for endothelial cell function. The poor kinase activity may be due to the lack of 
positive regulatory phosphorylation
by the enzymes. In VEGFR1 case, the folding of the juxtamembrane domain prevents the 
exposure of the regulatory sequences in the kinase domain. 
-binding ligands and dimeric complexes.
VEGFR homo- and heterodimers. 
FRs signaling. Each sm
-like fold. The oval circles represent VEGF isoforms. The red 
Adapted from Olsson et al., 2006
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membrane protein and as a soluble spliced isoform (sVEGFR1). Both VEGFR1 forms have 
high affinity to bind VEGF-A, higher than does VEGFR2, therefore implicating VEGFR1 as a 
negative regulator of angiogenesis by clustering VEGF. Flt1
-/-
 mice die in utero at E9 because 
of excessive proliferation of endothelial progenitors which failed to organize into vascular 
channels, indicating that, at least during embryonic development, VEGFR1 is a negative 
regulator of VEGF action (Ferrara et al., 2003; Koch & Claesson-Welsh, 2012; Olsson et al., 
2006). 
VEGFR2 is alternatively named KDR (kinase insert domain receptor) in the human and 
FLK1 (fetal liver kinase 1) in the mouse, and is also activated by binding of VEGF-A, but with a 
10-fold lower affinity than VEGFR1. Proteolytically processed VEGF-C and VEGF-D also bind 
to VEGFR2. Recently, it was described an alternatively spliced soluble isoform (sVEGFR2), 
which is present in various tissues. sVEGFR2 binds to VEGF-C preventing it to bind to 
VEGFR3, functioning as a decoy receptor and inhibiting lymphatic endothelial cell 
proliferation. Flk1
-/-
 mice lack of vasculogenesis and failure to develop blood islands and 
organized blood vessels, which results in their death in utero at E8.5, similarly to the Vegfa
-/-
 
mice. Thus in vivo evidence states that VEGFR2 is the major mediator of the mitogenic, 
angiogenic and permeability-enhancing effects of VEGF. VEGFR2 on the plasma membrane 
can exist in a complex with other RTKs, VEGFR1 and VEGFR3, and non-RTKs proteins, like 
Nrp1, VE-cadherin, certain integrins and other receptors as ephrin-B2. Intracellularly, it can 
be associated with tyrosine phosphatases including phosphotyrosine phosphatases (PTPs) 
such as PTP1B, density enhanced phosphatase 1 (DEP1), vascular endothelial PTP (VEPTP) 
and TCPTP (T-cell protein tyrosine phosphatase) (Ferrara et al., 2003; Koch & Claesson-
Welsh, 2012).  
VEGFR3 (also denoted Flt4 in mouse) mRNA is found in venous endothelium in early 
stages of embryonic development but soon becomes restricted to developing lymphatic 
vessels in later stages and in adult life. Like VEGFR2, VEGFR3 binds to VEGF-C and VEGF-D. 
VEGFR3 forms either homodimers or heterodimers with VEGFR2, thus modulating the signal 
input. The kinase activity of VEGFR3 is regulated by phosphorylation of conserved residues in 
the kinase domain activation loop. Vegfr3
-/-
 mice die at E10-11 due to cardiovascular 
remodeling defects. Later in development, VEGF-C/VEGFR3 are critical regulators of 
lymphendothelial function, as the phenotype of naturally occurring VEGFR3 mutants proves. 
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VEGFR3 is the only VEGFR for which naturally occurring mutations have been described and 
all of them show impairment of lymphatic vessels function (Koch & Claesson-Welsh, 2012; 
Olsson et al., 2006).  
There are 2 Nrp homologs, Nrp1 and Nrp2, which are single spanning transmembrane 
proteins with a small cytoplasmatic domain lacking intrinsic catalytic function. They were 
first identified as receptors for semaphorins, a family of soluble molecules with neuronal 
guidance function. Nrp1 binds exon 7-containing VEGF-A isoforms such as VEGF-A165, and 
forms a ternary complex when bridges with VEGR2. Both overexpression and disruption of 
Nrp1 in mice lead to embryonic lethality at E12.3-13.5 due to either an excess of vessel 
formation or a range of vascular abnormalities, respectively. Nrp2
-/-
 mice show normal 
development of arteries and veins but show marked deviations in the development of 
capillaries and small lymphatics. Genetic studies suggest that Nrp1 is preferentially 
expressed in arteries and Nrp2 in veins and lymphatic vessels. Nrps are implicated in 
intracellular trafficking of VEGFR2 and VEGFR3, and Nrp1 is essential in VEGF-A-induced 
vasculature biology  (Ferrara et al., 2003; Koch & Claesson-Welsh, 2012). 
 
1.2.3. Signaling cascades upon VEGF receptors activation 
The entire VEGF signaling system is very tightly controlled at multiple levels, as 
regulation of gene expression, message stability, protein stability and proteolytic processing, 
ligand-receptor interactions and, at last, endocytosis and recycling. VEGF signaling starts 
with binding of VEGF to its cognate VEGF receptor in cis or trans (as for HSPGs binding) and 
its homo- or heterodimerization. The consequent change in receptor conformation exposes 
the ATP-binding site in the intracellular kinase domain, activating the kinase, leading to the 
auto- or trans-phosphorylation of the tyrosine residues on the receptor dimer itself and on 
downstream signal transducers. Tyrosine phosphorylation is rigorously regulated by 
internalization and degradation of the ligand-receptor complex or by dephosphorylation by 
PTPs, such as DEP1, VEPTP, SRC Homoloy 2 (SH2) domain PTP (SHP2) and PTP1B. The 
intracellular signaling cascades then culminate in known biological responses, such as cell 
survival and proliferation, and cell migration (Koch & Claesson-Welsh, 2012; Simons, 2012). 
VEGFR1 and VEGFR3 signaling will be briefly referred, while the signaling pathways 
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dependent on VEGFR2 activation will be described in more detail, as this receptor is the 
main responsible for VEGF biologic responses. 
Although the tyrosine kinase activity of VEGFR1 is dispensable for vascular 
development, VEGFR1 regulates endothelial cell function indirectly, through macrophage 
recruitment, followed by deposition of angiogenic factors by these cells, possibly in a 
vascular bed-specific fashion. In monocytes, the VEGFR1 ligands VEGF-B and PlGF induce 
signaling pathways known to operate downstream of most RTKs like extracellular signal-
regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), phosphoinositide 3’ kinase 
(PI3K)/protein kinase B (PKB/AKT) and the stress kinase p38MAPK, but other signaling 
pathways remain to be delineated. Furthermore, VEGF-B also promotes fatty acid uptake in 
endothelial cells, which is critical in organs with high metabolic stress such as the heart 
(Ferrara et al., 2003; Koch & Claesson-Welsh, 2012; Olsson et al., 2006). 
VEGFR3 mediates activation of the ERK/MAPK in a protein kinase C (PKC)-dependent 
manner, as well as activation of the PI3K-PKB/AKT pathway, both important during the 
embryonic development. Moreover, Nrp2 also modulates VEGFR3 signal transduction (Koch 
& Claesson-Welsh, 2012; Olsson et al., 2006).  
Binding of VEGF-A to VEGFR2 promotes its dimerization, further stabilized by 
interactions between membrane-proximal Ig-like domains, which facilitate 
autophosphorylation of intracellular tyrosine residues (Figure 1.7). The major 
phosphorylation sites are tyrosines Y951 in the kinase insert domain, Y1054 and Y1059 
within the kinase domain and critical for the kinase activity, and Y1175 and Y1214 in the 
carboxyl terminal domain. Upon phosphorylation Y951 serves as a binding site for the T cell-
specific adapter molecule (TSAd). In the case of Y1175, phosphorylation creates a binding 
site for numerous signaling mediators like PLCγ (phospholipase C gamma) and the adapter 
proteins SHB and SCK. Likewise, phosphorylated Y1175 (pY1175) can bind SHCA and GFB2, 
which recruit the nucleotide-exchange factor son of sevenless (SOS) to VEGFR2. Accordingly 
these 5 tyrosine are the vital residues that perpetrate the signaling cascades involved in 
vascular development and angiogenesis (Koch & Claesson-Welsh, 2012). 
 
Figure 1.7 – VEGF-A165-mediated signal transduction of VEG
survival and permeability are the biological responses mediated by VEGF
through a complex network of intracellular signal transduction pathways. Upon binding to 
extracellular Ig-like domains 2 and 3 of VEG
respective phosphorylation sites (indicated by numbers) in the intracellular domain, activating 
downstream mediators (oval boxes). VEGFR2 continues to signal after internalization, as 
endosomes follow recycling or degradative trafficking pathways. Adapted 
Claesson-Welsh, 2012.  
 
VEGF-A stimulates proliferation through VEGFR2
RAS/RAF/ERK/MAPK pathway. RAS 
sphingosine kinase (SPK) but the exact mechanism is not clear yet. The RAS signaling chain 
also leads to generation of pleiothropic lipid mediators [prostanglandins (PGl
cytoplasmatic phospholipase A
happens in most other RTKs, but via pY1175
subsequent PKCs. Phosphorylated PLCγ hydrolyses the membrane phospholipid 
phosphatidylinositol (4,5)-biphosphate (
FR2. Proliferation, migration, 
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(DAG) and IP3. Generation of IP3 leads to an increase of intracellular Ca
2+
 and DAG activates 
PKC family. PKC activation also causes activation of protein kinase D (PKD), thus promoting 
nuclear translocation of hystone deacetylases (HDAC) 5 and 7, following by phosphorylation 
of cAMP-response-element binding protein (CREB) and HSP27 (Koch & Claesson-Welsh, 
2012).   
VEGFR2 migration-induced signals implicate a different set of molecules. pY1175 
binds SHB which becomes phosphorylated in a SRC-dependent manner, and SHB binds to 
FAK (focal adhesion kinase). pY1214 recruits the non-catalytic region of tyrosine kinase 
adaptor protein 1/Fyn phosphotransferase (NCK/FYN) complex to VEGFR2, which mediates 
phosphorylation of p21-activated protein kinase-2 (PAK-2) and subsequent activation of cell 
divison cycle 42 (Cdc42) and p38MAPK. HSP27 is also activated on phosphorylation of Y1214, 
in a MAPKAPK-2-dependent manner. The docking protein GAB1 interacts with VEGFR2 by a 
non-identified yet residue and binds to p85 subunit of PI3K that generates 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) upon VEGF stimulation. Guanosine 
triphosphate (GTP)-binding RAC is activated and membrane ruffles are formed. Additionally 
the actin-binding protein IQGAP1 (IQ motif-containing GTPase activating protein 1) has been 
implicated in regulation of cell-cell contacts and cell motility (Koch & Claesson-Welsh, 2012). 
The production of VEGFR2-PI3K-induced membrane-bound PIP3 also initiates the 
signaling cascade responsible for cell survival. PIP3 mediates recruitment and 
phosphorylation of PKB/AKT by phosphoinositide-dependent kinases 1 and 2 (PDK1 and 
PDK2). AKT then phosphorylates BCL-2 associated death promoter (BAD) and caspase 9 
thereby inhibiting their apoptotic activity. The expression of some other proteins involved in 
cell survival pathways, like integrins, BCL-2, A1, inhibitors of apoptosis (IAP) family members 
XIAP and survivin is induced (Koch & Claesson-Welsh, 2012). 
At last, promotion of vascular permeability involves endothelial nitric oxide synthase 
(eNOS)-mediated generation of nitric oxide (NO). eNOS is activated either by PLCγ-
dependent Ca
2+
 influx or AKT-mediated phosphorylation. The endocytosis of VE-cadherin 
may also regulate junctional permeability via activation of SRC-VAV2-RAC and PAK (Koch & 
Claesson-Welsh, 2012).  
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Cellular uptake of almost all RTK is initiated by their ligand binding. This is followed by 
rapid clearance of receptors from the cell surface, or alternatively dephosphorylation by 
PTP. In the case of VEGFR2, it further undergoes ubiquitination and internalization into 
endosomes, followed by lysosomal degradation of the receptor-ligand complex. Additionally 
to ligand-activated endocytosis, VEGFR2 is also subject to constitutive recycling of inactive 
receptor. Both types of endocytosis use clathrin- and dynamin-dependent pathways and 
direct the receptor to early endosome antigen 1 (EEA1)-positive (EEA
+
) endosomes. The 
exact series of events and whether endocytosis will even take place at all are very much 
dependent on the state of the cell and the surrounding ECM. From the transmembrane point 
of view, VEGFR2 internalization is regulated by VEGFR3, Nrp1, VE-cadherin, ephrin-B2, 
thrombospondin receptor CD47 and certain integrins. The interaction of integrins with some 
ECM components also mediates VEGFR2 endocytosis. On the intracellular side, VEGFR2 is in 
close proximity to a number of PTPs, including CD148, VE-PTP and PTP1B, that can affect its 
endocytosis and signaling (Koch & Claesson-Welsh, 2012; Simons, 2012).  
Upon entry into the cell, VEGFR2 continues to signal, but its effectiveness is 
dependent on its location in a specific endosomal compartment and subsequent trafficking. 
VEGFR2 upon endocytosis is initially found in adaptor proteins APPL
+
 Rab5
+
 early endosomes 
and then transit to EEA1
+
 Rab5
+
 endosomes. This cargo movement is likely to occur due to 
EEA1 displacing APPL1/2 from the common Rab5 binding site. EEA1 endosomes then 
undergo intracellular trafficking using syntectin/myosin VI complex, known to orchestrate 
inward vesicle trafficking in a number of cell types. Syntectin is the key protein of this step as 
it is a single PDZ domain protein that binds a number of other crucial interacting proteins. In 
the absence of syntectin, following endocytosis, VEGFR2 remains for long period of time in 
EEA1
+
 endosomal compartment before moving on. This results in decreased phosphorylation 
of Y1175 site that is critical to activation of PLCγ/ERK signaling. However, phosphorylation at 
Y951, Y1054 and Y1059 residues remains unaffected. Therefore, ERK phosphorylation is 
reduced and PI3K signaling is normal. This effect is particularly important in quiescent 
endothelial cells maintaining a monolayer, where proliferation and migration signals are not 
imperative (Eichmann & Simons, 2012; Simons, 2012).   
VEGFR2 targeting for recycling back to the plasma membrane or for sequential 
proteasome and lysosomal degradation seems to depend on Nrp1. VEGFR2 is stored in 
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intracellular Rab4-negative (Rab4
-
) and Rab11
-
 vesicles in resting cells, and can be delivered 
to the plasma membrane upon VEGF-A stimulation in a SRC-dependent manner. When 
complexed with Nrp1, internalized VEGFR2 can be recycled through Rab4
+
, Rab5
+
 and 
Rab11
+
 vesicles. In Nrp1’s absence, VEGFR2 is sorted into Rab7
+
 vesicles for degradation. 
Thereby, Nrp1 serves to prolong VEGFR2 signaling (Koch & Claesson-Welsh, 2012; Simons, 
2012).  
The balance between endocytosis and exocytosis is another mechanism to regulate 
VEGFR2 signaling. Binding of VEGF to VEGFR2 on the plasma membrane stimulates 
trafficking of intracellular VEGFR2 sequestered in recycling endosomes back to the plasma 
membrane. At the same time, the binding event also initiates trafficking of newly 
synthesized, Golgi-resident VEGFR2 to the membrane. This later process is controlled by a 
Golgi-localized target membrane-soluble N-ethylmalemide attachment protein receptor (t-
SNARE) named syntaxin 6 (Simons, 2012).  
 
1.2.4. VEGF roles in physiological angiogenesis and beyond 
The proliferation of blood vessels is crucial for a wide variety of normal physiological 
processes as embryonic development, growth and differentiation, wound healing and 
reproductive functions. During embryonic development, VEGF is first detected within the 
first few days after implantation in the giant cells of the trophoblast. In the human fetus (16-
22 weeks), VEGF mRNA expression is detectable in virtually all tissues. At later stages in 
mouse or rat development, VEGF mRNA is expressed in several organs including heart, 
vertebrate column, kidney and brain, where the highest levels are associated with the 
choroid plexus and the ventricular epithelium. In the developing retina, both in animals and 
humans, VEGF expression is initially seen in the astrocytes adjacent to the inner membrane 
near the optic disc, and advances towards the periphery with a gradual downregulation in 
the central retina. VEGF expression then precedes the advancing blood vessels until they 
reach the peripheral margin of the retina. With advancing age, VEGF expression disappears 
from the superficial layer and is induced in the inner nuclear layer, collectively 
demonstrating that VEGF expression in the retina is spatially and temporally related to 
development of the vasculature. In adulthood, 5 retinal cell types have the ability to produce 
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and secrete VEGF: RPE, astrocytes, Müller glia cells, vascular endothelium and ganglion cells. 
VEGF role on vascular development was elucidated by the generation of several mice 
models. VEGF
164/164
 mice display normal vascular development indicating that this isoform is 
sufficient for directing vascular growth and remodeling. Conversely, retinas of VEGF
120/120
 
mice exhibit severe vascular defects, and VEGF
188/188
 mice display normal development of 
retinal veins but little or no arterial growth Moreover, the conditional inactivation of VEGF 
expression in the mouse RPE (VEGF
rpe+/-
) showed severe abnormalities, despite normal 
formation of choroidal vessels at reduced VEGF levels. Importantly, VEGF
rpe-/-
 mice revealed 
absence of a proper Bruch’s membrane and choriocapillaries, occurrence of microphthalmia 
and loss of visual function, reinforcing the notion that RPE-derived VEGF is a key factor in 
choroid development (Ferrara, 1997; Marneros et al., 2005; Penn et al., 2008). 
Consistently with the human fetus pattern, virtually every adult tissue expresses 
VEGF. In tissues where the vasculature is known to have a barrier function, like retina, brain 
and testis, relatively few cells express VEGF what might contribute to the impermeability of 
these vessels. On the other hand, the highest density of VEGF expressing cells is localized in 
epithelial tissues in contact with fenestrated vessels where secretory and/or filtration 
functions prevail, like the glomerulus (urine filtrate), choroid plexus (cerebrospinal fluid 
production), pancreas (exocrine and endocrine secretions) and liver (secretion and 
filtration). In human adults, VEGFRs are expressed in and outside of the retinal vasculature, 
being VEGFR1 the only receptor expressed in the retinal microvessels. Its scavenger function 
may act as a protective mechanism to maintain endothelial cell integrity. VEGFRs expression 
in the neural elements of the retina indicates the neuronal survival function that VEGF exerts 
in non-vascular retinal cells. Moreover, the expression of VEGF-C/VEGFR3 in the normal 
retina shows that VEGFR3 is not only restricted to the lymphatic and vascular systems 
(Ferrara, 1997; Maharaj & D’Amore, 2007; Witmer, Vrensen, Van Noorden, & Schlingemann, 
2003). 
VEGF was first identified as a survival and a potent vascular permeability factor for 
endothelial cells. Because endothelial cells do not generally express VEGF, this permeability 
is mediated via both VEGR1 and VEGFR2 in response to VEGF secreted in a paracrine 
manner, and results in the formation of transcellular gaps, vesiculovacuolar organelle 
formation and fenestrations. Moreover, VEGF may act on other cell types based on the 
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presence of either VEGFR1 or VEGFR2, and also on monocytes, macrophages, mast cells, 
eosinophils, dendritic cells, megakaryocytes, lymphocytes, leukocyte, bone marrow-derived 
circulating cells, type II lung alveolar epithelial cells and lens epithelium. In addition VEGF has 
been shown to mediate neuronal cells and neuronal stem cells growth and survival both in 
vivo and in vitro (Maharaj & D’Amore, 2007).  
 
1.2.5. VEGF roles in pathological conditions 
The growth of new vessels involves a dynamic phenotype interconversion of the 
various cells during the advancing of the new sprouts. Consequently, VEGF mRNA is 
upregulated in many human tumors, mediating angiogenesis. Hypoxic tumors cells 
overexpress different VEGF isoforms, resulting in abrogation of the coordinated VEGF 
guidance and deregulated vessel growth. Tumor vessels are then heterogeneously 
distributed lacking well-organized arteriole-capillary-venule structure, have variable 
diameters, and present irregular shapes with a leaky and chaotic blood flow. Together with 
inadequate lymphatic drainage, these features often lead to poor blood perfusion and high 
interstitial fluid pressure inside the tumors. Due to the diminished blood flow, tumors 
remain hypoxic and continue to overproduce VEGF, aggravating the abnormal tumor vessel 
phenotype. Although tumor cells represent the major source of VEGF, tumor-associated 
stroma is also an important player in VEGF deregulated production (Ferrara et al., 2003; 
Saharinen, Eklund, Pulkki, Bono, & Alitalo, 2011).     
VEGF is also implicated in hematologic malignancies, including multiple myeloma, T-
cell lymphoma, acute lymphoblastic leukemia, Burkitt lymphoma and chronic myelocytic 
leukemia. The expression of both VEGF receptors was also detected in some leukemia cell 
lines (Ferrara et al., 2003). 
In inflammatory disorders, like psoriasis and rheumatoid arthritis, VEGF levels are 
deregulated too. These are cases in which microvascular permeability and angiogenesis play 
an important role. The same is true for the pathologies of the female reproductive tract such 
as polycystic ovary syndrome, endometriosis and pre-eclampsia (Ferrara, 1997). 
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Intraocular neovascular syndromes are associated with retinal ischemia and 
neovascularization, and have VEGF as a major player. The most important eye diseases 
involving VEGF will be succinctly described below. 
 
1.2.5.1. Retinopathy of prematurity 
Retinopathy of prematurity (ROP) is a neovascularizing disease affecting preterm 
infants and is one of the most common causes of world’s childhood blindness. The incidence 
of the disease correlates with the gestational age of the infant at birth, as the retina is one of 
the last organs to be vascularized in the human fetus. ROP is caused by perturbation of the 
normal process of vascular development of the retina (Penn et al., 2008). 
ROP is a side effect of the highly effective use of hyperoxia to improve the survival of 
premature neonates in respiratory distress. Hyperoxia causes developing retinal vessels to 
obliterate, presumably because the stimulus for normal development and/or survival has 
disappeared. In the initial phase of ROP, normal retinal vascular growth is retarded as a 
consequence of exposure to extra-uterine hyperoxia. The increasing metabolic demands of 
the developing neural retina generate a relative retinal hypoxia, leading to the second phase 
of ROP, a hypoxia-driven vascular proliferation. This stage consists of VEGF release and other 
angiogenic factors that produce excessive growth of abnormal leaky blood vessels into the 
retina, causing vitreous hemorrhage and retinal detachment (Penn et al., 2008; Witmer et 
al., 2003).   
Much of the evidence for the role of VEGF in ROP has been acquired through careful 
studies in animal models of oxygen-induced retinopathy (OIR), being the mouse model of 
OIR the one that better reproduces the defining disease characteristics observed during the 
human OIR. In both rat and mouse models of OIR, Vegfa expression patterns are disrupted. 
However, Vegfa was found to be normally expressed in Igf1
-/-
 mice although retinal 
vasculature was significantly retarded, suggesting that IGF1 plays a key role in VEGF-A-
mediated stimulation of normal vascular growth, preventing ROP (Penn et al., 2008; Stahl et 
al., 2010; Witmer et al., 2003). 
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1.2.5.2. Diabetic retinopathy 
A variety of metabolic imbalances and vascular changes, such as thickening of the 
basement membrane, apoptosis of pericytes and endothelial cells, and diffusely increased 
vascular permeability, occur in diabetes mellitus’ retina, long before DR is clinically 
recognized. The retina is one of the few tissues that does not require insulin for glucose 
uptake; instead, glucose transporter 1 (GLUT1) facilitates glucose entry into retinal cells. 
Consequently, hyperglycemia is a major risk factor for the development and the progression 
of DR as high intracellular levels of glucose induce a ‘pseudohypoxia’ state. DR is the most 
frequent complication of diabetes and the leading cause of blindness in developed countries 
worldwide (Penn et al., 2008; Witmer et al., 2003). 
DR has a clinical progression pattern of an ischemic retinopathy. The initial 
alterations are manifested by biochemical signs of oxidative stress and AGEs formation, and 
cellular signs of subclinical inflammation. The earliest vascular changes include adhesion of 
leukocytes to the vessel wall (leukostasis), platelets’ aggregation, altered blood flow, 
degeneration of pericytes and thickening of the basement membrane. The blockage of the 
retinal capillaries may cause localized hypoxia, triggering tissue production of VEGF and 
other angiogenic factors with increased vascular permeability as a consequence. In contrast, 
retinal endothelial cells are sated by increased proliferation, and they may reach their 
replicative senescence after years of diabetes mellitus. At that time, vascular alterations, 
such as acellular capillaries, microaneurysms and ischemic areas are evident and vascular 
leakage increases, forming exudative deposits. Clinically, this is recognized as non-
proliferative DR (NPDR) (Penn et al., 2008; Witmer et al., 2003). 
Sometimes NPDR progresses to proliferative diabetic retinopathy (PDR), which is 
characterized by the growth of new blood vessels on the surface of the retina (Figure 1.8). 
These new vessels are fragile and may break, leaking blood into the neural retina and 
vitreous, thus compromising vision. Therefore, VEGF-A, which is known to act as a survival 
factor for endothelial cells via induction of antiapoptotic proteins, may be increased initially 
in preclinical DR as a mechanism to preserve the retinal vascular bed. In a later stage of DR, 
VEGF-A production in ischemic areas, where VEGFR2 is upregulated, leads to the vascular 
leakage and neovascularization (Penn et al., 2008; Witmer et al., 2003).      
 
 
 
 
 
Figure 1.8 – Fundus photograph of an eye of a patient with non
retinopathy (A) and of a patient with proliferative diabetic retinopathy 
characterized by intra-retinal hard exudates 
neovascularization prevails (B, black arrow)
 
1.2.5.3. Age-related macular degeneration
As previously mentioned, 
Although this disease develops late in life, 
genetic mutations. The pathologic expression of
patients. Evidence arises from the fact that 
that are epidemiologically linked to AMD and CNV
increased expression of Vegf. Moreov
regulating VEGF expression or receptor binding
AMD suggests once again a VEGF pathological expression
 
1.2.6. VEGF as a therapeutic target
The idea that a soluble, inducible 
tumor growth was first stated by Folkman in 1971. After definitive clinical studies, resulting 
in approval of several drugs by the United States Food and Drug Administration (FDA), it was 
established that VEGF-A is an important therapeutic target for cancer and wet AMD. 
Actually, AMD was the primary driver of ocular anti
detection of VEGF in neovascular membranes, the high incidence of blindness and aging of 
the population (Ferrara, Mass, Campa, & Kim, 2007; Stewart, 2012)
-proliferative diabetic 
(A, arrowheads). At later stages of disease, 
. Adapted from Witmer et al., 2003
 
AMD is one of the leading causes of vision loss worldwide. 
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The first anti-angiogenic agent approved by the FDA was bevacizumab (Avastin®) in 
2004, a humanized version of an anti-VEGF murine monoclonal antibody. In combination 
with chemotherapy and cytokine therapy is used in the treatment of several advanced 
metastatic cancers. Although bevacizumab is generally well tolerated, its systemic 
administration has some side effects including hypertension and proteinuria, and originally it 
was not considered an appropriate choice for intravitreal injections. In 2005, however, 
successful intravitreal injections of bevacizumab were performed for patients with AMD. 
From then on off-label intravitreal use of bevacizumab has spread all over the world (Ferrara 
et al., 2007; Penn et al., 2008). 
The concerns about effectiveness/safety ratio in bevacizumab use were overcome by 
engineering bevacizumab into a smaller fragment antigen-binding (Fab) (48 KDa compared 
to 148 KDa) and affinity-enhancing by 5- to 20-fold to create ranibizumab (Lucentis®), which 
potently neutralizes the biological activities of all known human VEGF isoforms. Ranibizumab 
was proposed to have better penetration in the RPE, as well as being more effective and 
safer for intravitreal use. FDA approved its use in AMD treatment in 2006. Nevertheless, 
bevacizumab became the drug of first choice because of its low cost (20-50-fold less 
expensive than ranibizumab) and “first to market” availability (Stewart, 2012).  
Other pharmacological anti-VEGF therapies for AMD include the use of pegaptinib 
sodium (Macugen®), a pegylated oligonucleotide aptamer that binds to and inactivates 
VEGF-A165, and VEGF-Trap, an engineered protein that contains Ig-like domains of both 
VEGR1 and VEGFR2 fused to a fragment crystallizable (Fc) segment of an antibody backbone. 
The chimeric molecule functions as a high-affinity soluble receptor that binds to and 
neutralizes both VEGF and PlGF (Figure 1.9). A variety of small-molecule RTK inhibitors are 
also under development, as well as small interfering ribonucleic acid (siRNA) molecules. For 
example, Cand5 and Sirna-027 inhibit the expression of genes encoding VEGF and VEGFR1, 
respectively (Ferrara et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 – Different strategies to inhibit VEGF signaling.
VEGF cellular actions are being used
anti-VEGFRs antibodies (b,c)
inhibitors (e). Adapted from Napoleon
 
Laser photocoagulation of the macula and peripheral retina has been the standard 
treatment for diabetic retinopathy, but a PKC inhibitor, ruboxistaurin, is in clinical trial for 
delay in diabetic macular edema progression. Int
ROP therapy, and other treatments are under study 
The introduction of anti
eye diseases, by stabilizing it, and, in many cases, reverse vision loss. Indeed, it is feasible 
that non-neoplasic conditions will show a greater clinical response, given 
chance of nontransformed cells to activate alternative angiogenic pathways and thus 
develop resistance. Nevertheless, the identification of reliable markers that can predict 
which patients are more likely to respond to anti
treatments) is of extreme importance 
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1.3. Rab GTPase proteins in intracellular trafficking  
As eukaryotic cells and organisms evolved, the need to transfer content between 
distinct membrane-enclosed organelles in a specific and regulated manner emerged. A 
typical transport reaction involves the budding of vesicular carriers from donor membranes, 
followed by their transport to specific acceptor membranes, and culminates in their docking 
and fusion. The result of this four-step process is the combination of contents from both 
carrier and acceptor compartments. The specificity of membrane tethering and fusion is 
critical to preserve organelle identity and maintain proper flow of the cargo within the cell, 
and coordination of all these events is crucial for proper cellular function (Stenmark, 2009; 
Zerial & McBride, 2001).  
 
1.3.1.  Ras superfamily of GTPases 
The Ras superfamily of GTPases encloses a large group of small GTP-binding proteins, 
which maintain a structurally and mechanistically preserved GTP-binding core despite 
considerable divergence in sequence and function. All these proteins share a common 
enzymatic activity by producing guanosine diphosphate (GDP) by the hydrolysis of GTP. 
Minor modifications in sequence, structure and cellular regulation of members of the 
superfamily will affect binding to regulators and consequently cell signaling (Rojas, Fuentes, 
Rausell, & Valencia, 2012). 
There are 5 different families within the Ras superfamily of proteins: Ras, Rho/Rac, 
Rab, Arf and Ran. Ras family members act as signaling nodes that are activated by 
extracellular stimuli and regulate intracellular signaling pathways of cell growth and 
differentiation, known to be involved in oncogenic events. The Rho/Rac family signaling 
networks regulate cytoskeleton organization, cell cycle progression, cell polarity and 
hematopoiesis. The Rab (Ras-related proteins in brain) family forms the largest family of the 
Ras superfamily and plays fundamental roles in vesicular transport and intracellular 
trafficking. Members of Arf family are the most divergent ones and are also implicated in 
vesicle trafficking, signaling through a wide range of coat complexes and lipid-modifying 
enzymes. Finally, only one member of the Ran family is found in all eukaryotic lineages, 
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excepting plants. Ran proteins are the most abundant in the cell and are involved in nuclear 
transport (Rojas et al., 2012).  
The different groups of Rab family have representative proteins in all lineages, 
indicating that this family appearance was an important evolutionary event. RAB genes were 
found in all eukaryotes investigated, which underlines their importance in eukaryotic cell 
biology. In several cases, a mammalian Rab can functionally replace its yeast counterpart, 
validating the conservation of proteins’ functions within the eukaryotes. Rab family has 
experienced extensive gene duplication, given that various subfamilies of closely related Rab 
GTPases with 75-95% sequence identity and overlapping functions can be identified, named 
Rab isoforms. Moreover, isoforms diversity is generated through ongoing messenger RNA 
(mRNA) processing in the form of alternative splicing. Some Rab proteins are ubiquitously 
expressed, whereas others are expressed in a tissue-specific developmentally regulated 
manner. Pylogenetic analyses and dendrogram clustering classify Rab family into 14 
subfamilies, based on distinct subfamily-specific sequence motifs (Rojas et al., 2012; 
Schwartz, Cao, Pylypenko, Rak, & Wandinger-Ness, 2008; Stenmark & Olkkonen, 2001).  
Structurally, Rab proteins share a feature that is common to all small GTPases of the 
Ras superfamily, which consists of a 6-stranded β-sheet, comprising 5 parallel strands and 
one antiparallel strand, surrounded by 5 α-helices. The elements responsible for guanine 
nucleotide and Mg
2+
 binding, and GTP hydrolysis are located in the 5 loops that connect α-
helices to β-strands. This GTP-binding site is made up of a core of essential residues that 
participate in the conformational changes linking GTPase activity to effector binding, and 
they can easily be used to recognize any small GTPase. The 2 regions that undergo 
modifications upon GTP binding and hydrolysis are named switch I and switch II domains. 
Furthermore, 5 Rab family (RabF)-specific amino acid stretches were identified, 
distinguishing them from other Ras-like proteins. The RabF1 region is located in the effector 
domain, in the switch I region. The remaining 4 regions, RabF2, RabF3, RabF4 and RabF5 all 
reside in and around the switch II region. There are also 4 Rab subfamily regions (RabSF), 
highly conserved within subfamilies, localized on 2 different surfaces of the GTPases. RabSF 
allow specific binding of downstream effector molecules, which must recognize a specific 
Rab or Rab subfamily in addition to detecting the nucleotide-binding state. Thus, it was 
proposed that effector molecules bind to RabF regions to discriminate between the 
40 
 
nucleotide-bound state and to RabSF regions to confer specificity. Rab proteins identity is 
lastly conferred by the cysteine motif at the very carboxyl terminus, where a post-
translational modification takes place (Leung, Baron, & Seabra, 2006; Stenmark & Olkkonen, 
2001). 
Ras-like proteins undergo co-translational or post-translational lipid modifications, 
with the exception of Ran proteins. These act as hydrophobic membrane anchors, 
interacting with the cytoplasmic leaflet of cellular membranes and/or participating in 
protein-protein interactions. The most common lipid modification affecting small GTPases is 
protein prenylation, which involves the covalent addition of either farnesyl (15 carbon) or 
geranylgeranyl (20 carbon) pyrophosphate to proteins via thioesther bonds catalyzed by 
protein prenyl transferases. The prenylation of Ras, Rho/Rac and Rab is absolutely critical for 
the proper function of the protein in cellular processes. There are 3 distinct prenyl 
transferases classified into 2 main classes: the CAAX prenyl transferases, consisting of 
farnesyl transferase (FT) and geranylgeranyl transferase type I (GGT-I), and the Rab 
geranylgeranyl transferase (RGGT, or GGT-II). The first class has CAAX-containing 
farnesylated proteins, like Ras and nuclear laminins, and geranylgeranylated proteins of the 
Rho/Rac family for substrates. RGGT has Rab protein family members as exclusive 
substrates, and adds one or 2 highly hydrophobic geranylgeranyl groups to the carboxyl 
terminus where a cysteine motif resides (CXXX, CC, CXC, CCXX or CCXXX, being X any amino 
acid). RGGT is a heterodimeric protein consisting of distinct α- and β-subunits, and it does 
not recognize either short peptides containing the Rab carboxyl terminal prenylation motif, 
or the Rab protein alone. The post-translational modification requires the initial recognition 
of the newly synthesized Rab protein by a Rab escort protein (REP), which presents it to the 
RGGT. The majority of Rab proteins contains 2 terminal cysteine residues and undergo 2 
geranylgeranlyation reactions via independent steps. This double prenylation confers Rab 
proteins extra hydrophobicity, which is the reason why REP is required as a chaperone. REP 
functions as a chaperone that keeps Rab proteins soluble and delivers them to the 
appropriate membrane (Leung et al., 2006; Stenmark & Olkkonen, 2001). 
Post-prenylation processing is also a factor in membrane recruitment of Rabs. Rab 
proteins with a CXC motif, but not a CC motif, are carboxylmethylated on the C-terminal 
prenylcysteine by enzymes localized in the endoplasmic reticulum. Thus, both monocysteine 
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and CXC Rab proteins transiently interact with the endoplasmic reticulum after prenylation 
and before delivery to the target membrane, whereas Rab proteins with a CC motif are 
delivery directly to the membrane (Leung et al., 2006).  
 
1.3.2. Rab proteins’ switch and its circuitry 
Rab proteins operate as molecular switches, cycling between inactive GDP-bound and 
active GTP-bound states, and these changes are coupled to reversible association with their 
target membranes. Both GDP/GTP and membrane association/dissociation cycles are 
important for controlling Rabs’ activity, being the latter a critical step: a protein must be 
both GTP-bound and membrane-associated to be in a truly activated state. Moreover, Rabs 
on/off regulatory function is restricted to the membrane compartments where they are 
localized (Seabra & Wasmeier, 2004; Zerial & McBride, 2001). 
The cycle of switching events is coordinated by several factors (Figure 1.10). 
Geranylgeranylated Rabs are delivered to their target membranes by REP or a Rab GDP 
dissociation inhibitor (RabGDI). This delivery is mediated by interaction with a membrane-
bound GDI displacement factor (GDF), and by specific targeting factors, probably some 
unidentified ones. The conversion of GDP-bound Rab into GTP-bound form occurs through 
the exchange of GDP for GTP, which is catalyzed by a guanine nucleotide exchange factor 
(GEF). GEF recognizes specific residues in the switch region and facilitates GDP release. The 
high cytosolic concentration of GTP ensures that it binds as soon as GDP has been released 
from the Rab. Activated GTP-bound Rabs recruit a wide variety of downstream effector 
molecules to the membrane, reflecting the diverse functions that Rabs play in membrane 
traffic. Rab proteins return to their inactive state through hydrolysis of GTP, which is 
catalyzed by a GTPase-activating protein (GAP). GDP-bound Rabs become susceptible to 
extraction from the membrane by RabGDI, with whom they form stable cytosolic complexes 
representing a cytoplasmic reservoir of Rab proteins. RabGDI and REP are crucial players in 
this cycle by binding GDP-Rab and presenting them to the relevant membrane. While 
RabGDI binds to recycling Rabs, REP captures newly synthesized Rab proteins and presents 
them to the RGGT before targeting them to the membrane delivery (Seabra & Wasmeier, 
2004; Stenmark, 2009). 
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Figure 1.10 – Schematic representation of Rab proteins
form a cytosolic complex with RabGDI or REP 
RabGDI/REP displacement is mediated by a GDF and specific targeting factors 
activation follows through a GEF
able to recruit effector molecules to the membrane 
converting Rab protein in its active state again, turning it to a substrat
extraction by RabGDI (e). Adapted from 
 
GDFs play a crucial part in target
RabGDI complexes and promoting GDI release, therefore facilitating the association of the 
geranylgeranylated Rab GTPase
REP and serves as a recycling factor allow
retrieval of the Rab GTPases
reaction intermediate than for di
relatively unstable interaction of the second geranylgeranyl group may facilitate the transfer 
of the lipid anchor from RabGDI into the membrane bilayer 
Stenmark & Olkkonen, 2001; Stenmark, 2009)
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1.3.3. Rab GTPases’ functions in vesicle trafficking 
The mammalian Rab GTPases were first identified in the 1980s as evolutionary 
conserved, essential regulators of membrane trafficking. Rab GTPases are molecular 
switches, cycling between active and inactive states and serving as scaffolds to integrate 
both membrane trafficking and intracellular signalling in a temporally and spatially sensitive 
manner. This regulation is done by recruiting effector proteins, such as sorting adaptors, 
tethering factors, kinases, phosphatases and cellular motors. Despite the small sizes of Rab 
proteins (20-25 KDa), they have multiple interaction surfaces through which they associate 
with regulatory molecules and downstream effectors to exert their functions. Rab proteins 
are present on all compartments of the endomembrane system (endoplasmatic reticulum, 
Golgi, endosomes and lysosomes), nucleus, plasma membrane, including cell junctions and 
focal adhesions, mitochondria and centrioles (Figure 1.11). In addition to their essential roles 
in exocytic and endocytic membrane trafficking, they contribute for the control of cell 
proliferation and differentiation, and for cell-type specific functions, such as regulated 
secretion in endocrine and exocrine cells, synaptic transmission in neurons and phagocytosis 
in macrophages and dendritic cells. In epithelial cells, Rab proteins help in polarity 
generation by regulating the trafficking of junctional proteins and integrins and by defining 
epithelial transport circuits to cilia. Given the range of cellular functions embraced by Rab 
proteins, it is expected their functional impairment to be associated with diseases, such as 
immunodeficiencies, cancer and neurological disorders (Seabra & Wasmeier, 2004; 
Stenmark, 2009; Zerial & McBride, 2001).  
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Figure 1.11 – Intracellular localization and associated vesicle transport pathway(s) of Rab 
GTPases. Rab proteins are represented as black circles and are identified by the inner number. 
Rab1 regulates ER-Golgi traffic while Rab2 is involved in recycling from Golgi and the ERGIC back 
to the ER. Rab6 regulates intra-Golgi traffic. Several Rabs including Rab8, Rab10 and Rab14 
regulate biosynthetic traffic from the trans-Golgi network (TGN) to the plasma membrane, as it 
happens with the glucose transporter GLUT4. Several secretory vesicles and granules use Rab3, 
Rab26, Rab27 and Rab37 to exocytose their cargo. Rab27 is also implicated in melanosome 
transport along with Rab32 and Rab38. Most early endocytic steps rely on Rab5, which mediates 
fusion of endocytic vesicles to form the early endosome. Traffic can be directed towards the 
lysosome for degradation, which relies on action of Rab7, or to various recycling compartments to 
return factors to the plasma membrane. Rab9 regulates late endosome transport back to TGN. 
Rab17 in involved in transcytosis. Rab15 directs membrane traffic from the early endosome to the 
recycling endosome. Rab4 and Rab11 regulate fast and slow endocytic recycling, respectively. 
Rab22a is involved in protein recycling to plasma membrane, while Rab31 (also Rab22b) directs 
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transport from TGN to endosomes. Rab30 and Rab36 localize to Golgi but their functions remain 
unknown. Specialized Rab functions include Rab18-mediated regulation of lipid droplets. Rab24 
and Rab33 mediate formation of the pre-autophagosomal structure. Rab21 and Rab25 regulate 
transport of integrins to control cell adhesion and cytokinesis. Rab13 directs traffic to and 
regulates formation of tight junctions in polarized epithelial cells. Rab23 also interacts with the 
transcription factors activated by the Sonic hedgehog (Shh) pathway. Rab40 recruits components 
of the ubiquitination machinery to regulate Wnt signaling. Rab35 controls plasma membrane 
recycling of an essential factor in cytokinesis, and it is poorly characterized. Rab34 and Rab39 are 
found in the Golgi, with undefined roles so far. AP, autophagosome; ERGIC, ER-Golgi intermediate 
compartment; ER, endoplasmic reticulum; EE, early endosome; LD, lipid droplet; LE, late 
endosome; L/V, lysosomes/vacuole; PAS, pre-autophagosomal structure; RE, recycling endosome; 
SV, secretory vesicle/granule; TGN, trans-Golgi network. Adapted from Hutagalung & Novick, 
2011. 
 
Each transport step requires that activated Rab proteins bind to soluble factors that 
act as effectors, transducing the signal of the Rab GTPase in the transport mechanism. The 
fact that those effectors are such structurally heterogeneous implies that they are highly 
specialized molecules whose activities are exclusively tailored for individual organelles and 
transport systems. Despite so, all steps of vesicle transport are coordinated by the same 
regulatory machinery (Figure 1.12) (Zerial & McBride, 2001). 
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Figure 1.12 – Rab GTPases and its effectors regulate distinct membrane trafficking steps 
from donor to acceptor membranes.
sort a receptor into a budding vesicle 
PI composition of a transport vesicle might be altered thereby causing uncoating through the 
dissociation of PI-binding coat proteins 
cytoskeletal tracts by binding directly to motors or by recruit motor adaptors 
vesicle tethering by recruiting factors that interact with SNAREs and their regulators in the acceptor 
membrane (d), which results in membrane fusion 
Rab GTPases are converted into 
membrane in a complex with GDI. Adapted from 
 
 An active GTP-bound Rab can activate a sorting adaptor to 
(a). Throughout the recruitment of PI kinases or phosphatases, 
(b). Rab GTPases can mediate vesicle transport along 
(e). Following membrane fusion and exocytosis, 
their inactive GDP-bound forms and targeted back to the donor 
Stenmark, 2009. 
(c). Rabs mediate 
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Cargo’s sorting is mediated by the association of transmembrane proteins, 
representing cargo or cargo receptors, with cytosolic coat complexes. This coat assembly is 
cargo-specific, and other elements, such as membrane curvature, lipid composition and Rab 
GTPases, ensure specific coat recruitment to distinct intracellular membranes. For instance, 
Rab9 and its effector TIP47 facilitate sorting of mannose-6-phosphate receptors (M6PRs) 
from late endosomes to the TGN, and Rab1 is involved in budding of vesicles from the ER. 
Rab5 complexed with GDI modulates the half-life of clathrin-coated vesicle (CCVs) pits on the 
plasma membrane and is essential for clathrin-mediated endocytosis of transferring 
receptor. Thus, depending on the event, Rab proteins might directly or indirectly influence 
vesicle budding. Rabs can regulate the concentration and/or assembly of coat components 
or help to selectively incorporate cargo molecules into the nascent vesicles. Otherwise, they 
can be a checkpoint that ensures the delivery of a vesicle to its suitable target compartment 
(Stenmark, 2009; Zerial & McBride, 2001).    
Vesicle coat complexes interfere with membrane fusion and must be shed prior to 
engagement with the acceptor membrane. Rab GTPases are also involved in this step by 
recruiting phosphoinositides (PIs) kinases or phosphatases. The conversion of PI alters PI 
composition of a transport vesicle, thus causing its uncoating through the dissociation of PI-
binding coat proteins. Once again, Rab5 and its GEF, GAPVD1 (GTPase-activating protein and 
VPS9 domain-containing protein 1), promote uncoating of clathrin coat- endocytic vesicles 
containing AP2 (adaptor protein complex) by either a direct displacement of a kinase or 
recruitment of other kinases and phosphatases, that will increase PIP2 turnover (Stenmark, 
2009).  
The movement of vesicles and organelles along cytoskeleton filaments requires 
directionality and efficacy. Local transport is facilitated by actin filaments, while long-range 
vesicle transport involves microtubules. Microtubule-dependent membrane traffic towards 
the cell periphery requires plus-end-directed motors of the kinesin family. On the contrary, 
vesicle traffic towards the pericentriolar region is powered by dynein. Rab GTPases regulate 
both types of vesicle motility, reflecting the central role they have in attaching the right 
transport vesicle to the right motor. Rab27a at the membrane of melanosomes recruits the 
adapter melanophilin which then connects the melanosomes to myosin Va. The motor 
protein modulates melanosomes transport to the cell periphery. Synaptotagmin-like protein 
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2 (SLP2) is then recruited by Rab27a to mediate the correct peripheral distribution of 
melanosomes. Rab11a
+
 endocytic recycling vesicles are linked to myosin Vb by an adaptor 
RAB11FIP2 (RAB11 family-interacting protein 2). Myosin Vb also functions as a direct effector 
of both Rab8a and Rab11a in endocytic recycling pathways. Kinesin rabkinesin6 (or KIF20A) is 
an effector of the Golgi-localized Rab6. Kinesins can be involved indirectly too, like KIF16B, 
which are recruited to endosome membranes by Rab5-induced phosphatidylinositol 3-
phosphate (PI3P) formation. The Rab7 effector Rab-interacting lysosomal protein (RILP) 
mediates late endosomes trafficking through a dynein-associated dynactin complex. 
Similarly, the Rab6 effector bicaudal D1 mediates attachment of Golgi vesicles to the dynein-
dynactin complex in Golgi-to-ER transport (Stenmark, 2009; Zerial & McBride, 2001). 
The specificity of membrane tethering and fusion is crucial to preserve organelle 
identity and proper flow of cargo within the cell. Rab proteins mediate tethering of an 
incoming vesicle by recruiting elongated tethering complexes that form long-distance 
contacts between the vesicle and the acceptor membrane. Subsequently, the specific 
topological pairing of cognate SNAREs (soluble NSF attachment protein receptor, where NSF 
stands for N-ethyl-maleimide-sensitive fusion protein) between the 2 bilayers (SNARE pins) 
ensures precision in the fusion event. SNAREs are inevitably spread throughout many cellular 
compartments, and they are enriched in some of them, which helps to identify the correct 
target and to limit nonspecific fusion events. An extra level of regulation is therefore needed 
to ensure trans-SNARE complexes fuse membranes only at the proper time and in the 
correct place (Stenmark, 2009; Zerial & McBride, 2001).    
In the early endocytic pathway, Rab5 regulates homotypic early endosome fusion and 
heterotypic endocytic vesicle to endosome fusion. This regulation is an example of how Rab 
GTPases cooperate with SNAREs and other components of the vesicle docking and fusion 
machinery. Rabenosyn 5 and EEA1 are the Rab5 effectors that mediate tethering/docking of 
early endosomes. EEA1 is a largely coiled-coil domain protein that contains 2 zinc-fingers and 
2 Rab5-binding domains at the amino and carboxyl termini, which makes it a candidate for a 
tether between Rab5
+
 vesicles. The coordination of Rab5-mediated tethering with docking 
and fusion occurs by direct interaction between rabenosyn 5 and vacuolar protein sorting-
associated protein 45 (VPS45), a member of the Sec1 family of SNARE regulators. 
Furthermore, EEA1 and rabenosyn 5 can also interact with the endosomal SNAREs syntaxin 6 
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and syntaxin 13, and syntaxin 7 respectively. In general, the concentration of Rab effectors 
within a restricted membrane area would increase the apparent affinity and enhance the 
rate of Rab effectors-SNARE and SNARE-SNARE complex formation. Likewise, these 
interactions contribute to the steady-state localization of SNAREs, despite their regular cycle 
between organelles. Membrane fusion is then achieved by architectural arrangement and 
bridging of trans-SNARE pairs which involves conformational changes of both membrane 
complexes (Stenmark, 2009; Zerial & McBride, 2001).   
Vesicle tethering at the Golgi, however, functions by permanent association of some 
Rab effectors with the Golgi matrix, instead of being recruited, like in the case of COPII (coat 
protein) vesicle-mediated transport between the ER and the Golgi. Rab1, present at the 
Golgi, recruits the tethering protein p115 during COPII vesicle budding, but fusion of the 
vesicles with the cis-Golgi requires an additional Rab1 effector. GM130 is a subunit of a 
tethering complex that is permanently associated with the cis-Golgi, and interacts with p115, 
which in turn can also bind to and regulate SNARE proteins. Rab1 is the key regulatory factor 
in this process that is recruited by its GEF, the multi-protein complex TRAPP (transport 
protein complex), to COPII-coated ER-derived vesicles to assembly its accessory factors. Thus 
Rab1-TRAPP tether the incoming vesicles to the Golgi membrane for SNARE-mediated fusion 
(Hutagalung & Novick, 2011; Stenmark, 2009).  
Exocytosis studies also revealed the role of Rab proteins in controlling SNARE 
complexes. Rab27a controls docking of exocytic dense-core vesicles to the plasma 
membrane via its effector granuphilin (or SLP4). Granuphilin interacts directly with the Sec1-
related munc 18-1 (also known as syntaxin-binding protein 1). This docking step is controlled 
by another Rab27a- and Rab3-effector, rabphilin, through an interaction with SNAP25, a 
plasma membrane SNARE synaptosomal-associated protein 25. This SNARE is also important 
for the exocyst tethering. The exocyst is an octameric complex that tethers secretory vesicles 
to the plasma membrane in preparation for fusion. It is recruited by the vesicle associated 
Rab Sec4-interaction with one of its subunits, Sec15, and it has both direct and indirect 
interactions with components of the SNARE machinery. The exocyst subunit Sec6 interacts 
with Sec9, a trans-SNARE and SNAP25 homolog found at the plasma membrane (Hutagalung 
& Novick, 2011; Stenmark, 2009). 
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Following membrane fusion and exocytosis, Rab GTPase is converted to its inactive 
GDP-bound form. Targeting of Rab-GDI complex back to the membrane is mediated by 
interaction with a membrane-bound GDF. Rab protein is then converted into the active GTP-
bound state, ready for another trafficking cycle (Stenmark, 2009). 
 
1.3.4. Harmonization of Rab GTPases’ functions 
Although Rab proteins are localized on the same organelle, they are spatially 
segregated in defined membrane microdomains, which are referred to as Rab domains 
diverging in their lipid composition. Both early and recycling endosomes are enriched in 
multiple combinations of Rab4, Rab5 and Rab11 domains. These are dynamic but do not 
significantly intermix over time. Early endosomes contain separate domains of Rab5 and 
Rab4, which are involved in fusion and endocytic recycling, respectively. The recycling 
endosome contains domains enriched in Rab4 and Rab11, crucial for vesicle trafficking from 
the early endosome and to the plasma membrane, respectively. In the same way, late 
endosomes contain different membrane domains that are positive for Rab7 and Rab9 that 
mediate trafficking to lysosomes and the TGN, respectively (Stenmark, 2009; Zerial & 
McBride, 2001).  
The existence of mechanisms for lateral segregation of Rab GTPases into membrane 
domains with distinct functions helps to explain the coordination of Rab proteins function. 
Effector proteins can associate with additional molecules in the organelle membrane, 
causing segregation. Moreover, local activation of GEF activity will also enrich a Rab GTPase 
in certain microdomains, by positive-feedback loops-mediated amplification. This 
mechanism is created when a Rab effector complex contains GEFs for the same Rab GTPase 
that recruited them in the first place, amplifying its activation and enrichment at that 
domain. Lastly, effector binding often stabilizes Rab proteins in their GTP-bound 
conformations at the membrane and some Rab effectors contain separate binding sites for 2 
or more different Rab GTPases. This feature is particularly important for membrane 
interactions in trans conformation during vesicle tethering, for the maintenance and 
cooperation between separate Rab domains in cis conformation. The Golgi coiled-coil 
protein GCC185 is an example of an effector that binds different Rab GTPases: it localizes to 
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Golgi membranes through interactions with Rab6 and Arl1, and it contains multiple other 
Rab-binding sites (Stenmark, 2009). 
PIs also play a role on the recruitment of effector proteins to membranes, and Rab 
GTPases confer membrane identity by controlling local levels of PIs. PI levels are also 
controlled by cyclical regulation by phospho-regulatory enzymes. The D-myo-inositol head 
group of PIs can be modified at the hydroxyl groups at the 3’ position, 4’ position and/or 5’ 
position to generate 7 different possible phosphorylated species. This PIs’ network is 
controlled by dedicated PI kinases and phosphatases, which create a switch between distinct 
biochemical states. PI lipids serve to recruit specific protein complexes to membranes, 
thereby cooperating with Rab proteins in 3 ways, described below. First, Rabs and PIs can act 
in interdependent pathways, in which one acts as an effector and recruits a regulatory 
enzyme for the other. Second, both can cooperate in shared recruitment of common 
effectors with dual recognition domains. This increases the affinity and specificity of effector 
localization, and is mostly important for the specificity in responses to PI subpools at distinct 
membrane compartments. Third, Rab proteins and PIs can be under coordinated regulation 
at the same enzyme complex. The simultaneous regulation of Rabs and conversion of PIs is 
needed for membrane progression or maturation. Thus Rab proteins might control cascades 
of PI phosphorylation and dephosphorylation reactions to precisely define the PI 
composition in restricted membrane domains (Jean & Kiger, 2012; Stenmark, 2009). 
Control of PI metabolism provides a mechanism for crosstalk between 2 Rab 
GTPases, as it happens with the retromer coat complex in the sorting of cargo that is 
destined for recycling from endosomes and the TGN. Rab5 mediates the formation of PI3P 
on endosome membranes, which in turn recruits the retromer subunits SNX1 and SNX2. 
These subunits detect PI3P and the high membrane curvature found in endosomal tubules, 
therefore associating with the cargo-interacting retromer subcomplex VPS26-VPS29-VPS35, 
which is an effector of Rab7. Rab conversion is then an additional mechanism for ensuring 
crosstalk between 2 Rabs in the same pathway: it requires the recruitment of a GEF for one 
Rab GTPase by another Rab GTPase that acts upstream. This is elegantly demonstrated by 
the maturation of Rab5
+
 early endocytic structures into Rab7
+
 structures (Figure 1.13). Rab5 
activates Rab7 until it reaches a threshold upon which it inactivates Rab5 through a 
negative-feedback loop. The negative effect involves Rab7-mediated recruitment of a Rab5 
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GAP and it ensures a rapid inactivation of Rab5 as soon as a certain level of Rab7 has been 
reached (Stenmark, 2009). 
Figure 1.13 – Rab conversion in early endosome maturation as an example of 
coordination of Rab functions. The early endosomes are partially marked by the presence of 
Rab5 and its effectors, EEA1 and Rabenosyn5 (1). Rab5-mediated recruitment of the HOPS 
complex initiates a Rab cascade, as its subunit VPS39 is a Rab7 GEF (2). Gradual inactivation 
and replacement of Rab5 and its effectors along with the recruitment and activation of Rab7 
and its effectors leads to maturation of early into late endosomes (3). GDI-Rab complex 
mediates Rab protein membrane delivery and extraction. Adapted from Grosshans, Ortiz, & 
Novick, 2006.  
 
1.3.5. Rab GTPases and receptor signaling  
Plasma membrane receptors transfer the extracellular stimuli to the cellular interior 
and initiate signaling cascades that finally result in a physiological response. Endocytosed 
receptors are shuttled to early endosomes, commonly regarded as a central sorting station. 
In case cells need to stay desensitized for certain cues, the receptors are sorted to late 
endosomes and finally to lysosomes for degradation. If cells need to be resensitized for the 
corresponding stimulus, the receptor is shuttled back to the plasma membrane directly or 
via recycling endosomes. Among the multiple regulators that relay receptor signaling to the 
endosomal membrane trafficking machinery are the Rab GTPases, as briefly exemplified 
below (Platta & Stenmark, 2011).  
Endosomal Rab23 is important for attenuation of Shh signaling downstream of Shh 
receptor, patched 1, and its effector, smoothened. Likewise, the late-endosomal Rab7 
controls apoptosis downstream of growth factor withdrawal. The most well characterized 
example of a Rab protein involvement in receptor signaling and trafficking belongs to Rab5-
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mediated events that occur downstream of an active growth factor receptor, like epidermal 
growth factor receptor (EGFR) and VEGFR2, members of the RTKs family (Figure 1.14) 
(Stenmark, 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 – Rab GTPase modulation of growth factor receptor signaling. Signaling 
cascade is initiated upon growth factor binding to its receptor. Tyrosine residues are 
phosphorylated with subsequent recruitment and activation of Ras GEF SOS1. Rab5 is 
activated via GEF RIN1, a Ras-effector, and stimulates macropinocytosis through activation of 
its effector N-terminus of tre (RN-tre). RN-tre is recruited by associating with epidermal growth 
factor receptor kinase substrate 8 (EPS8) and RAC1 adaptor E3B1, and controls actin dynamics. 
Rab5 is indirectly involved in cell migration (through Rab5-dependent translocation of RAC1 to 
endosomes), survival (through Rab5 effector APPL1 that mediates the activity of AKT1) and 
transcription [through the nuclear translocation of APPL1 and APPL2 and their interaction with 
nucleosome remodeling and histone deacetylase (NuRD) complex and chromatin remodeling]. 
Adapted from Stenmark, 2009. 
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Activation of Rab5 facilitates receptor trafficking through the stimulation of 
endosomal fusion, and transmits signals for cytoskeletal regulation. Binding of a growth 
factor to its receptor causes receptor’s phosphorylation on its tyrosine residues, leading to 
the recruitment and activation of the Ras GEF SOS1, and consequent activation of Ras. Ras-
effector RIN1 acts as a GEF for Rab5, activating it. Rab5 stimulation of macropinocytosis 
occurs through the Rab5 effector N-terminus of tre (RN-tre or USP6NL), which controls actin 
dynamics either by direct or indirect interaction with actinin 4 protein. RN-tre is recruited to 
growth factor receptors by associating with epidermal growth factor receptor kinase 
substrate 8 (EPS8), a growth factor receptor-binding protein that activates RAC1 through the 
adaptor E3B1. RAC1 protein can also be activated upon Rab5-dependent endocytosis and 
recruitment of the Rab5 GEF, alsin, stimulating cell migration. Rab5 is also involved in a 
direct signaling pathway downstream of growth factor receptor trough its effectors APPL1 
and APPL2. They reside on a subpopulation of endosomes and translocate to the nucleus in 
response to growth factor stimulation. Once in here, APPL1 and APPL2 interact with the 
NuRD histone deacetylase complex, which is involved in chromatin rearrangements, and 
control gene expression and proliferation. APPL1 also mediates cell survival by activating a 
cytoplasmic signaling cascade that regulates AKT1 survival kinase activity (Stenmark, 2009).   
The first described role of Rab proteins in VEGF biology regards the internalization 
and signaling upon VEGF binding to its receptor, as referred. Rab5a and Rab7a have been 
directly implicated in both VEGFR2 trafficking and signaling in endothelial cells. This study 
shows that different effectors are recruited to VEGFR2 to impose a spatiotemporal 
framework for trafficking and signaling leading to changes in vascular physiology in response 
to VEGF-A. But recently new roles have been granted to Rab proteins, and more should 
come in the next years. Rab11 along with Arf1 and Arf6 were described as regulators of sFlt1 
trafficking along the secretory pathway in endothelial cells. Ectopic expression of dominant-
negative forms of Arf1, Arf6 and Rab11 and siRNA-mediated knockdown (KD) of these 
GTPases blocked secretion of sFlt1 during normoxic and hypoxic conditions, suggesting a role 
for these proteins in physiological and pathological conditions. Moreover, Rab25 was shown 
to be involved in pathogenesis of triple-negative breast cancer. Rab25-mediated modulation 
of VEGF and VEGFR1 expressions’ enhances apoptosis and suppresses angiogenesis and 
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invasion, suggesting a tumor suppressor function of Rab25 in breast tumors (Cheng et al., 
2010; Jopling et al., 2009; Jung et al., 2012).  
 
1.3.6. Rab GTPases in disease 
The physiological importance of Rab GTPases is reflected by the association of these 
proteins and their regulators and effectors with many diseases. Infectious, neurological and 
endocrinological diseases can result from pathogen-induced or inherited dysfunctions of Rab 
pathways, consistent with Rab crucial role for membrane trafficking in immunity and 
regulated exocytosis. Participation of Rab GTPases in cell signaling is demonstrated by the 
association of Rab dysfunctions with cancer (Stenmark, 2009). 
 
1.3.6.1. Inherited disorders associated with Rab GTPases 
Many of the monogenic diseases driven by dysfunctions in Rab GTPases and their 
effectors are rare orphan diseases, affecting only a limited number of human families. 
Despite mutations targeting ubiquitous Rabs, trafficking defects remain pathologically 
limited to specific cell types, predominantly cells in the nervous system. This is mainly due to 
the distance that vesicles have to transverse to successfully import/transport/export various 
cargoes being several magnitudes higher in neurons than in any other cell lineage (Mitra, 
Cheng, & Mills, 2011). Several diseases resulting from dysfunction of Rab proteins and/or 
their effector proteins are described below.  
Loss of function in REP1, one of the 2 REP isoforms, leads to choroideremia (CHM). 
CHM is an X-linked form of retinal degeneration of slow onset and progression, with affected 
males suffering blindness by middle age. The pathology results from degeneration of RPE 
and the adjacent layers, the choroid and the photoreceptors. The limited phenotype of REP1 
dysfunction can be explained by the presence of the REP2 isoform, which can compensate 
for the loss of REP1. However, the compensation is not absolute as Rab27a is poorly 
geranylgeranylated in CHM cells, suggesting that retinal degeneration in CHM could be 
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caused in part by loss of Rab27a function, as there is accumulation of unprenylated Rab in 
the RPE (Seabra, Mules, & Hume, 2002; Stenmark, 2009).  
A rare form of nonspecific X-linked mental retardation is caused by a mutation in Rab 
GDI1, one of the 2 GDI isoforms in humans. Rab GDI1 is essential for neurotransmission, 
along with Rab3a, as evinced by onset of neuronal hypersensitivity and epileptic seizures in 
Rab Gdi1-deficient mice. Rab3 is also implicated in Warburg Micro and Martsolf syndromes, 
where mutations in the catalytic and non-catalytic subunits of Rab3 GAP result in failure of 
exocytic release of ocular and neuro-developmental trophic factors. Symptoms include 
developmental abnormalities of the eye and the nervous system, and microgenitalia (Mitra 
et al., 2011; Stenmark, 2009). 
The Griscelli syndrome (GS) is a rare autossomal recessive disorder caused by 
mutations in MYOSINVA (GS1), RAB27A (GS2) or melanophilin (MLPH) (GS3) genes, and 
characterized by pigment dilution of the hair (silvery hair), due to accumulation of pigment 
in melanocytes, and by hemophagocytic syndrome caused by uncontrolled T-cell and 
macrophage activation. Rab27a was the first Rab to be implicated in a human genetic 
disease. GS2 patients have impaired lytic granule exocytosis, leading to episodes of a life-
threatening uncontrolled T lymphocyte, macrophage activation and infiltration into various 
organs, including the brain, causing convulsions and neurological injury (Mitra et al., 2011; 
Seabra et al., 2002).  
Hermansky-Pudlak syndrome (HPS) is a genetically heterogeneous disorder 
characterized by partial albinism, tendency for bleeding and lysosomal accumulation of 
ceroid lipofucsin. This phenotype reflects defects in lysosomes and lysosomes-like organelles 
such as melanosomes and platelet-dense granules. Several genes have been implicated in 
HPS patients and 15 known mouse models, including gunmetal (gm). Gm mice contain a 
splice-site mutation in the Rggta gene resulting in a decreasing of RabGGT activity to 
approximately 20% of wild-type (wt). As in CHM, the gm phenotype results from partial 
defects in prenylation and function of multiple Rabs. Rab38-mutant mice (chocolate) also 
have a partial albinism, but there is little data on whether this feature contributes for HPS 
phenotype (Seabra et al., 2002).  
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Carpenter syndrome is caused by 3 truncating mutations and one missense mutation 
in the RAB23 gene. As a major regulator of the Shh pathway, RAB23 absence is manifested 
by craniosynostosis, polysyndactyly, obesity and cardiac defects. There is also evidence that 
Rab23 affects the intraflagelar transport proteins, which could contribute to obesity in these 
patients (Mitra et al., 2011).  
Genetic lipid storage disorders such as Batten disease and Niemann-Pick type C 
disease are caused by Rab GTPase inactivation, resulting in cholesterol accumulation due to 
impaired lysosomal hydrolase trafficking. Ablation of ceroid-lipofuscinosis neuronal 3 (CLN3) 
gene results in reduction in maturation of lysosomal proteins, as this gene codifies a 
lysosomal transmembrane protein that interacts with Rab7, Rab 9 and Rab11 (Agola, Jim, 
Ward, Basuray, & Wandinger-Ness, 2011). 
Bardet-Biedl syndrome (BBS) is the first ever identified ciliopathy, arising from 
defects in primary cilia formation. Rab8 and its GEF Rabin8 have been identified as critical 
players in ciliogenesis, and disruption of vesicular trafficking for the cilium causes retinal 
degeneration, obesity, hypogonadism and mental retardation, among other features. Rabin8 
is also a direct downstream effector of Rab11, implicating this Rab protein in BBS syndrome 
(Mitra et al., 2011). 
In neurological diseases Rab proteins are implicated in both Huntington’s and 
Parkinson’s disease. Huntington’s disease is a devastating neurologic disorder caused by the 
expression of mutant huntingtin (Htt) proteins. Normal Htt’s function promotes Rab 
activation and motor protein assemblies that drive vesicular transport on cytoskeletal 
networks. Loss of function of Htt causes the accumulation of abnormal intracellular protein 
aggregates and inclusions. In Parkinson’s disease, the ER-Golgi transport is disrupted due to 
mutations in α-synuclein gene (SNCA), and intracellular proteins aggregates in neurons are 
also a pathological feature. Some Rabs are described to interact with α-synuclein, as Rab3a, 
Rab5 and Rab8, suggesting the deregulation of several membrane pathways when α-
synuclein is mutated  (Agola et al., 2011; Hutagalung & Novick, 2011). 
Charcot-Marie-Tooth disease type 2B (CMT2B) disease involves a gain of function 
mutation in a housekeeping Rab that is ubiquitously expressed. The missense mutations in 
RAB7 target the conserved GTP binding and hydrolysis domain of Rab protein results in 
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altered nucleotide dissociation rates, stabilizing Rab7 GTP-bound form. Growth factor-
regulated cell survival and apoptotic pathways become therefore deregulated in neural cells, 
leading to neurodegeneration (Mitra et al., 2011). 
 
1.3.6.2. Acquired disorders associated with Rab GTPases 
Several Rabs have been implicated in the progression of multiple cancers since 
membrane traffic plays a significant role in cancer biology, primarily in loss of cell polarity 
and in metastatic transformation of tumor cells. Accordingly, aberrant endocytosis, vesicle 
targeting and receptor recycling represent emerging hallmarks of cancer. Elevated levels of 
Rab1a, Rab2b, Rab5a, Rab7b, Rab23, Rab25 and Rab38 have been reported in diverse 
cancers. The best characterized example of a Rab protein implicated in cancer is Rab25, a 
Rab closely related to Rab11 that regulates apical endocytosis and transcytosis in epithelial 
cells. Rab25 is upregulated in certain ovarian and breast cancers due to amplification of a 
chromosomal region containing the RAB25 gene. The resulting overexpression of Rab25 is 
associated with more aggressive forms of cancer and a lower patient survival rate 
(Hutagalung & Novick, 2011; Mitra et al., 2011). 
Rabs and their effectors have become targets for infectious microorganisms that 
have developed strategies to evade host defenses mechanisms by hiding and replicating in a 
hostile intracellular microenvironment. The majority of intracellular pathogens hijack Rab 
proteins involved in the endocytic pathway, thus avoiding host cell degradation machinery. 
Salmonella enterica serovar Typhimurium is such an example, where 18 Rab GTPases 
associate with their phagosomes during different stages of their maturation. Legionella 
pneumophila, on the other hand, recruits membranes from the ER and the ERGIC to create a 
replicative intracellular niche. Upon alveolar macrophages’ infection, these bacteria secrete 
2 proteins that directly target the GTPase cycle of Rab1. The functional consequence of their 
expression is that L. pneumophila-containing vacuoles recruit Rab1 and behave functionally 
as ER or ERGIC membranes, thereby evading destruction in lysosomes (Hutagalung & Novick, 
2011; Stenmark, 2009). 
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Several intracellular pathogens have developed strategies for interfering with Rab 
GTPases function. Helicobacter pylori secretes a toxin that hijacks Rab7, localizing it to the 
bacterium-containing phagosome, thereby creating a protective niche for intracellular 
survival of the bacterium. By contrast, mycobacteria use a distinct strategy by secreting 
factors that prevent Rab7 acquisition by the phagosome, thus preventing phagosome 
maturation. Listeria monocytogenes and serovar Typhimurium secrete factors that prevent 
the recruitment or activation of Rab5. Chlamydia also avoids being directed to host 
lysosomes by releasing proteins that prevent recruitment of Rab5, Rab7 and Rab9. In Chagas 
disease, Trypanosoma cruzi impairs endocytosis in the host by altering the recycling Rab7 
and Rab11 (Hutagalung & Novick, 2011; Mitra et al., 2011; Stenmark, 2009). 
Some viruses also hijack Rab-dependent pathways to induce their own 
internalization. Group B coxsackievirus enters epithelia through internalization of tight 
junctions by a mechanism that is dependent on Rab5 and Rab34. In the case of hepatitis C 
virus, the host Rab1 GAP is hijacked by a viral non-structural protein to promote viral 
membrane-associated RNA replication and propagation (Mitra et al., 2011; Stenmark, 2009). 
 
1.3.6.3. Rab GTPases as therapeutic targets 
Due to the importance of Rab proteins in maintenance of physiological cellular 
conditions we can infer that by controlling Rab proteins’ functions through pharmacological 
or genetic modulation it would be possible to establish important new therapies, not only 
for genetic diseases but also for some of the most common diseases affecting the 
population. There are some perspectives on potential therapeutic modulation of GTPase 
activity through small molecule interventions, by targeting membrane association, 
nucleotide binding or exchange and protein-protein interactions. Currently, there are several 
studies under development, such as siRNA and stapled peptides, that aim at “target the 
untargetable”, raising the future possibilities of targeting Rab GTPases’ function (Agola et al., 
2011; Seabra et al., 2002).  
Blockage of membrane recruitment, through inhibition of protein prenylation is 
another possible strategy. However, lipid modifications are crucial for proper functioning of 
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many proteins, including GTPase families. Moreover, the activity of prenylation inhibitors 
would affect both farnesyl and geranylgeranyl transferases. Therefore, an example of such 
approach is the development of nitrogen-containing biphosphonate (NE10790), a farnesyl 
diphosphate synthase inhibitor specific for osteoclasts and macrophages. This inhibitor 
blocks bone resorption and farnesylation of numerous small GTPases including Rab6. The 
statin family of drugs, inhibitors of isoprenoids’ synthesis, can also be effective in block Rab 
GTPases’ membrane targeting (Agola et al., 2011). 
Inhibitors of guanine nucleotide binding would be expected to block activation of 
GTPases in cells, as it had been shown for Rho-family selective inhibitors. However, Rab GEFs 
and GAPs’ list is still increasing, and more studies are needed to refine the selectivity of 
competitive inhibitors or activators worth to use as a therapeutic strategy. In some cases, 
may be beneficial to target associated signaling pathways rather than directly target the Rab 
GTPase. For example, valproic acid has been used to impact pathways linked to Rab5- and 
Rab7-regulated functions. This molecule is a histone deacetylase inhibitor that promotes 
neuronal differentiation and modulates ERK pathway. Although valproic acid does not target 
GTPases directly, it has been used in CMT2B patients for improvement of neurite formation 
and alteration of gene expression and signaling (Agola et al., 2011). 
Recently, 2-hydroxypropyl-β-cyclodextrin was approved for treatment of Niemann-
Pick type C disease. This treatment was reported to relieve Rab GTPase inhibition in patients 
by reducing cholesterol levels in storage organelles. It is important to state that despite 
being useful in correction of cholesterol homeostasis, 2-hydroxypropyl-β-cyclodextrin 
derivatives can worsen protein aggregates which underlie neurodegeneration. Therefore, its 
use must be carefully monitored (Agola et al., 2011).  
So far REP1 is the only Rab protein regulator in study for ocular gene therapy. 
Lentiviral vectors carrying Chm/Rep1 cDNA transgene were proved to rescue the prenylation 
defect in CHM mouse RPE. Clinical trials using this transgene are now undergoing as an 
effort to restore REP1 activity in CHM patients (Tolmachova, Tolmachov, Tracey-white, & 
Seabra, 2012).  
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1.4. Specific aims of the work 
Despite significant progresses in the treatment and management of retinal disease, 
novel therapeutic strategies are necessary to improve efficacy and increase cure rates, as 
well as to eliminate therapy-related undesirable side effects and to improve patients life 
quality. The main target of ocular gene therapy continues to be VEGF. Nevertheless, 
intraocular anti-VEGF therapies need to be controlled, given VEGF’s role in maintenance of 
retinal physiologic homeostasis. There is clear evidence of Rab proteins and their effectors’ 
involvement in VEGF-deregulated diseases, namely those affecting RPE. As loss or corruption 
of Rab proteins’ function(s) alters cellular activity, the study of their role in VEGF secretion 
by RPE cells in vitro and in vivo should allow further progress in understanding the molecular 
pathogenesis underlying retinal degeneration and CNV. More importantly, it will also leads 
to opportunities to develop novel treatments.   
In conjunction with the current knowledge of VEGF contribution to eye diseases 
involving CNV, we are confident that this work will provide a better understanding of the 
pathogenesis behind this angiogenic growth factor in the eye. The aim of this work is to 
elucidate the molecular mechanisms of VEGF secretion involving Rab proteins by RPE cells. 
We intend to identify key regulatory proteins involved in both the secretory and endocytic, 
as well as recycling pathways of VEGF, and how their disruption could lead to retinal and 
choroidal pathology. 
In order to fulfill this work purpose, mouse RPE cell models available to study Rab 
proteins’ function will be first characterized. Thereafter, novel molecular tools to achieve 
silencing of key proteins will be developed to scrutinize the consequences of Rab proteins’ 
absence or diminished levels. Subsequently the effect of Rab proteins’ absence on VEGF 
secretion will be assessed by performing an extensive screening where different Rab 
proteins will be silenced, both individually and in multiple combinations considering their 
cellular/compartment location. The ultimate goal is to identify several Rab GTPases as 
possible important intervenient in VEGF secretion by RPE cells in vitro.   
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2.1. Materials 
Standard laboratory chemicals were obtained from Sigma-Aldrich and VWR. 
 
2.2. Tissue culture methods 
2.2.1. Growth and maintenance of mammalian cell lines 
Human embryonic kidney HEK-293A and HEK-293FT were obtained from Life 
Technologies. STAR-Rdpro cells were obtained from the European Collection of Cell Cultures 
(ECACC). Mouse RPE cell line (B6-RPE07) was kindly provided by Dr. Heping Xu (Queen’s 
University Belfast, Ireland) (M. Chen et al., 2008). Both cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Lonza) supplemented with 10% Fetal Bovine Serum (FBS) 
(Life Technologies), 100 U/mL penicillin and 100 µg/mL streptomycin (Pen Strep) (Life 
Technologies) (DMEM complete). 
Human RPE cell line ARPE19 and Madin Darky Canine Kidney (MDCK) cell line were 
obtained from American Type Culture Collection (ATCC). These cells were cultured in 1:1 
mixture of DMEM and Ham’s F12 nutrient mixture (DMEM-F12) (Lonza) containing 10% FBS 
and Pen Strep.  
For cell polarization studies Transwell® inserts (Corning) of 6.5 mm diameter were 
used. These inserts contain a polyester membrane of 0.4 µm pore size. MDCK cells required 
a previous collagen-A coating for 3 hours at 37
o
C, and then 1x10
5
 cells were plated/insert in 
DMEM-F12 containing 1% FBS and Pen Strep. 
All cell lines were maintained at a humidified cabinet at 37
o
C and 5% CO2.  
 
2.2.2. Mouse RPE primary cells isolation 
C57BL/6 mice were bred and maintained in Faculdade de Ciências Médicas’ Animal 
House (Alvará de utilização de animais ao abrigo da Portaria nº 1005/92 de 23 de Outubro). 
Mice were sacrificed by cervical dislocation between day 20 and day 24 and eyes were 
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collected in phosphate buffer saline (PBS) (137 mM NaCl, 2,7 mM KCl, 10 mM Na2HPO4 and 2 
mM KH2PO4). In the hood, eyes were dipped in 70% ethanol and then placed in DMEM, 
without any FBS or Pen Strep. Eyes were incubated in 2% dispase (Life Technologies) in 
DMEM for 30 minutes at 37
o
C for gentle dissociation of tissues. Enzymatic activity was 
stopped by washing eyes twice with DMEM complete. Eyes were positioned in a filter paper 
embedded in PBS and cornea, lens and vitreous were removed by piercing with the scalpel 
and cutting the front. Eye cups were subsequently incubated in DMEM complete for 8 
minutes at 37
o
C, 5% CO2. Detachment of neuroretina was performed by gentle pressing the 
back of the scalpel on the eye cup. For release of RPE sheets and individual cells, eye cups 
were flushed with 70 µL pulses of DMEM complete. Medium and cells were spinned down at 
260 g for 4 minutes. Cell pellet was ressuspended in DMEM supplemented with 5% FBS, Pen 
Strep, 50 ng/mL Amphotericin B and 2.5 mg/mL Gentamycin and plated in 96-well plates. 
Medium was changed after 48 hours and everyday afterwards.  
For Transwell® insert cultures a serum-free epithelial medium (Complete epithelial 
cell media – CECM) (Sera Lab) was used. Inserts were coated with fibronectin (5 µg/mL) for 3 
hours at 37
o
C before cell plating.   
 
2.2.3. Transfection of mammalian cells with plasmid DNA 
HEK-293FT cells were grown in 6-well plates until 80-90% confluence was reached 
and transfection of plasmid deoxyribonucleic acid (DNA) was carried out using the cationic 
lipid-based Lipofectamine™ 2000 (Life Technologies). The DNA mix was prepared using 1 µg 
of miRNA expression vector and 0.5 µg of positive control plasmid in Opti-MEM I (Life 
Technologies). Separately, Lipofectamine™ 2000 mix was prepared in Opti-MEM I in a ratio 
of 3 µL Lipofectamine™ 2000/1 µg DNA. The 2 solutions (total volume: 500 µL) were mixed 
gently and incubated for 45 minutes at room temperature (RT) to allow DNA-liposomal 
complexes to form. 
 
67 
 
Cells were washed with PBS, and then the transfection mix was added gently to each 
well and incubated for 6-7 hours at 37
o
C, 5% CO2. Transfection medium (DMEM without Pen 
Strep and FBS) was added to the cells and left to incubate overnight. Next morning 
transfection mix and medium were removed and replaced by DMEM complete, and 
incubated for an additional 8 hours before harvesting.  
 
2.2.4. Production of viral stocks 
2.2.4.1. Production of adenoviruses 
On the day before transfection, HEK-293A cells were plated in T25 flasks in DMEM 
complete to reach 80% confluence on the next day. Five micrograms of purified plasmid DNA 
of pAd-DEST expression construct were digested with PacI (New England Biolabs) in order to 
expose the left and right viral inverted terminal repeats (ITRs). This step allowed the removal 
of bacterial sequences and proper viral replication and packaging. 
The transfection proceeded as previously described. Medium containing adenoviral 
particles and cells was collected when approximately 80% cytopathic effect (CPE) was visible 
(10-13 days post-transfection). To obtain a crude viral lysate 3 cycles of freeze at -80
o
C/thaw 
at RT were used, followed by centrifugation at 4100 g for 10 minutes to pellet cell debris. 
This first lysate was used to prepare all re-amplifications of viral particles. By adding 500 µL 
of the initial viral particles into a new 10-cm dish of confluent HEK-293A cells, the CPE will be 
much quicker and the viral titer will increase. The re-amplified supernatant was collected 
and prepared as described. Both first and second viral preparations were aliquotted and 
stored at -80
o
C.  
Titration of adenoviral stocks was performed using B6-RPE07 cells, the cell line of 
interest. Cells were plated at a known density and transduced with serial dilutions of 
adenoviral stock. After 24 hours cells were harvested and cell pellet was prepared for flow 
cytometry. The percentage of transduced cells was determined by counting green 
fluorescent protein (GFP)
+
 cells (total of 30000 events) using FACSCalibur (BD Biosciences). 
The viral titer was expressed as green fluorescent units per mL (gfu/mL). 
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2.2.4.2. Production of lentiviruses 
The production of lentiviral stocks preferentially requires a cell line that expresses the 
proteins needed for a correct packaging of the virus. STAR-Rdpro cells stably express 
synthetic HIV Gag-Pol, HIV tat and HIV rev sequences and RD114 envelope protein that help 
on the packaging of the virus. Despite so, 3
rd
 Generation Packaging System plasmids 
(Addgene) were co-transfected with pLenti6/V5-GW/miR. The plasmids pMD2.G, 
pMDLg/pRRE and pRSV-Rev encode for more advanced packaging and envelope viral 
proteins and are crucial for the improvement of lentiviral stocks’ quality. 
On the previous day, STAR-Rdpro cells were plated in 10-cm dishes in DMEM 
complete to reach 90% confluence on the next day. DNA mixture was prepared using 3 µg of 
purified plasmid DNA of pLenti6/V5-GW/miR expression construct, 1.5 µg of pMD2.G, 2 µg 
of pMDLg/pRRE and 1 µg of pRSV-Rev. The DNA-liposomal complexes were set up and 
incubated at RT for 45 minutes. The transfection proceeded as previously described. 
Supernatants were collected 72 hours post-transfection and centrifuged at 4100 g for 10 
minutes to pellet cell debris. Aliquots of viral stocks were stored at -80
o
C.  
Titration of lentiviral stocks was performed using B6-RPE07 cells. Cells were plated at 
a known density and transduced with serial dilutions of lentiviral stock. Polybrene® (6 
µg/mL) was added to facilitate virus entry on cells. After 72 hours, cells were harvested and 
prepared for flow cytometry. The percentage of transduced cells was determined by 
counting GFP
+
 cells (total of 30000 events) using FACSCalibur (BD Biosciences). The viral titer 
was expressed as gfu/mL. 
 
2.2.5. Cytotoxicity Assay 
Cells were plated in a 24-well plate and treated with the compound of interest. MTT 
(3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) in Opti-MEM I was added to 
the wells (500 mM) and samples were incubated for 3 hours at 37
o
C. Removal of MTT 
solution preceded addition of 200 µL of acidic isopropanol (0.04 M HCL in absolute 
isopropanol) for solubilization of formazan salts. The optical density was measured at 595 
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nm (iMark, BioRad). Percentage of cells’ survival was determined relative to untreated cells 
and is presented as mean average value ± standard deviation (SD). 
 
2.2.6. Immunofluorescence 
Cells used for immunofluorescence were seeded at appropriate confluence. When 
ready, cells were washed with PBS and then fixed with 4% (w/v) paraformaldehyde (PFA) in 
PBS for 15 minutes at RT. After washed twice, cells were incubated with 50mM NH4Cl for 10 
minutes and permeabilized for 45 minutes in 0.05%/0.5% BSA (bovine serum albumin) in 
PBS. All incubations and washings were done using this solution. Incubation with primary 
antibodies followed, at the appropriate dilution, for 60 minutes. Four washings preceded 60 
minutes incubation with Alexa 488-conjugated and Alexa 547-conjugated secondary 
antibodies (Invitrogen, 1:1,000). Samples were mounted using ProLong Gold Antifade 
Reagent with DAPI (4',6-diamidino-2-phenylindole) (Life Technologies) and visualized either 
in an inverted  microscope (Olympus IX51 U-RFL-T) or confocal microscope (LSM 710 from 
Carl Zeiss).  
Table I – Primary antibodies used for immunofluorescence. 
Antigen Source Dilution 
ZO1 Zymed 40-2200 1:100 
ATP1α1 Abcam ab7671 1:100 
ATP1β1 Abcam ab8344 1:100 
 
 
2.2.7. Flow cytometry 
In order to access viral-driven GFP expression using flow cytometry cells were 
washed in PBS/BSA 0.1% once after tripsinization. Cells were then fixed in PBS/BSA 0.1%/PFA 
0.4% and kept at 4
o
C until acquisition. Samples were acquired using FACSCalibur ™ (BD 
Biosciences) and analyzed with the program FlowJo (Tree Star). 
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2.3. DNA techniques 
2.3.1. Transformation of competent cells 
Escherichia coli (E. coli) DH5α competent cells (Life Technologies) were transformed 
by heat-shock protocol. Plasmid DNA was added to the cells in pre-cooled tubes and kept on 
ice for 30 minutes. Cells were heat-shocked for 1 minute at 42
o
C and then placed again on 
ice for 2 minutes. One mL of pre-warmed Luria Broth (LB) medium (10 g/L NaCl, 10 g/L 
tryptone, 5 g/L yeast extract) was added to the cells and these were incubated for 90 
minutes at 37
o
C under agitation [250 revolutions per minute (rpm)]. Cells were spinned 
down and platted on selective LB agar (LB medium + 15 g/L agar) containing the appropriate 
antibiotic (Ampicilin 50 µg/mL, Kanamycin 50 µg/mL and Spectinomycin 50 µg/mL). Plates 
were incubated overnight at 37
o
C. Single colony PCR screening was performed next day to 
evaluate which colonies contain the expected insert. PCR products were run on a TAE (40 
mM Tris-acetate, 1 mM EDTA) agarose gel of appropriate pore diameter. One or 2 colonies 
were selected for DNA isolation and restriction endonuclease digestion. 
 
2.3.2. Isolation of DNA 
Plasmid DNA was isolated using Qiagen kits according to the manufacturer’s 
instructions. DNA concentration was determined by measuring optical density (OD) at 260 
nm (1 OD = 50 µg/mL) on a SmartSpec™ Plus spectrophotometer (BioRad). 
 
2.3.3. Restriction endonuclease digestion 
DNA digestion was performed using 1 µL of each restriction enzyme (1U/1 µL, Takara 
Bio Inc.) in the appropriate buffer according to the manufacturer’s instructions. Digestions 
were incubated for 90 minutes at 37
o
C and then analyzed by agarose gel electrophoresis.  
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2.3.4. Polymerase Chain Reaction (PCR) 
Standard polymerase chain reactions (PCR) were performed using: 
- 0.1 µM of both forward and reverse primers 
- 0.25 mM deoxynucleotide triphosphates (dNTPs) 
- Appropriate enzyme buffer 
- 50 µM MgCl2 
- Taq polymerase (Promega) 
- 1:100 DNA template or isolated colony 
The PCR program was performed in MyCycler (BioRad) and standard conditions were 
the following: 2 minutes initial denaturation step at 95
o
C; 32 cycles of 20 seconds 
denaturation step at 95
o
C, 30 seconds annealing step at 58
o
C and 1 minute/kb at 72
o
C; 10 
minutes final extension step at 72
o
C. 
 
2.3.5. DNA sequencing 
Primer extension sequencing was performed using BigDye® Sequencing kit (Applied 
Biosystems) starting from 1 µg DNA and 0,1 µM of appropriate primer. Capillary 
electrophoresis was carried out using a Hitachi sequencer. 
 
2.3.6. Generation of miRNA-containing viral plasmids 
2.3.6.1. Design of single-stranded DNA oligos  
In order to design the desired 2 single-stranded (ss) DNA oligonucleotides, one 
encoding the target pre-microRNA (miRNA) (top-strand oligo) and the other its complement 
(bottom-strand oligo), the BLOCK-iT™ RNAi Designer web tool (Life Technologies) was used. 
This tool makes use of an optimized, proprietary algorithm to design miRNA sequences with 
100% homology to their targets.  
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The top-strand oligo has a 4-nucleotide, 5’ overhang (TGCT) complementary to the 
expression vector, which is required for directional cloning. A 5’ G and a short 21-nucleotide 
antisense sequence (mature miRNA) derived from the target gene comes next. Then there is 
a loop sequence, as a short spacer of 19 nucleotides, and finally a short sense target 
sequence with 2 nucleotides removed to create an internal loop. 
 
2.3.6.2. Generation of double-stranded DNA oligos 
In order to generate double-stranded (ds) DNA oligos it was necessary to anneal 
equal amounts of the top and bottom strand oligos. The annealing reaction was performed 
in 20 µL of total volume, including 50 µM of each ss oligo and 10X Oligo Annealing Buffer 
(Life Technologies). The PCR program was run twice as follows: 
- 5 minutes at 95oC; 
- 1 minute at 72oC; 
- 10 minutes temperature gradient from 72oC to 25oC; 
- 10 minutes at 25oC. 
The efficiency of the annealing was checked by agarose gel electrophoresis on 2.5% 
agarose gel prepared with TAE buffer. Gels were run at 30 milliamps (mA) overnight to allow 
a proper separation of the products.  
The heavier fragments were excised and DNA was isolated using the QIAquick Gel 
Extraction Kit (Qiagen) following the manufacturer’s instructions. The final elution was 
performed using 20 µL of 10 mM Tris HCl pH 8.  
 
2.3.6.3. Generation of DNA expression clones 
The ds DNA oligo was cloned into the pcDNA
™
6.2-GW/EmGFP-miR vector from 
BLOCK-iT™ Pol II miR RNAi Expression Vector kit (Life Technologies). Ligation reactions 
included 1 µL of the ds oligo DNA (1:2,000 dilution), 1 µL of linearized pcDNA
™
6.2-
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GW/EmGFP-miR vector (5 ng), 5X ligation buffer and 1 U T4 DNA ligase. The reactions were 
incubated overnight at RT. 
Two microliters of the ligation reaction were transformed into One Shot®TOP10 
Chemically Competent E. coli (Life Technologies) as previously described. Screening of the 
positive clones was performed using primers recommended by the manufacturer (EmGFP 
forward primer, GGCATGGACGAGCTGTACAA, and miRNA reverse primer, 
CTCTAGATCAACCACTTTGT). For each construct 3 positive clones were chosen for DNA 
isolation and transient RNAi analysis. 
 
2.3.6.4. BP/LR recombination reaction 
The basis of Gateway® Technology includes 2 recombination reactions to create a 
desired destination vector. This universal cloning method takes advantage of the site-specific 
recombination properties of bacteriophage Lambda to provide a rapid and efficient way to 
move the DNA sequence of interest into multiple vector systems. The cloning of the pre-
miRNA expression cassette into adenoviral and lentiviral vectors involved pAd/CMV/V5-
DEST™ and pLenti6/V5-DEST™ plasmid backbones, respectively. 
The first recombination reaction was performed between the expression clone of 
interest (150 ng) linearized by EagI restriction enzyme and the donor vector (150 ng) using 
BP clonase™ II enzyme mix (total volume: 10 µL). The mix was incubated overnight at 25
o
C. 
The second recombination reaction was set up using 150 ng of the appropriate 
destination vector and a fraction of the previous BP reaction, catalyzed by LR Clonase™ II 
enzyme mix. The reaction was incubated for 6 hours at 25
o
C.   
Three microliters of LR reaction were used to transform One Shot® Stlb3™ 
Competent E. coli (Life Technologies) and isolated DNA from chosen colonies was obtained 
to produce adenovirus and lentivirus.  
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2.3.7. Gene expression quantification by quantitative reverse transcriptase PCR 
(qRT-PCR)  
Total RNA was obtained from cells using a RNAse Mini kit (Qiagen) according to the 
manufacturer’s instructions. One µg of RNA was converted into complementary DNA (cDNA) 
using random primers and SuperScript II reverse transcriptase (Life Technologies). Each 
amplification reaction was performed using 10 ng of cDNA and SYBR Green Master Mix. 
Samples were run in quadruplicate using the ABI Prism 7900HT System (Applied Biosystems), 
and were standardized to actin as an endogenous control (mouse actin-β forward primer, 
AGCCATGTACGTAGCCATCC, and reverse primer, CTCTCAGCTGTGGTGGTGAA). Results were 
expressed as the relative expression using the delta-delta Ct method.  
 
2.3.8. Enzyme-Linked Immunosorbant Assay (ELISA) 
Conditioned media were collected from cell lines and primary cells and assayed for 
mouse VEGF levels by ELISA (VEGF120 and VEGF164) (R&D Systems) according to the 
manufacturer’s instructions. The capture antibody goat anti-mouse VEGF was diluted in PBS 
to 0.4 µg/mL and immobilized overnight in proper 96-well ELISA plates. The biotinylated 
detection antibody was used at a concentration of 100 ng/mL.  
 
2.4. Protein techniques  
2.4.1. Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
To separate proteins according to their molecular weight a SDS-PAGE was performed. 
The pergentage of mono/bis acrylamide used was 12.5% for the resolving gel and 5% for the 
stacking gel, both were polymerised using Ammonium Persulfate (APS) and N,N,N,N’-
Tetramethyethylene-diamine (TEMED). Resolving gels were prepared using 1.5 M Tris HCl, 
0.4% SDS at pH 8.8. The stacking gels were prepared using 0.5 M Tris HCl, 0.4% SDS at pH 
6.8.  
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Samples were mixed with Laemmli buffer (Laemmli 2X buffer: 4% SDS, 10% 2-
mercaptoehtanol, 20% glycerol, 0.004% bromophenol blue and 0.125 M Tris HCl) in the 
appropriate ratio, sonicated for a few seconds and then boiled for 5 minutes for protein 
denaturation. Electrophoresis was performed at 30 mA per gel in running buffer (25 mM Tris 
base, 190 mM glycine and 0.1% SDS) and prestained molecular markers (Bio-Rad 
Laboratories) were loaded for molecular weight calibration.  
 
2.4.2. Western blotting 
Polyvinylidene fluoride (PVDF) membranes were used for blotting (Immobilon, 
Millipore). They were activated by pre-soaking in 100% methanol and equilibrated in 
transfer buffer (25 mM Tris base, 190 mM glycine and 10% methanol). Proteins were 
transferred to the PVDF membrane for 90 minutes at 500 mA. The membranes were washed 
in PBS + 0.02% Tween20 (PBST). To prevent non-specific binding of the antibodies the 
membranes were blocked in 4% non-fat milk in PBST for 60 minutes at RT under agitation, 
followed by 3x8 minutes washes in PBST. Appropriate primary antibody dilutions were 
carried out in PBST and membranes were incubated for 60 minutes at RT, under agitation. 
Residual antibody was removed by washing the membrane 3x8 minutes. Horseradish 
peroxidase (HRP)-conjugated secondary antibodies (1:10,000) were used in 4% non-fat milk 
in PSBT and membranes were incubated for 60 minutes at RT, under agitation. The 
membranes were then washed 3x8 minutes in PBST. Membranes were incubated with ECL 
Plus (GE Healthcare) and chemiluminescence was detected using ChemiDoc (BioRad). 
Western Blot analysis was performed using Fiji software.  
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Table II – Primary antibodies used for Western Blot experiments. 
Antigen Source Dilution 
Actin Invitrogen 1:10,000 
GFP SICGEN Lot002260412 1:500 
Calnexin SICGEN Lot0037160412 1:2,000 
GAPDH SICGEN Lot0049090412 1:7,500 
CRALBP Abcam ab15051 1:1,000 
RPE65 Abcam ab13826 1:1,000 
VEGF Abcam ab3109 1:200 
 
2.4.3. Determination of protein concentration 
The bicinchoninic acid (BCA) colorimetric method was used according to the 
manufacturer’s instructions (Pierce). A standard curve ranging from 0 – 2,000 µg/mL was 
performed using BSA. Samples were mixed with appropriate buffer and incubated for 30 
minutes at 37
o
C. The OD was measured at 595 nm (iMark, BioRad).  
 
2.5. Statistical analysis 
 
Statistical significance was determined using the two-tailed non-parametric T test. 
Differences were considered statistically significant when p≤0,05 (*0,05≤p<0,01; 
**0,01≤p<0,001; ***p≤0,001). Analyses were performed using Graphpad Prism 6 software.  
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3.1. Characterization of in vitro models of RPE 
3.1.1. State-of-the-art 
The search for cure of diseases has been the main motif for people to explore more 
and more accurate methods of investigation. Human body continues to be the best model, 
and other in vivo models are fundamental as well. However, in vitro models are needed to 
first test potential therapeutic agents and techniques, and to avoid their harmful effects.  
Back in the 19
th
 century, it was possible to keep in culture tissue explants from the 
chicken embryo. This was the first step towards cell culture as we know it nowadays. One 
hundred years ago, in 1912, Alexis Carrel reported his experiments about how to prolong the 
life of a tissue outside the organism. He was aware of the limited time cells can be cultivated 
in vitro and proposed that removal of toxic substances and renewal of the medium could 
prevent cell death. Carrel was the pioneer of the cell passage concept: longevity of cells was 
improved in aseptic environment as long as cell nutrition was accessible (Carrel, 1912).  
Ten years later, in 1922, epithelial cell culture was reported for the first time, and cell 
culture was born. By then it was believed that passage of cells could last forever. When 
George Gey reported the infinite culture of cells from a cervical carcinoma the previous 
paradigm was reinforced, and HeLa cells became the first establish malignant cell line (Gey, 
1952). 
Meanwhile Leonard Hayflick discoveries challenged Carrel’s views. The phenomenon 
of cellular ageing arose as he described how normal human fibroblasts had finite replicative 
capacity. He established the Hayflick’s Limit as a consequence of telomeres’ shortening 
every time DNA replicates, with cells becoming senescent when replication stops. On the 
contrary, neoplasic cells overcome this limit and give rise to tumors if appropriate conditions 
arise. Since this milestone telomere biology plays a role in human ageing and cancer 
investigations (Hayflick & Moorhead, 1961; Shay & Wright, 2000).     
Cell culture-based research only succeeds if cells retain most of their characteristics 
as they multiply in vitro, and for RPE specifically, this is a very sensitive issue. Attempts to 
cultivate RPE in vitro started in the 70’s with choroid explants and have been improved all 
80 
 
over the years. The main challenges regarding RPE cell culture result from 
microheterogeneity of cells and lack of signals from the choroid and the neural retina in 
vitro. The heterogeneity present in the eye is converted in cell shape variants when RPE cells 
are released from monolayers to growth in culture. Apparently, they form homogeneous 
monolayers of cells in situ, but, although looking similar, RPE cells are not identical (Burke, 
Skumatz, Irving, & McKay, 1996; Engelmann & Valtink, 2004; Maminishkis et al., 2006).  
Despite significant efforts to mimic in vivo cellular microenvironment, the weakness 
of RPE cell culture system is the absence of full spectrum of signals from the retina and the 
choroid that contribute for RPE’s epithelial phenotype. Once in culture, RPE cells can 
undergo deadaptation or transdifferentiation from epithelial to mesenchymal phenotype. 
Deadapted cells alter their morphological and functional appearance, by loosing 
pigmentation and exhibiting elongated cell morphology, for instance. In order to provide 
specific conditions similar to in vivo microenvironment, several groups reported cell media 
formulations enriched in growth factors and serum, and have also tested different matrices 
trying to reproduce Bruch’s membrane composition (Engelmann & Valtink, 2004; 
Maminishkis et al., 2006). 
Epithelial-mesenchymal transition (EMT) is a biological process in which epithelial 
cells lose their differentiated phenotypes and become mesenchymal-like cells. EMT is crucial 
in embryogenesis and organ development and it is important in wound healing and tissue 
regeneration. Nevertheless, EMT also plays a key role in pathological processes, such as 
cancer metastasis. It is now well accepted that EMT can be classified into 3 different 
biological subtypes. Type 1 EMT is associated with implantation, embryo formation and 
organ development, processes where mesenchymal cells can give rise to secondary 
epithelia. In type 2 EMT fibroblasts and other related cells are generated to reconstruct 
tissues following trauma and inflammation injury. Lastly, the changes occurring in type 3 
EMTs result in outcomes far different from those observed in the other 2 types of EMT, 
involving cancer progression and metastasis (Kalluri & Weinberg, 2009).  
In the eye EMT has been suggested to contribute to PVR. Using RPE cell cultures 
several authors demonstrated that normal cell-cell and cell-matrix interactions are disrupted 
due to an environmental change of chemokines and growth factors. In this scenario, type 2 
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EMT is promoted and a mesenchymal phenotype is present along with epithelial features. 
Until now PVR is the only reported condition where RPE goes through transdifferentiation 
(Grisanti & Guidry, 1995; Kalluri & Weinberg, 2009; Tamiya, Liu, & Kaplan, 2010). 
 
3.1.2. Cell culture of mouse RPE cells 
Primary cell culture of RPE has been commonly used from diverse species, and 
improvements were made in culture of polarized cells, being human RPE cells the most 
popular. However, there are obstacles to their cultivation, such as isolation of sufficient vital 
cells and induction of proliferative activity in RPE cells after long post-mortem times. 
Recently, protocols came up describing culture of RPE cells from human fetal donor eyes, 
overcoming post-mortem limitations. Nevertheless, some authors say that highly polarized 
human RPE monolayers may not reflect integrally what occurs in multifactorial diseases such 
as AMD. The argument is that human RPE cells in vitro produce VEGF as a result of the 
specific culture conditions, which may induce an “injury-type” phenotype of cells, 
comparable to those observed in vivo in wound healing and other pathological conditions 
(Engelmann & Valtink, 2004; Geisen, McColm, King, & Hartnett, 2006; Hu & Bok, 2001; 
Maminishkis et al., 2006; Shozo Sonoda et al., 2009).  
Mouse RPE cells have also been used to study RPE function, and their advantages as 
an experimental model are further highlighted. First, their genetic definition is enhanced; 
second, there is an increasing range of available reagents, and third, modification of a 
specific gene is feasible. These 3 reasons were determinant for the choice of mouse as an 
experimental model for the purpose of this work (M. Chen et al., 2008). 
 
3.1.2.1. Mouse RPE primary cells 
Mice features are determinant for the success of RPE isolation procedure, particularly 
their age. Three week old mice were used in this work. At this age eye development is 
complete and the animals’ eyes have been open for at least one week. Moreover, the organ 
is of a reasonable size to allow correct handling and connection between neural retina and 
82 
 
RPE is not fully completed yet. Moreover, we confirmed that the use of older animals 
resulted in lower yields and contamination with neural retina cells. 
RPE cells were obtained by dispase digestion according to described protocols. 
Dispase is a bacterial neutral protease that is used for gentle dissociation of animal tissues to 
release individual cells. The period of time used for this incubation step is of great 
importance. Longer periods than the one described for dispase digestion may destroy ECM; 
conversely, a shorter incubation time may result in incomplete dissociation of the tissue 
layers, and subsequent lost of RPE cells. When in culture RPE cells proliferate from a starting 
patch of pigmented cells. In the first 24 hours after plating, the cell patch adheres to the 
bottom of the well, and cells at the edge can be seen spreading (Figure 3.1, A). At 72 hours 
more cells are seen extending from the initial patch, and a different cell type contaminating 
the culture is detected (Figure 3.1, B, white arrow). Contaminating cells are usually choroidal 
melanocytes that were detached from the choroid during the isolation procedure. Choroidal 
melanocytes do not divide in culture and die when cells are splitted. Seven days after 
isolation RPE cells continue spreading and dividing (Figure 3.1 C). Cells at the centre of the 
patch remain as non-dividing cells, since epithelial cells arrest growth by contact. After 2 
weeks confluent RPE cells resemble their in vivo characteristics (Figure 3.1, D) (Geisen et al., 
2006).  
 
 
 
 
Figure 3.1 – Mouse RPE primary cell
proliferating from an initial patch of pigmented cells, and after 15 
in vivo characteristics. Cells are seen spreading from the patch 24 h
hours cells start to extend, and 
After 7 days cells are actively 
patch remain as non-dividing 
Scale bars, 200 µm.  
 
 
Large clusters of RPE 
performed in this work. By capture different levels of the 3D’s architecture of the cluster, it 
is possible to notice how RPE cells are displayed 
cellular edges (Figure 3.2). 
 
 
 
 
 
s grow in vitro after isolation. 
days RPE cells resemble their
ours after plating 
some choroidal melanocytes are detected (white arrow)
dividing and start to form a monolayer, while central 
(C). After 15 days RPE cell culture is a confluent monolayer 
cells were obtained in some of the isolation proc
in vivo, with tight junctions nicely defining 
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RPE cells start 
 
(A). At 72 
 (B). 
cells of the 
(D). 
edures 
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Figure 3.2 – In vitro mouse RPE primary
At day 5 after isolation the central region
the RPE cluster resembles its 
pigment granules, and tight junctions 
µm (A), 20 µm (B, C).  
 
 cell clusters resemble RPE morphology
 of the cluster is not attached yet (A)
in vivo characteristics, with RPE cells containing
being well defined between cells (B, C)
 in vivo. 
. Morphology of 
 a high amount of 
. Scale bars, 50 
 
The isolation protocol 
obtained from the eye. Patches of pigmented cells 
from the start, but large clusters are rare due to the mechanical action of pipeting outsized 
cell clumps. One of the biggest clusters of mouse RPE primary cells obtained using this 
protocol is depicted at Figure 3.3.  
 
 
 
 
 
 
 
 
 
Figure 3.3 – Mouse RPE primary cells 
culture. At day 5 after isolation 
individual cells clearly distinguishable
 
 
 
 
 
 
per se contributes to the heterogeneity of RPE cells that are 
with different sizes are
 
can form large patches of pigmented cells in 
cells are adherent and keep growing as a monolayer, with 
 (white arrow). Scale bar, 50 µm.  
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RPE primary cells can be passaged when they reach confluence in culture. However, 
as other groups reported, we observed that the newly formed monolayer does not display 
distinct cellular phenotypes as before, like elongated fusiform cells and epithelioid cells. 
Trypsin treatment for passage of cells appears to reinitiate the process of cytoplasmatic 
organization entailed for epithelial morphogenesis. For epithelial cell lines only a few days in 
confluency are needed for cells to achieve a similar shape. For primary RPE cells, on the 
other hand, several weeks are again required for redevelopment of cellular phenotypes 
(Burke et al., 1996).  
In the present work mouse RPE primary cells were trypsinized usually 7 days after 
plating, when confluence was reached. At day 5 after passage 1 (P1), no distinctive 
phenotypes were detected (Figure 3.4, A). The pigment granules were less in number, 
suggesting that melanosomes were shared between the mother and daughter cells (Figure 
3.4, B and C). Other groups have also reported RPE to lose melanin content when in culture 
(Engelmann & Valtink, 2004). As cultivation time increased, cells became larger and took 
more time to duplicate. Mouse RPE primary cell cultivation was tested until P4 but only a 
few cells remained. However, other studies reported that mouse RPE primary cells could be 
a useful RPE cell type at least until P5 (Geisen et al., 2006; Rambhatla, Chiu, Glickman, & 
Rowe-Rendleman, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 – In vitro mouse
increases. As mouse RPE primary cells are splitted, n
(A), but cell number decreases as cell cycle is detained, at P2 
are vestigial (C). Scale bars, 200 µm (A), 20 µm (B, C). 
 
 RPE primary cell morphology varies as passage number 
o distinct phenotypes are detected 
(B). At P3 the pigment granules 
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at P1 
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Cultured RPE primary cells can bear a resemblance to in vivo condition if polarized 
state is potentiated. In such a case, the relevant integral membrane transporters would be 
appropriate polarized and transport of water and ions would occur. In order to achieve RPE 
cell polarization in vitro, permeable supports for cell culture were developed and tested 
using other epithelial cell types, allowing them to take up and secrete molecules on both 
their basal and apical surfaces (Shozo Sonoda et al., 2009). A representative working model 
of the Transwell® culture system is depicted at Figure 3.5. 
 
 
 
 
 
 
 
 
 
Figure 3.5 – Schematic diagram of RPE cells growing in a well with a Transwell® insert. 
The polycarbonate filter contains pores of 0,4 µm, generating 2 compartments. In the depicted 
model, the upper compartment corresponds to the apical domain of the cells facing 
photoreceptors, and the lower compartment corresponds to choroidal facing side of RPE 
(basolateral domain). Adapted from Sonoda et al., 2009.   
 
Over the years several matrices suitable for cell culture were tested to help 
polarization process by mimicking Bruch’s membrane composition. Cell cultures of RPE using 
Matrigel™, laminin, fibronectin, collagen I and collagen IV have been reported, with 
improvements in cell growth and differentiation (Dunn, Aotaki-Keen, & Putkey, 1996; 
Maminishkis et al., 2006; Tian, Ishibashi, & Handa, 2004).  In the present work we tested 
laminin, collagen IV and fibronectin as substrates for mouse RPE primary cell culture in 
Transwell® inserts. In the end, neither laminin nor collagen IV promoted a uniform cell 
attachment, and fibronectin came out as the most suitable coating substrate to use (Figure 
3.6).  
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Figure 3.6 – Mouse RPE primary cell growing in a fibronectin-coated Transwell® insert. 
Mouse RPE primary cells were splitted and platted in a fibronectin-coated Transwell® insert 
(P1) and cultivated for 30 days. Scale bar, 200 µm.  
 
Since culture conditions play an important role in development and maintenance of 
RPE cell polarity, cell culture media has also been pinpointed as crucial for polarization’s 
achievement. Several groups have tested different formulations of media, with low and high 
glucose percentage, and diverse supplements adapted for each RPE cell culture type. For 
mouse RPE primary cells, usage of DMEM-high glucose supplemented with 10% FBS has 
been described, and it was the medium chosen for our in vitro studies. For Transwell® 
inserts’ cultures, it was reported the change of FBS-medium’s percentage on the day after 
plating. Low serum medium (1% FBS) would prevent overcrowding of RPE cells, and 
contribute to attainment of a monolayer culture. Moreover, there is also some evidence of 
Transwell® cultures of RPE cells using serum-free epithelial medium (CECM). We have also 
tested CECM medium and used it for some experiments (M. Chen et al., 2008; Geisen et al., 
2006; Hu & Bok, 2001; Maminishkis et al., 2006; Shozo Sonoda et al., 2009).  
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3.1.2.2. Mouse RPE cell line B6
Alternatively to the use of primary cells, cell lines offer considerable less physiological 
variability between experiments. Some RPE cell lines have been spontaneously created 
during sub-culturing of primary cells. The arising of a rat RPE cell line was r
1993, and soon human RPE cell lines were 
RPE cell line was isolated and characterized. Other 
with oncogenes or viral proteins, such as rat RPE
Liggett, Griffiths, & Gaillard, 2009; McLaren, Sasabe, & Li, 1993; Na
Gould, Gundersen, & Rodriguez
A mouse RPE cell line 
characterized a continuous cell line from an 8
RPE cells. B6-RPE07 cell line displays cobblestone morphology (Figure 3.7) and it is 
phenotypically similar to other RPE cell
2008). The mouse RPE cell line used in this work, B6
Heping Xu.   
 
 
 
 
 
 
 
 
Figure 3.7 – B6-RPE07 cell line morp
display a typical epithelioid shape 
µm. 
-RPE07 
subsequently described. More recently a bovine 
RPE cell lines arose due to transformation 
-J cells (Davis et al., 1995; Dunn et al., 1996; 
bi, Mathews, Cohen
-Boulan, 1993). 
was only generated in 2008 when Dr. Heping Xu and his team 
-week-old primary culture of C57BL/6 mouse 
 line types, with no melanin granules 
-RPE07, was kindly provided by Dr. 
hology in a confluent culture (P19
in culture, with no visible melanin granules. 
eported first, in 
-
(Chen et al. 
). B6-RPE07 cells 
Scale bar, 100 
 
3.1.3. Transepithelial resistance of 
The ability of epithelium to act as a barrier between 
of the junctional complexes. The tight junction is the most apical 
types of junctions, and seals off 
represents the anatomic substrate of the outer blood
diffusion barrier (Jin, Barron, He, Ryan, & Hinton, 2002; Powell, 1981)
The pioneering work of Hans Ussing back in 1940’s introduced the concept of 
different conductance properties between apical and basal membranes of epithelia. Based 
on electrical circuit modeling, Ussing’s team began to understand how transcellular and 
paracellular transports are physiologically coupled (Figure 3.8) 
2009).  
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – Model of electrical circuit of series and paracellular resistances across 
trans- and paracellular pathways of an epithelial cell monolayer.
pathway has much higher resistance than the paracellular 
plasma membrane. Tight junction
Rbasolateral. RTJ, Rtight junction. RLIS, R
 
Transcellular transport is controlled by transporters in apical and basolateral 
surfaces, which explains why cell membranes are gener
Rbasolateral). Given that there is little evidence for the physiological relevance of the R
intercellular space, it is the Rtight junction
is high or low (Anderson & Van Itallie, 2009)
mouse RPE cell models 
2 layers depends on the integrity 
component among other 
completely the space between cells. In the eye, RPE 
-retinal barrier since it acts as a passive 
.    
(Anderson & Van Itallie, 
 
due to transporters located 
’s claudins define the transepithelial resistance. R
lateral intercellular space. Adapted from Anderson & Van Itallie 2009
ally of very high resistance (R
 that determines whether the transepithelial resistance (TER) 
.  
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. 
apical and 
lateral 
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As a consequence of acting as a seal that restricts paracellular and intramembrane 
diffusion, tight junctions are often rate limiting to paracellular solute movement. Thus 
alterations in TER are often used as an index of tight junction permeability. By passing a 
pulse of known amplitude across epithelial cells, the corresponding transepithelial voltage 
deflection is measured. The Ohm’s law is then used to calculate resistance. An epithelial 
voltohmmeter (EVOM) is used for TER measurements in Transwell® inserts, being the 
electrodes placed in the inner and outer chambers. Net TERs are calculated by subtracting 
value of a blank filter without cells from experimental value. The final resistance-area 
products are obtained by multiplication with effective growth area (Ω.cm
2
) (Madara, 1998; 
Shozo Sonoda et al., 2009).  
The existing RPE cell culture models exhibit different TER values such as it happens 
for other models of or natural epithelia. Among cell lines, human RPE cell line ARPE19 has 
been reported to have low TER levels (30-40 Ω.cm
2
). Regarding primary cells, RPE cultures 
derived from human fetal cells are consistently the ones reporting higher TER values, above 
500 Ω.cm
2
 (Dunn et al., 1996; Geisen et al., 2006; Hu & Bok, 2001; Maminishkis et al., 2006; 
Shozo Sonoda et al., 2009). For mouse RPE primary cultures, however, there is only one 
known report. Geisen et al. showed that mouse primary cells in culture for 35 days (P3) have 
low TER values (<30 Ω.cm
2
). This shortage of information indicates the difficulty of culturing 
mouse RPE primary cells on Transwell® inserts for longer time. Regarding B6-RPE07 cell line, 
there is no information in the literature concerning TER measurements. 
In this work mouse RPE primary cells at P1 were cultured on Transwell® inserts over 
time. After 7 days in culture on 96-well-plates, mouse RPE cells were trypsinized and plated 
in Transwell® inserts in CECM medium reaching confluence. Therefore there was little space 
for cell division, which enhanced the polarization process. TER measurements were 
performed over time to evaluate primary RPE cells and B6-RPE07 cells’ epithelial resistance 
(Figure 3.9). MDCK cells and mouse embryonic fibroblasts (MEF) were used as positive and 
negative controls for TER, respectively. MDCK cells are widely used as a model of polarized 
epithelial cells. MEFs are fibroblasts isolated from the mouse embryo, and as constituents of 
tissue stroma, they do not display polarized phenotype or TER, and therefore they were 
considered as negative control for TER measurements.  
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Transwell® experiments were performed using CECM media, as described in the 
paper describing B6-RPE07 cells for the first time (M. Chen et al., 2008). Within all 
experiments 2 populations of mouse RPE primary cultures consistently arose. The first type, 
fewer in number, displayed TER values of 50-60 Ω.cm
2
 during the first 8 days of culture 
(Figure 3.9). At day 11, however, TER decreased to 30 Ω.cm
2
. These data are in accordance 
with previous report by Geisen et al., and these cultures were named as mouse RPE - 
Polarized cultures (mRPE-P, Figure 3.9). The second type of RPE cells includes the vast 
majority of mouse RPE cells plated on Transwell® inserts. These cultures displayed low TER 
values from the first measurement, with a slight increase by day 8. TER values stabilized 
around 15 Ω.cm
2 
within time. According to the literature, low TER values represent an 
unpolarized state, with low tight junction resistance. This may be caused by an incomplete 
polarization process, due to post-isolation primary cell behavior. Mouse RPE cultures 
displaying low TER were denominated mouse RPE – Low polarized cultures (mRPE-LP, Figure 
3.9). B6-RPE07 cells were also cultured on Transwell® inserts. The TER values obtained were 
similar to those of mRPE-LP, ranging from 5 to 35 Ω.cm
2
 during the 20-days of culture time 
(B6-RPE07, Figure 3.9). Here we report, for the first time, that B6-RPE07 cell line display low 
levels of TER when growing in Transwell® inserts. MDCK cells were also cultured on 
Transwell® inserts to provide a positive control for net TER. TER values obtained were 
effectively higher than primary cultures’ TER (MDCK, Figure 3.9). MDCK are known for their 
highly polarized state in vitro, and their high TER values, constituting a model for epithelial 
studies (Geisen et al., 2006). However, in this work, values obtained were lower than the 
ones published by other groups. Still TER values of MDCK cells were higher than the ones 
displayed by mouse RPE primary cells. MEFs were used as a control for non-polarized cells, 
and they displayed TER values ranging from 3 to 7 Ω.cm
2
 over 20 days-culture (MEF, Figure 
3.9). MEF’s TER values reinforced the results obtained with mRPE-LP cells, and stated that 
those cells were note in a polarized state indeed. 
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Figure 3.9 – Transepithelial resistance over time differs between in vitro RPE cell 
models. MDCK cells were used as a positive control, and net values were higher than mouse 
RPE primary cells. Two distint populations of mouse RPE primary cells were cultured in 
Transwell® inserts: mRPE-P achieved some degree of polarization and displayed TER values 
around 60 Ω.cm
2
, and mRPE-LP were unable to display TER values above 15 Ω.cm
2
. B6-RPE07 
cells displayed TER values ranging from 5 to 35 Ω.cm
2
. MEF were used as a control for non-
polarized cells. Mouse RPE – Polarized cells (mRPE-P, N=3); mouse RPE – Low polarized cells 
(mRPE-LP, N=10); MDCK cells (N=5); B6-RPE07 (N=3); MEF (N=3). The results are presented as 
mean average value (base 10 logarithmic scale) ± SD.  
 
3.1.4. Expression of RPE markers in RPE cell models  
 
The presence of known markers of RPE cells was investigated to better characterize 
isolated cells in vitro. In this work the expression of both epithelial cell markers and visual 
cycle proteins were evaluated in mouse RPE primary cells and in mouse RPE cell line B6-
RPE07. 
Polarized epithelial cells display distinct functional and biochemical domains. Apically, 
the junctional complex makes the contact between adjacent cells and mediates their 
communication through specialized components. As tight junction proteins zonula occludens 
(ZO) help in the diffusion barrier formation, the expression of ZO1 is a typical feature of RPE 
(Rodriguez-boulan & Nelson, 1989).  
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The ion transporter Na
+
/K
+
 ATPase is also used as a RPE marker. This protein is 
important for providing a Na
+
-rich environment for photoreceptors’ proper function and is 
located preferentially at the apical surface of RPE cells. Na
+
/K
+
 ATPase is composed of a 
catalytic α-subunit and a glycoprotein β-subunit, and 3 isoforms are known for each subunit. 
The expression of different isoforms seems to follow a tissue-specific pattern: α1- and β1-
subunits are expressed in most tissues including RPE, whereas α2-, α3- and β2-subunits are 
produced mostly in the brain  (Ruiz, Bhat, & Bok, 1995; Shozo Sonoda et al., 2009).  
Intracellularly, visual cycle proteins are unique of RPE cells, serving as identification 
characters. Visual cycle proteins include mainly protein carriers and chaperones, essential 
for the light transduction process into nervous signal that occurs between RPE and 
photoreceptors (Strauss, 2005). We focused on 3 visual cycle proteins to better characterize 
our RPE cell models: RPE65, a chaperone first isolated in RPE, CRALBP and RGR. 
A gene expression study of referred RPE markers was performed, and primers used 
are listed in Table III. The hypoxanthine phosphoribosyl transferase 1 gene (Hprt1) was 
selected as endogenous control to evaluate purity and stability of RNA. The ideal 
endogenous control should have a constant RNA transcription level under different 
experimental conditions and be sufficiently abundant across different tissues and cell types. 
Hprt1 housekeeping gene is involved in purine metabolism and has shown a relative stability 
crosswise a number of tissues (De Kok et al., 2005).  
A RT-PCR analysis to both B6-RPE07 cell line and different mouse RPE primary cell 
cultures was performed and only in the tubes containing the reverse transcriptase there was 
a PCR product (Figure 3.10). All samples showed stable expression of Hprt1 gene, indicating 
therefore that cDNA preparations of all samples were prone to be used in further RT-PCR 
analysis. 
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Figure 3.10 – B6-RPE07 cells and mouse RPE primary cells stably express
Total RNA was extracted from B6
cultures. cDNA was prepared using reverse transcriptase (+RT) and no reverse transcriptase 
(-RT), as negative controls. Hprt
(375 bp) Hprt1 was detected in B6
H2O corresponds to negative control of PCR reaction, with no cDNA. M, DNA ladder marker.  
 
Table III – List of primer sequences used in gene expression study of RPE markers.
 
Gene 
Endogenous 
control 
Hprt1 
Forward
Rev
Epithelial 
markers 
Tjp1 
Forward
Reverse
Atp1a1 
Forward
Reverse
Rpe65 
Forward
Reverse
Visual cycle 
proteins 
Rlbp1 
Forward
Reverse
Rgr 
Forward
Reverse
VEGF 
biology 
Vegfa 
Forward
Reverse
Flt1 
Forward
Reverse
Flk1 
Forward
Reverse
-RPE07 cells and from 7 different mouse 
1 gene expression was examined by RT-PCR. A single band of 
-RPE07 cells and in all different RPE primary cell 
Sequences (5’- 3’) 
 ATCACATTGTAGCCCTCTGTGTGCTCAAGG
erse GTCTGGAATTTCAAATCCAACAAAGTCTGGC
 ATGGTTAACGGAGTTTCAATGGATAA
 GGTCGACTACTCATCTCTTTGCACTACCATTTTT
 ATGAAGAACTGCCTGGTGAAGAACT
 GTCGACTCATTTCTTCAAGTTATCAAAAATCAG
 ATTGAACACCCTGCTGGTGGCTA
 GCCCACATCGGAGGAGACTGC
 TCCGTGCCCGCAAGTTCGAT 
 GGCCTCGATAGTGCAGCGGA 
 CTGCCTGCTGGTTTGGGGGAA
 AGCAGGTTGCTGGGAGTCCGC
 ACCTCCACCATGCCAAGTGGTCC
 AGGGTCTCAATCGGACGGCAGT
 CGGCTGTCCATGAAAGTGAA 
 TTGCAGGCGAGCCATCTT 
 CAGCTCGAGACCAACTTGGAAGTCATTATCCTCGTC
 CATGGTACCTCAAATATAGTCTTTGCCATCCTGCTGC
GC 
 Hprt1 gene. 
RPE primary 
   
cultures. 
 
 
Size 
(bp) 
 
375 
 
 
573 
 
 
1275 
 
 
127 
 
74 
 
143 
 
 
121 
 
70 
 
1269 
 
3.1.4.1. Epithelial
Expression of tight junction protein ZO1 was investigated at mRNA level 
the expression of the correspondent gene 
only in the tubes containing the reverse transcriptase 
In addition, we have also verified that b
express Tjp1, indicating that these cells have the ability to develop into 
phenotype with the formation of a
 
 
 
 
 
Figure 3.11 – B6-RPE07 cells and mouse RPE primary cells stably express
Total RNA was extracted from B6
cultures. cDNA was prepared using reverse transcriptase (+RT) and no reverse transcriptase 
(-RT), as negative controls. Tjp
(573 bp) Tjp1 was detected in B6
corresponds to negative control of PCR reaction, with no cDNA. M, DNA ladder marker.  
 
Despite the presence of 
respective cellular localization into the tight junctions’ complex depends on the polariz
state of RPE cells. Here, we show that
and B6-RPE07 cell line (Figure 3.12). ZO1 protein was detected in a cluster of RPE primary 
cells cultured for 5 days (Figure 3.12, B). The cellular edges’ at the 
not well seen at the bright-field image (Figure 3.12, A), but ZO1 staining helps to define them 
(Figure 3.12, B). Moreover, ZO1 protein
image co-localizes with well-
image. In Transwell® insert cultures ZO1 was also detected by immunofluorescence (Figure 
 cell markers 
tight junction protein 1 (Tjp1). We observed that 
there was a PCR product (Figure 3.11). 
oth B6-RPE07 cells and mouse RPE primary cultures 
 diffusion barrier.  
-RPE07 cells and from 7 different mouse 
1 gene expression was examined by RT-PCR. A single band of 
-RPE07 cells and in all different RPE primary cells. 
mRNA in the cells, the assembly of ZO1 
 ZO1 protein is expressed in mouse RPE primary cells 
center of the cluster are 
’s expression pattern in the immunofluorescence 
defined gap junctions seen at the correspondent bright
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by analyzing 
a polarized 
 Tjp1 gene. 
RPE primary 
   
H2O 
 
protein and 
ed 
-field 
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3.12, C). Use of a confocal microscope revealed ZO1 
of mouse RPE primary cells 
protocol, cells’ plasma membranes 
(Figure 3.12, C). B6-RPE07 cells display a ZO1 pattern different from RPE primary cultures 
(Figure 3.12, D). In B6-RPE07, 
plasma membrane. One possible explanation is that the cell line was not in a highly polarized 
state in culture. Therefore, tight junctions between cells are not being assembled
the protein is being synthesized. 
 
 
 
 
 
 
 
 
 
Figure 3.12 – Mouse RPE primary cells
marker ZO1. Mouse RPE primary cells 
plating (A). Expression pattern of ZO1
fluorescence microscope (B) 
RPE primary cells cultured on a Transwell
cellular edges (C). ZO1 expression pattern in cultured B6
probably because cells are not in a polarized state 
100 µm (D).    
protein’s distribution at the membrane 
cultured for 20 days. Due to cell shrinkage during fixation 
have been separated, and black holes lie between cells 
ZO1 staining is localized all over the cytoplasm, and not in the 
 
 and B6-RPE07 cell line express
can form clusters in a monolayer culture at day 5 after 
 protein in RPE clusters is visualized by an inverted 
and is localized in tight junctions between individ
® insert for 20 days also display ZO1 staining at 
-RPE07 cells (P25) is more diffuse, 
(D). Scale bars, 200 µm (A and B), 10 µm (C), 
, despite 
 the epithelial 
ual cells. Mouse 
 
Expression of the ion transporter 
analyzed and only in the tubes containing the reverse transcriptase there was a PCR product 
(Figure 3.13). At the mRNA level both B6
express Atp1a1 gene.  
 
 
 
 
 
 
Figure 3.13 – B6-RPE07 cells and mouse RPE primary cells stably express 
Total RNA was extracted from B6
cultures. cDNA was prepared using
(-RT), as negative controls. Atp1a1
(1275 bp) Atp1a1 was detected in B6
corresponds to negative control of the PCR reaction, with no cDNA. M, DNA ladder marker.  
  
As it happens for ZO1
polarized state of epithelial cells. In 
ATP1α1 protein’s staining is similar to ZO1 (Figure 
is higher and better defined in cells localized in the centre of the patch (Figure 
B). In addition, this feature is enhan
seen at bright-field microscopy,
day 15 (Figure 3.14, C). However, 
composing the cluster (Figure 
maintained in vitro after cell 
expressing Atp1a1 (Figure 3.13), these cells
(ATP1β1)  (Figure 3.14, E). Again, similarly to ZO1 staining in B6
pattern is dispersed all over the cytoplasm in the majority of cells
intense at the plasma membrane. Based on 
Na
+
/K
+
 ATPase α1-subunit (Atp1a1
-RPE07 cells and mouse RPE primary cultures
-RPE07 cells and from 6 different mouse RPE primary 
 reverse transcriptase (+RT) and no reverse transcriptase 
 gene expression was examined by RT-PCR. A single band of 
-RPE07 cells and in all different RPE primary cells. H
 distribution, Na
+
/K
+
 ATPase localization also depends on the 
mouse RPE primary cultures established in this work
3.14). We can observe that signal i
ced when cells are cultured in a Transwell
 the cluster is an undefined aggregate of pigmented cells at 
ATP1α1 staining revealed the contours of the cells 
3.14, D), showing that some RPE characteristics are 
isolation. For B6-RPE07 cells, we observed that besides 
 also express the β1-subunit of 
-RPE07 cells, ATP1β1 staining 
 being, in some
Na
+
/K
+
 ATPase cytoplasmic localization, w
99 
) gene was also 
 
Atp1a1 gene. 
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, 
ntensity 
3.14, A and 
®
 
insert. When 
Na
+
/K
+
 ATPase 
 cells, more 
e can 
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emphasize the notion that B6
growing in vitro on a plate culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 – Mouse RPE primary cells
marker Na
+
/K
+
 ATPase. Mouse RPE primary cells grow in a monolayer culture (P0) for 25 days 
(A) and display epithelial-like morphology, by expressing ATP1α1 protein
an inverted fluorescence microscope. When growing on a Transwell
RPE primary cells (P1) can form clusters 
(P25) express Na
+
/K
+
 ATPase β1
-RPE07 cells do not reach a highly polarized state when 
 
 
 and B6-RPE07 cell line express 
 (B)
®
 
insert for 15 days, 
(C), which also express ATP1α1 (D)
-subunit (ATP1β1) (E). Scale bars, 200 µm (A-D) and 50 µm (E).
the epithelial 
, visualized using 
mouse 
. B6-RPE07 cells 
 
 
3.1.4.2. Visual cycle proteins
Expression of visual cycle markers genes 
and Rpe65 was investigated at mRNA level and 
transcriptase there was a PCR product 
mRNA from the 3 genes subjected to analysis. However, the same is not true for B6
cells that lack both Rgr and Rpe
RPE primary cells ex vivo was expected as they were actively part of the visual cycle 
B6-RPE07 were obtained from a subclone of mouse RPE primary cells, but their subculturing 
processes may have caused the silencing of visual cycle genes, once this metabolic cycle 
does not occur in vitro nor in isolated RPE cells. A small amount of 
detected, although, reinforcing the idea of previous lively translation and expression of this 
gene. 
   
 
 
 
 
 
 
 
 
Figure 3.15 – B6-RPE07 cells and mouse RPE primary cells express mR
and Rpe65 visual cycle proteins.
different mouse RPE primary cultures. cDNA was prepared using reverse transcriptase (+RT) and 
no reverse transcriptase (-RT), as
single band of (134 bp) Rgr was detected in all different 
B6-RPE07 cells (A). A single band of (74 bp) 
primary cells (B). A single band of (127 bp) 
being absent from B6-RPE07 cells
 
Rgr, Rlbp1 (retinaldehyde binding protein 1
only in the tubes containing the reverse 
(Figure 3.15). All mouse RPE primary cultures express 
65 mRNA expression. The presence of these genes
NA of 
 Total RNA was extracted from B6-RPE07 cells and from 7 
 negative controls. Gene expression was examined by RT
mouse RPE primary cultures
Rlbp1 was detected in both B6-RPE07 cells and in all 
Rpe65 was detected only in RPE primary cultures, 
 (C). 
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) 
-RPE07 
’ mRNA in 
in vivo. 
Rlbp1 mRNA was 
Rgr, Rlbp1 
-PCR. A 
 but not in 
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Expression of visual cycle proteins CRALBP and RPE65 by B6
primary cells was assessed by Western Blot analysis from whole cell lysates (Figure 3.16).  
Cell lysate from mouse embryonic eye was used as a positive control for CRALBP expression. 
We found that neither B6-RPE07 cells (Figure 3.16, A, lane 2) nor
3.16, A, lane 3) expressed CRALBP protein
(Figure 3.15). CRALBP protein production might have been reduced or silenced as none of 
the cells tested was involved in visual cycle when in culture 
cycle protein, we only detected its expression on
being absent in B6-RPE07 cell line (Figure 3.16, B, lane 
by a residual expression of RPE65 protein from RPE primary cells, 
culture for long. 
 
 
 
 
 
 
 
 
 
Figure 3.16 – B6-RPE07 cell line and mouse RPE primary cells differently express visual 
cycle proteins. Cell lysates were prepared according to the described method. Forty 
micrograms of total protein were loaded into the gel and calnexin was used as loading control 
for Western Blot analysis. Mouse embryonic eye cell lysate was used as a positive co
CRALBP protein expression (A
lane 3) did not show CRALBP protein expression. RPE65 protein expression
RPE primary cells (B, lane 2), but not
-RPE07 and mouse RPE 
 RPE primary cells (Figur
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3.1.5. VEGF biology in mouse RPE cell models 
Expression of Vegfa by RPE cells is a well-documented fact, as clinical and 
experimental observations indicate a role for RPE-derived VEGF in the maintenance of 
choriocapillaries. There are reports of Vegfa expression from primary cells from different 
species in unstimulatory conditions (Geisen et al., 2006; Klettner, Doths, & Roider, 2012; 
Marneros et al., 2005).  
In this work we evaluated expression of Vegfa and its receptors Flt1 and Flk1, and 
VEGF secretion in our RPE cell models. Mouse RPE cells have already been described as 
expressing Vegfa gene and secreting VEGF protein in vivo, but to date there is no 
information regarding Vegfa expression and VEGF secretion by mouse RPE primary cultures 
and B6-RPE07 cell line  (Ford, Saint-Geniez, Walshe, Zahr, & D’Amore, 2011; Kurihara, 
Westenskow, Bravo, Aguilar, & Friedlander, 2012) 
 
3.1.5.1. Vegfa expression in mouse RPE cell models 
 
Expression of Vegfa was investigated at both mRNA and protein levels. Regarding RT-
PCR reaction, only in the tubes containing the reverse transcriptase there was a PCR product 
(Figure 3.17). Both B6-RPE07 cells and mouse RPE primary cultures express Vegfa gene. 
These results confirm the existence of Vegfa mRNA in our mouse RPE cells and in the B6-
RPE07 cell line. 
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Figure 3.17 – B6-RPE07 cells and mouse RPE primary cells express 
RNA was extracted from B6-RPE07 cells and from 5 different RPE primary cultures. cDNA
prepared using reverse transcriptase (+RT) and no reverse transcriptase (
controls. Vegfa gene expression was examined by RT
detected in B6-RPE07 cells and in all different RPE primary cultures
negative control of PCR reaction, with no cDNA. M, DNA ladder marker.  
 
Presence of intracellular VEGF protein in our RPE cel
by Western Blot using whole cell lysates (Figure 3.18). B6
primary cells showed equal intracellular expression of VEGF protein (Figure 3.18, lanes 1 and 
2).  
 
 
 
 
 
 
 
Figure 3.18 – B6-RPE07 cell line and mouse RPE primary cells express 
lysates were prepared according to the described method. 
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B6-RPE07 cells (lane 1) and RPE primary cells 
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3.1.5.2. VEGF receptors
 
In addition to their role in VEGF secretion, RPE cells are also capable of autocrine and 
paracrine VEGF signaling by actively displaying VEGFR1 and VEGFR2 at their surface
al., 2008). We evaluated whether our RPE m
receptors. Once again, there was no information regarding B6
the literature so far. 
Expression of Flt1 and 
containing the reverse transcriptase there was a PCR product 
Both B6-RPE07 cells (Figure 3.19, A) and mouse RPE primary cultures (Figure 3.19, B) express 
Flt1 gene which codifies for VEGFR1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 – B6-RPE07 cells and mouse RPE primary cells express 
was extracted from B6-RPE07 cells and from 5 different RPE primary cul
prepared using reverse transcriptase (+RT) and no reverse transcriptase (
controls. Flt1 gene expression was examined by RT
detected in B6-RPE07 cells 
corresponds to negative control of PCR reaction, with no cDNA. M, DNA ladder marker.  
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(Figure 3.19 and Figure 3.20). 
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VEGFR2 results from transcription of
cells (Figure 3.20, A) and in RPE primary cultures (Figure 3.20, B). 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 – B6-RPE07 cells and mouse RPE primary cells express 
was extracted from B6-RPE07 cells and from 5 different RPE primary cultures. cDNA was 
prepared using a reverse transcriptase (+RT) and no reverse transcriptase (
controls. Flk1 gene expression was examined by RT
detected in B6-RPE07 cells (A)
the negative control of the PCR reaction, with no cDNA. M, DNA ladder marker.  
 
 Taken together, our results regarding 
that our RPE cell models should be able to respond to VEGF, either in a paracrine or 
autocrine way. 
 
3.1.5.3. VEGF secretion in 
 
The ability of RPE to secrete VEGF to cell media reproduces its feature as part of a 
barrier epithelium involved in maintaining cell homeostasis. The secreted soluble VEGF 
(sVEGF) molecules can be detected 
VEGF levels of tissue culture supernatants
et al., 2006; S Sonoda, Sreekumar, Kase, & Spee, 2010)
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kit that detects both sVEGF120 and sVEGF164 isoforms. The reduction of variability between 
assays was accomplished by using the same plates, solutions and washing equipment, 
allowing us to achieve reproducibility between experiments.  
The use of reduced-FBS medium to evaluate soluble growth factors by ELISA is well 
documented for other RPE cell types (Cordeiro, Seyler, Stindl, Milenkovic, & Strauss, 2010; 
Rosenthal et al., 2007; Slomiany & Rosenzweig, 2004). There are reports on the use of 
serum-free medium for short-term incubations, as well as low percentage FBS-media, 
ranging from 0,1% to 5%, for short and longer periods of time. For mouse primary cells, we 
used serum-free cell medium for 24 hours before testing for VEGF secretion (Rosenthal et 
al., 2007), while for B6-RPE07 cells further tests were performed, as there was no 
information regarding VEGF secretion by these cells. 
VEGF secretion by mouse RPE primary cells was evaluated in cultures from P0 to P3 
after a few days in culture. Five percent FBS-medium was replaced for fresh serum-free 
medium and supernatants (conditioned media) and cell pellets were collected after 24 
hours. A VEGF ELISA was performed using supernatants’ samples and results are presented 
as sVEGF/100 µg protein (pg/mL/100 µg protein) (Figure 3.21). 
 
 
 
 
 
 
 
 
Figure 3.21 – In vitro mouse RPE primary cells secrete sVEGF. RPE primary cells were 
cultured in 96-well plates (P0 to P3) in 5% FBS-media. After 5 days in culture, medium was 
replaced by serum-free medium. Conditioned media and corresponding cell pellets were 
collected 24 hours later. Supernatants’ levels of sVEGF were analyzed by ELISA and results are 
presented as mean value ± SD (P0, N=7; P1, N=9; P2, N=5; P3, N=4), and normalized to total 
amount of protein.  
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 The heterogeneity of values among P0 RPE cultures demonstrates the primary nature 
of these cells. Some culture samples formed confluent monolayers earlier in time, while in 
others cells were more dispersed all over the well, growing and dividing more rapidly. All 
cultures showed measurable sVEGF levels, including at higher passages. However, the 
amount of sVEGF cannot be directly compared between passages as cells are not from the 
same initial source. Moreover, as passage number increases, it got more difficult to have 
enough cells to perform a molecular assay like ELISA. Total amount of protein decreased as 
cells were subcultured, and quantification of whole cell lysate was sometimes impracticable. 
That is the reason why the number of valid samples decreases from P0 to P3. It is important 
to note that even at P3 mouse RPE primary cells continue to secrete sVEGF (Figure 3.21).   
 We have shown, for the first time that B6-RPE07 cells express VEGF protein 
intracellularly (Figure 3.18), but it was necessary to address if sVEGF basal secretion levels 
were detectable in cell culture medium of B6-RPE07 cells. For ELISA experiments, B6-RPE07 
cells between P20 and P30 were considered, and we proved B6-RPE07 secrete basal levels of 
sVEGF overtime (Figure 3.22). In this experiment, serum-free medium and 1% FBS-medium 
were used, and supernatants and cell pellets were collected at 8, 24 and 48 hours after 
medium feeding. A VEGF ELISA was performed using supernatants’ samples and results are 
presented as sVEGF/100 µg protein (Figure 3.22). We observed that sVEGF secretion 
increases with time, and is higher in the presence of 1% FBS-medium. Absence of FBS slows 
down cell metabolism, and explains the difference between sVEGF secretion levels with 1% 
FBS and without, for each timepoint considered. Longer timepoints (72 and 96 hours) were 
tested but not considered in this work, because cell viability without FBS was compromised.  
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Figure 3.22 – B6-RPE07 cells secrete sVEGF. B6-RPE07 cells in culture were fed with serum-
free medium or with 1% FBS-medium. Conditioned media and cell pellets were collected at 
indicated time (8, 24 and 48 hours). Supernatants’ levels of sVEGF were analyzed by ELISA and 
results are presented as mean average value ± SD (N=4), and normalized to total amount of 
protein.  
 
 Serum starvation is known to reduce basal activity of cells and to synchronize cell 
cycle (Pirkmajer & Chibalin, 2011). Moreover, considering VEGF secretion, serum starvation 
period would also work as a clearance time, where cells respond to existing VEGF in cell 
media and activate signal transduction pathways. But one would expect that new synthesis 
and signaling are restrained, with cells becoming more prone to respond to a change in cell 
culture environment. Therefore, we evaluated secretion of sVEGF by B6-RPE07 cells after an 
overnight period of serum starvation. We kept B6-RPE07 cells on serum-free medium for 
approximately 12 hours, and then replaced it for 1% FBS-medium. Supernatants and cell 
pellets were collected at 8, 24 and 48 hours after medium replacement. A VEGF ELISA was 
performed using supernatants’ samples and results are presented as sVEGF/100 µg protein 
(Figure 3.23). We verified that sVEGF secretion increases with time, in a similar way to the 
previous experiment. Several reports point to the use of low percentage of serum in medium 
for measurement of sVEGF secretion levels by RPE cells (Blaauwgeers et al., 1999; Kannan et 
al., 2006; Rosenthal et al., 2007). Since there is no dramatic difference in sVEGF secretion 
between the 2 experimental conditions, with or without serum starvation, we decided to 
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perform further studies regarding sVEGF secretion using a starvation period, followed by 48 
hour-time on 1% FBS-medium. 
 
 
 
 
 
 
 
 
 
Figure 3.23 – B6-RPE07 cells in culture secrete sVEGF in 1% FBS-medium after a serum 
starvation-overnight period. B6-RPE07 cells in culture were fed with fresh serum-free 
medium for approximately 12 hours. Cell medium was then replaced by 1% FBS-containing 
medium. Conditioned media and cell pellets were collected at indicated time (8, 24 and 48 
hours). Supernatants’ levels of VEGF were analyzed by ELISA and results are presented as 
mean average value ± SD (N=3), and normalized to total amount of protein.  
 
3.1.6. Discussion of chosen model 
The advantages of using mice as an experimental model have already been 
mentioned above. Considering RPE cells, the question is what cell model is better: primary 
cells or cell lines? 
The protocol for attain RPE primary cells is considered per se an “isolation” 
procedure. Cells are removed from their in vivo environment and one could only aim for 
them to keep approximately unaltered in vitro, which is highly unfeasible. Clusters of RPE 
cells are always obtained, despite their size variation, and cell monolayers are formed in 
culture. RPE primary cells can be splitted as other cells, but RPE cell cultures rarely display 
the previous phenotype, as process of epithelial morphogenesis is reinitiated upon trypsin 
treatment. Moreover, in order to have enough material to perform a single experiment we 
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always have to pool RPE cells from several mice. Therefore, mouse individuality is lost, and 
differences between mice are attenuated as cells are isolated together. Cell lines came to 
standardize the epithelial morphogenesis process. Only a few days are needed for cells to 
achieve a similar shape as they have before being subcultured. Furthermore, there will be 
less physiological variability from experiment to experiment, and subsequently more 
reproducibility of obtained results. However, we have to keep in mind that during the 
immortalization process some cellular transformations might occur and therefore cells 
derived from a cell line could be different from primary cells. So, in the future, studies using 
primary cells will be required to further confirm results.    
Both mouse RPE primary cells and B6-RPE07 cells used in this work express the 
epithelial markers considered, tight junction protein ZO1 and ion transporter Na
+
/K
+
 ATPase. 
Presence of mRNA of visual cycle proteins CRALBP, RPE65 and RGR confirms RPE nature of 
primary RPE cells. However, B6-RPE07 cells only expressed Rgr mRNA, which might indicate 
that like other visual cycle proteins, expression was silenced or inhibited during the 
immortalization process, because they were not essential for growing in vitro. VEGF was also 
detected at mRNA and protein levels, and both cell types display basal levels of sVEGF 
secretion. Primary mouse RPE cells worked well for characterization procedures, but it 
would be impracticable to use RPE primary cells for experiments where several conditions 
had to be considered at the same time, due to cell number isolation limitation. This problem 
was overcome by using B6-RPE07 cell line, which was the chosen RPE model for subsequent 
studies of this work.    
 
3.2. Generation of molecular tools to study Rab proteins’ function 
3.2.1. State-of-the-art 
The use of RNA interference (RNAi) as a tool to trigger gene-silencing was first 
revealed by Andrew Fire when Caenorhabditis elegans fed on a bacteria expressing GFP 
double stranded (ds) RNA showed silencing of a GFP reporter. This finding led to a revolution 
in the understanding of gene regulation. Subsequently, different groups reported other 
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miRNA generation principles were worldwide adapted to both scientific research and 
DNA recombination techniques for achievement of target gene silencing. In the present 
work, miRNA principles were applied to viral vectors so that miRNA molecules could be 
delivered to our cell models, both RPE primary cells and mouse RPE cell line. Nowadays, 
several technologies exist that can generate miRNAs. To study Rab GTPases involvement on 
VEGF secretion by RPE cells we have used BLOCK-iT™ Pol II miR RNAi Technology (Life 
Technologies). This technology is based on the Gateway® system, and uses expression 
vectors that allow expression of miRNA-based KD cassettes driven by RNA Polymerase II 
promoter in mammalian cells. Co-cistronic expression of EmGFP permits visual selection of 
cells expressing pre-miRNA. miRNA sequences for target genes were designed and cloned in 
an expression vector (pcDNA
™
6.2-GW/EmGFP-miR), enabling subsequent generation of 
replicative-deficient adenoviral or lentiviral particles, for transient or stable RNAi analysis, 
respectively.  
It is important to take in account that no single vector system is likely to be optimal 
for all potential gene therapy applications, and in most cases, viral vectors are part of the 
treatment along with standard pharmacological substances. Retroviruses are the most 
common vectors used, and adenoviruses follow because they are ubiquitous, have a rapidly 
transduction rate, and low pathogenicity in humans. Moreover, their genome does not 
undergo rearrangements at a high rate, they can accommodate relatively large segments of 
DNA and, most important, they are easy to manipulate using recombinant DNA techniques. 
Since adenoviral vectors transmit their genes to host cell nucleus, but they do not insert the 
genes into the host genome, adenoviral vector-based approaches limit gene therapy to 
treatment strategies in which only temporary protein expression is needed. For long term 
expression lentiviral vectors are desirable. Retroviral vectors have been long favoured for 
gene transfer because they integrate efficiently into the chromatin of target cells without 
transfering any viral genes. Unlike retroviruses, which do not transduce non-dividing cells, 
lentiviruses transduce actively dividing as well as resting and differentiated cells and thus, 
lentiviral vectors are usually preferred for long-term expression of transgenes (Manjunath, 
Wu, Subramanya, & Shankar, 2009; Vorburger & Hunt, 2002). 
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For the purpose of this work we generated both adenoviruses and lentiviruses, but 
the first were preferred for screening experiments in B6-RPE07, allowing transient 
expression of miR KD cassette.  
 
3.2.2. Rab proteins’ expression in mouse RPE cell models  
Some of the known Rab proteins have already been studied in the RPE context, 
mainly due to their loss-of-function in RPE diseases, like choroideremia and GS (Pereira-Leal, 
Hume, & Seabra, 2001). But, until now, there is no wide-ranging study on Rab proteins’ 
expression by RPE cells.  
A Rab expression profile of our RPE cells is fundamental at foremost. We evaluated 
Rab proteins’ expression in both mouse RPE primary cultures and B6-RPE07 cell line so we 
can compare results among them. A RT-PCR analysis was performed using primer sequences 
already validated by another study (Diekmann et al., 2011) (Table VIII, see Supplementary 
Material). We also considered including Rab29 and Rab40c, whose primer sequences are 
listed in Table IV. 
Table IV –Primer sequences used for Rab7l1 and Rab40c expression study in RPE cells. 
Gene Sequences (5’- 3’) Size (bp) 
Rab7l1 
(Rab29) 
Forward ATGGGCAGCCGAGATCACCTGTTT 
619 
Reserve CCAACTAGCAGCATGTCCAGCCAGAGGA 
 
Rab40c 
Forward AGCCATGAACGCTGTCATGATGCACGGC 
 164 Reverse ATGTCTAGGAGATCTTGCAGTTGCTCCG 
  
 
RT-PCR screening was performed using B6-RPE07 cells and 5 different RPE primary 
cultures (see Figure 6.1, Supplementary Material). By using cDNA preparations from 5 
different cultures we are considering a wider range of RPE cells, and eliminating individual 
disparities. Rab expression profile of our RPE cells is summarized in Table V. Analysis of our 
screening results allowed us to conclude that most of Rab GTPase family members are 
expressed both in all mouse RPE primary cells and cell line. We have also noticed that Rab5a 
and Rab13 are not present in all RPE primary cells, but only in 4/5 and 2/5, respectively. The 
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list of Rabs not expressed in RPE cells includes Rab3c, Rab17, Rab19, Rab25, Rab26, Rab37, 
Rab39a, Rab40b and Rab44. mRNA for these Rabs was not detected in either B6-RPE07 cells 
or in none 5 different RPE primary cells. Moreover, Rab9b and Rab33a mRNA was detected 
only in mouse RPE primary cells; these 2 Rab proteins were not expressed in B6-RPE07 cell 
line. The information accomplished here is pioneer in the field, and valuable for the next 
tasks of this work, which include the generation of molecular tools to achieve Rab proteins’ 
silencing.  
 
Table V – Rab proteins’ expression profile of primary RPE cells (pRPE) 
and B6-RPE cell line. 
Rab B6-RPE07 pRPE Rab B6-RPE07 pRPE 
1a + 5/5 19 - 0/5 
1b + 5/5 20 + 5/5 
2a + 5/5 21 + 5/5 
2b + 5/5 22a + 5/5 
3a + 5/5 22b + 5/5 
3b + 5/5 23 + 5/5 
3c - 0/5 24 + 5/5 
3d + 5/5 25 - 0/5 
4a + 5/5 26 - 0/5 
4b + 5/5 27a + 5/5 
5a + 4/5 27b + 5/5 
5b + 5/5 28 + 5/5 
5c + 5/5 29 + 5/5 
6a + 5/5 30 + 5/5 
6b + 5/5 32 + 5/5 
7a + 5/5 33a - 5/5 
7b + 5/5 33b + 5/5 
8a + 5/5 34 + 5/5 
8b + 5/5 35 + 5/5 
9a + 5/5 36 + 5/5 
9b - 5/5 37 - 0/5 
10 + 5/5 38 + 5/5 
11a + 5/5 39a - 0/5 
11b + 5/5 39b + 5/5 
12 + 5/5 40b - 0/5 
13 + 2/5 40c + 5/5 
14 + 5/5 42 + 5/5 
15 + 5/5 43 + 5/5 
17 - 0/5 44 - 0/5 
18 + 5/5 
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3.2.3. Cloning of miRNA-silencing sequences for target genes 
Rab GTPases were the target genes of interest for this work. Some of the 59 isoforms 
were not expressed in our RPE model, but we decided to include them in subsequent cloning 
task of miRNA-silencing sequences. Molecular tools for such Rab proteins are therefore 
available for future studies, despite they not have been used in the present work. 
 The ssDNA oligos were designed and annealed to create dsDNA oligos as previously 
described in Chapter 2. These silencing sequences were cloned into an expression vector. 
The purpose was to clone all mouse Rab proteins considered in the previous RT-PCR 
screening, but due to limitations in designing an efficient KD sequence, some Rab proteins 
had to be excluded. Table VI summarizes miR sequences that were designed and cloned for 
each target protein (named as part of a database), as well as the corresponding adenoviral 
and lentiviral constructs. For each target protein at least 2 silencing sequences were 
designed at first. However, for Rab22b only one was cloned into viral vectors, as the other 
did not work well. For some Rab proteins more than 2 sequences were cloned. The efficiency 
of each sequence on target proteins’ KD was further tested. Unfortunately, by using this 
approach of miRNA design, we did not manage to get silencing sequences for Rab1a, Rab1b, 
Rab33a, Rab39b and Rab44. 
 
Table VI – List of miRNA sequences designed and cloned into adenoviral and lentiviral 
viruses for corresponding Rab proteins. Table VI is divided into the next 3 pages.  
The last 2 columns refer to the clone number obtained. 
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3.2.4. Transfection of mammalian cells to achieve transient RNAi analysis using an 
expression vector 
In order to quickly test for the KD efficiency of different cloned sequences of miRNA, 
HEK-293FT cells were co-transfected with both miR expression vector and a positive control 
vector. In this work vectors encoding for a GFP-tagged version of the protein of interest were 
used as positive controls.  
Transfection procedure was performed as previously described in Material and 
Methods. Cells were harvested in lysis buffer (150 mM Tris-HCl pH 7.4, 50 mM NaCl) after 24 
hours and prepared for blotting. Western Blot analysis was carried out using anti-GFP 
antibody for all target proteins and we have obtained similar levels of KD for most tested 
Rab proteins. Figure 3.25 depicts the results obtained for Rab6a and Rab11a to exemplify 
transiently KD efficiency evaluation. For both Rab6a and Rab11a most colonies of vectors 
containing miR-silencing sequences showed to reduce the corresponding GTP-tagged Rab 
protein (positive control on the right side of Figure 3.25). For Rab6a (Figure 3.25, A), both 
chosen sequences of miR proved to be silencing the overexpressed protein, but the KD effect 
of miR 625/626 is stronger. Colonies C14 of miR 623/624 and C28 of miR 625/626 were 
selected for sequencing. Their sequences were correct and were used for adenoviral and 
lentiviral production. Other colonies were kept in stock despite not used primarily. 
Regarding Rab11a (Figure 3.25, B), miR 399/400 proved to be more effective in KD the target 
protein than miR 401/402, as in this case C60 did not work at all, because no silencing effect 
was detected. Colonies C1 and C31 of expression vectors containing both miR 399/400 and 
miR 401/402, respectively, were selected for sequencing and further viral production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 – GFP-tagged Rab6a and 
transiently KD by miR-silencing sequences.
plasmids, one encoding a GFP
other encoding miRNAs in test
the gel and actin was used as 
tested per miRNA plasmid due
were evaluated by anti-GFP staining relative to control for Rab6a
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3.2.5. Transduction of RPE cells using adenoviral particles 
To evaluate Rab GTPases role on VEGF secretion from the 59 potential targets we 
decided to focus on key Rab proteins belonging to secretory, endocytic and recycling 
pathways, according to the literature. Rab3a, Rab3b, Rab3d, Rab6a, Rab6b, Rab8a, Rab8b, 
Rab10, Rab14, Rab27a and Rab27b were selected as secretory Rab proteins. From endocytic 
and recycling pathways we chose Rab4a, Rab4b, Rab5a, Rab5b, Rab5c, Rab7a, Rab11a, 
Rab11b, Rab15, Rab21, Rab22a and Rab22b to study their involvement in sVEGF secretion by 
RPE cells. In total we investigated the role of 23 Rab proteins, but others were left aside.  
 
3.2.5.1. Viral titer calculation 
An accurate and rapid viral titration is essential for optimization and reliability of 
experiments. More precisely, it is the titer of infectious particles that better reproduces the 
ability of infectious adenoviral vectors to produce quantifiable biological events. Viral titer 
can be quantified by plaque assay, being this assay considered a standard method because 
its accuracy and reproducibility; however it is time-consuming and operator-dependent for 
absolute determinations (Gueret, Negrete-Virgen, Lyddiatt, & Al-Rubeai, 2002). Since our 
adenoviral vectors contain the EmGFP reporter gene we could reliably use flow cytometry to 
easily perform this quantification. A method for rapid titration of adenoviral infectivity by 
flow cytometry was described and validated using the old-fashion plaque assay (Gueret et 
al., 2002). Adjustments to this model were made in order to use it for our B6-RPE07 cells. 
Using flow cytometry we were able to calculate the viral titer of each preparation of 
adenoviruses to further use. Viral titer determination allowed us to calculate the multiplicity 
of infection (MOI) for B6-RPE07 cells. MOI usually refers to the number of virions that are 
added per cell during transduction. MOI determination helps on standardization of 
experiments, and is calculated using the formula (volume of virus in mL x viral titer)/cell 
number. The right MOI for an experimental purpose needs to be determined for the system 
in use. Usually a range of values is first tested and their effect on cells’ biology evaluated. 
Until now, there was no information on B6-RPE07 cells transduction by adenoviruses neither 
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on required MOI. So we further tested whether these cells were adenoviral-transduced, and 
the required MOI to achieve target proteins’ KD.  
Three preparations from previous generated GFP-expressing adenoviruses were 
considered as representatives: one containing a random miR sequence that does not target 
any known vertebrate gene (negative control), therefore referred as miR-Neg, one 
containing a miR silencing sequence for Rab22b, and one containing GFP-tagged Rab22a. 
The use of these adenoviral particles containing GFP-tagged Rab proteins is widely reported 
from previous studies (Lopes da Silva et al., 2012; Lopes et al., 2007). A wide range of volume 
of each virus (between 0.15 and 300 µL) was added to B6-RPE07 cells, and transduction was 
left to occur overnight. On the next day cells were prepared for flow cytometry and the 
corresponding percentage of GFP
+
 cells was determined (Figure 3.26). We verified that, for 
small volumes of virus, there is a linear relationship between percentage of transduced GFP
+
 
cells and virus volume used. For higher volumes the saturation peak is reached and there is 
no noticeable difference in percentage of GFP
+
 cells. Moreover, there was no difference in 
transduction capacity among different adenoviruses tested (miR-Neg, GFP-tagged Rab22a 
and miR-Rab22b). In the linear zone, one transduced cell corresponds to a single viral 
particle delivery, and the titer can be calculated in gfu/mL using the formula [(% transduced 
cells x total cell number at time of transduction/volume of inoculum) x viral dilution factor] 
adapted from Gueret et al., 2002.  
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Figure 3.26 – Correlation of percentage of GFP
+
 B6-RPE07 cells with volume of virus 
used for transduction. B6-RPE07 cells were transduced with increasing volumes of 3 
different viral preparations containing GFP reporter cassette. Flow cytometry analysis was 
performed 24 hours later. Percentage of GFP
+
 cells correlates with volume of virus added. For 
small volumes a linear zone can be defined and used for titer calculation. No differences in 
percentage of infected cells were noted for different adenoviral backbones. Results are 
presented as mean average value (N=3) ± SD.  
 
 
Next, we selected one to 3 miR sequences-containing adenoviral vectors and the 
correspondent GFP-tagged Rab proteins for viral titration. All adenoviral preparations of 
these constructs were titrated using flow cytometry method based on GFP detection, and 
obtained titers are listed in Table VII. Only high titer preparations (10
9
 to 10
11
) were used for 
B6-RPE07 cell transduction in further experiments.  
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Table VII – Titer of adenoviral preparations used in study of Rab proteins’ function. 
Rab 
protein 
Viral 
contents 
Clone 
number 
Titer (gfu mL
-1
) 
Rab 
protein 
Viral 
contents 
Clone 
number 
Titer (gfu mL
-1
) 
 
miR-Neg #2810 C46 (2.24±0.82)E+10 
Rab8a 
GFP-Rab8a #1058 C52 (1.03±0.86)E+10 
Rab3a 
GFP-Rab3a #1451 C48 (2.15±0.74)E+09 miR 749/750 #3201 C63 (1.34±0.34)E+10 
miR 371/372 #1829 C7 (4.38±2.44)E+10 miR 751/752 #3202C115 (3.1±0.42)E+10 
miR 373/374 #1568 C2 (2.77±0.58)E+09 
Rab8b 
GFP-Rab8b #1059 C58 (9.07±6.87)E+09 
Rab3b 
GFP-Rab3b #1650 C59 (1.33±1.03)E+10 miR 693/694 #2963 C93 (4.23±1)E+10 
miR 375/376 #2292 C1 (1.77±0.99)E+10 miR 757/758 #3204 C86 (5.58±0.29)E+10 
miR 377/378 #2293 C82 (4.09±0.28)E+10 
Rab10 
GFP-Rab10 #1458 C83 (1.28±0.98)E+10 
Rab3d 
GFP-Rab3d #1714 C1 (2.75±0.92)E+09 miR 267/268 #2211 C2 (7.54±5.33)E+09 
miR 383/384 #2296 C90 (3.82±1.56)E+09 miR 269/270 #2212 C43 (6.1±0.16)E+09 
miR 385/386 #2297 C92 (3.62±0.53)E+10 
Rab11a 
GFP-Rab11a #1453 C57 (2.04±0.7)E+09 
Rab4a 
GFP-Rab4a #1452 C54 (9.87±7.14)E+09 miR 399/400 #2290 C74 (3.84±0.69)E+10 
miR 387/388 #2423 C24 (2.66±1.51)E+09 miR 401/402 #2291 C76 (3.67±0.66)E+10 
miR 389/390 #2424 C28 (4.02±1.85)E+09 
Rab11b 
GFP-Rab11b #1718 C5 (4.71±4.32)E+10 
Rab4b 
GFP-Rab4b #1898 C8 (9.31±6.22)E+09 miR 395/396 #2421 C19 (4.66±0.65)E+09 
miR 391/392 #2425 C16 (1.85±0.77)E+09 miR 397/398 #2422 C31 (1.35±0.39)E+09 
miR 393/394 #2426 C35 (1.47±0.62)E+09 miR 567/568 #2632 C15 (2.78±1.79)E+09 
Rab5a 
GFP-Rab5a #1456 C75 (1.03±0.75)E+10 
Rab14 
GFP-Rab14 #1449 C38 (6.94±4.56)E+09 
miR 305/306 #2215 C6 (3.65±1.69)E+10 miR 367/368 #2318 C56 (8.17±1.04)E+09 
miR 307/308 #2216 C60 (2.29±0.05)E+09 miR 369/370 #2319 C61 (1.37±0.5)E+10 
miR 309/310 #2217 C66 (7.02±0.74)E+09 
Rab15 
GFP-Rab15 #1715 C8 (2.38±1.71)E+09 
Rab5b 
GFP-Rab5b #1461 C97 (8.58±5.5)E+09 miR 579/580 #2675 C36 (1.03±0.93)E+10 
miR 347/348 #2312 C33 (9.43±2.21)E+09 miR 581/582 #2631 C14 (2.24±0.89)E+09 
miR 349/350 #2313 C38 (1.64±0.17)E+09 
Rab21 
GFP-Rab21 #1654 C90 (1.56±1.41)E+11 
Rab5c 
GFP-Rab5c #1543 C7 (1.5±1.1)E+10 miR 431/432 #2433 C26 (5.12±0.94)E+09 
miR 351/352 #2314 C41 (4.75±0.45)E+09 miR 433/434 #2434 C27 (2.19±0.17)E+09 
miR 353/354 #2315 C46 (1.34±0.17)E+09 
Rab22a 
GFP-Rab22a #1658 C30 (3.42±0.87)E+10 
Rab6a 
GFP-Rab6a #1462 C102 (3.93±2.32)E+10 miR 615/616 #2849 C17 (2.84±2.36)+09 
miR 625/626 #2955 C2 (3.74±0.42)E+09 miR 621/622 #2986 C159 (3.31±0.28)E+10 
miR 627/628 #2956 C63 (3.9±0.45)E+09 
Rab22b 
GFP-Rab22b #2221 C12 (6.08±3.97)E+09 
miR 723/724 #3199 C29 (2.56±0.25)E+10 miR 639/640 #2964 C102 (2.04±0.43)E+10 
Rab6b 
GFP-Rab6b #1459 C88 (1.5±0.94)E+10 
Rab27a 
GFP-Rab27a #1897 C5 (1.97±1.68)E+10 
miR 521/522 #2606 C12 (5.93±0.57)E+09 miR 459/460 #2522 C5 (1.65±0.27)E+09 
miR 523/524 #2607 C17 (1.86±0.48)E+10 miR 461/462 #2523 C8 (2.59±0.57)E+09 
Rab7a 
GFP-Rab7a #1280 C17 (1.72±1.3)E+10 
Rab27b 
GFP-Rab27b #1660 C38 (2.28±0.73)E+09 
miR 363/364 #2316 C49 (1.77±0.17)E+09 miR 743/744 #3209 C10 (1.77±0.99)E+10 
miR 365/366 #2317 C53 (1.89±0.34)E+09 miR 745/746 #3210C55 (1.16±0.18)E+10 
 
3.2.5.2. Influence of viral particles on cell survival 
Viral titers obtained were used in calculation of suitable MOI for B6-RPE07. For 
adenoviruses, MOI described to be used in literature vary from 1 to 10,000 depending on cell 
type. For B6-RPE07 cells we started to test MOI up to 1,000. Evaluation of cellular GFP 
intensity was performed using a fluorescence microscope and we concluded that at MOI 
1,000 only around 50% of cells were transduced at 24 hours post-transduction. We further 
tested higher MOI and their effect on cell survival since cell integrity needs to be assured.  
 We determined if high MOI of adenoviruses induce B6-RPE07 cell death using a MTT 
assay. We tested miR-Neg construct, 2 adenoviral vectors containing miR-Rab sequences 
(miR-Rab3a and miR-Rab14), and corresponding GFP-tagged Rab proteins constructs (GFP-
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tagged Rab3a and GFP-tagged Rab14
miR sequences were used together, at MOI 2
cell survival relative to non-transduced cells (NT) was determined at day 3 post
(Figure 3.27). Our results showed that in neither 
cell death. At MOI 2,500/ea none of viruses influenced cell survival. At MOI 5,000/ea 
GFP-tagged Rab14 adenovirus slightly increased cell survival. At last, at MOI 7,500/ea 
miR-Rab14 and GFP-tagged Rab14 
survival confirm that higher adenoviral MOI used in B6
and we extrapolated this fact for all the adenoviral vectors in use. 
of cell survival are not significant for 
the use of adenoviral MOI up to 10
Singh, 2008), and we verified 
5,000/ea). Therefore, in our posterior experiments
of each miR sequence-containing const
Figure 3.27 – High MOI of adenoviruses 
Adenoviral MOI of 2,500, 5,000 and 7
Adenoviral influence on cell survival was determined by MTT assay at day 3 post
At MOI 2,500/ea none of adenoviruses influenced cell survival. At MOI 5,000/ea GFP
Rab14 adenovirus slightly potentiated cell survival. 
tagged Rab14 adenoviruses 
value (N=4) ± SD. *0,05≤p<0,01; ***p
). For each Rab protein, both 2 constructs containing 
,500, 5,000 and 7,500 each (ea). Percentage of 
MOI tested adenoviruses caused B6
adenoviruses increase cell survival. These
-RPE07 cells do not cause their death, 
The results on increasing
the purpose of this work. Other groups have reported 
,000 (C. Y. Chen et al., 2011; Ramo, Cashman, & Kumar
that this MOI did not affect B6-RPE07 cells’ viability
 we decided to use adenoviral MOI 5
ruct to induce KD of target proteins.
slightly influence B6-RPE07 cell survival. 
,500 of each (ea) virus were tested in
At MOI 7,500/ea both miR
increased cell survival. Results are presented as 
≤0,001. 
-transduction 
-RPE07 
only 
both 
 results on cell 
 
-
 (MOI 
,000 
 
 B6-RPE07 cells. 
-transduction. 
-tagged 
-Rab14 and GFP-
mean average 
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3.2.5.3. Rab proteins’ KD by miR-containing adenoviruses 
The efficiency of KD of target proteins was verified earlier using the expression 
vectors (section 3.2.4.). In order to deliver miR sequences by transduction of B6-RPE07 we 
had to subsequently clone these sequences into adenoviral vectors, and therefore the 
efficiency of transduction’s step needed to be verified. Previous analysis of KD levels of Rab 
proteins involved a co-transfection with both GFP-tagged protein and miR sequence. 
Therefore, we have also transduced B6-RPE07 cells with GFP-tagged Rab protein adenovirus 
and corresponding adenoviruses containing miR sequences. Rab proteins’ KD level achieved 
by adenoviral delivery of miR sequences was assessed by Western Blot analysis of total cell 
lysates using an anti-GFP antibody.  
For each Rab protein there were one, 2 or 3 different miR sequences tested, which in 
total performed adenoviral MOI of 5,000, 10,000 or 15,000, respectively. MOI of GFP-tagged 
Rab protein adenoviruses used was 3,000, lower than miR adenoviruses, but enough to 
obtain transduction efficiency around 100% of cells. For each target protein, there were 2 
conditions for Western Blot analysis: a positive control (GFP-tagged Rab only) and GFP-
tagged Rab plus miR sequences viruses. Adenoviruses were added all at once, and 
transduction was left to occur for 5 to 6 hours. Cells were fed with fresh medium and were 
harvested at 24 hours post-transduction in lysis buffer and prepared for Western Blot 
analysis. Rab proteins’ KD levels were evaluated by probing membranes with an anti-GFP 
antibody and using calnexin as loading control (Figure 3.28).  
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Figure 3.28 – miRNA sequences 
proteins. B6-RPE07 cells were 
control) and corresponding adenoviruses containing miR sequences
protein. Cells were fed with fresh medium 
Western Blot analysis 24 hours
comparison of staining intensities: 
sequences (miR). Calnexin was used as loading control. 
delivered by adenoviruses perform KD of target Rab 
transduced with GFP-tagged Rab protein adenovirus (positive 
, plus GFP
5 to 6 hours after transduction, and harvested for 
 later. Anti-GFP staining revealed KD levels of target protein by 
positive control (+) versus GFP-tagged Rab plus miR 
 
-tagged Rab 
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Our results show 2 bands for GFP staining: one for GFP-Rab protein around 50 KDa 
(positive control) and another for EmGFP encoded by miRNA-containing vector (25 KDa). 
Two separate experiments were performed with approximately same outcome (see 
Supplementary Material, Figure 6.2). Efficiency of KD was evaluated by comparing the 
intensity of GFP-tagged Rab plus miR sequence staining with positive control alone. For most 
of Rab proteins tested KD levels were 50% or higher, except for Rab3a and Rab27b, whose 
silencing was not much efficient (20-30%). MOI added were consistent among samples but 
still there are differences on the intensity of EmGFP driven by adenoviruses between 
samples. This might be due to inherent variations among viral preparations despite their 
titration, and to the viral construct itself. Using this cell system and these tools we never got 
100% KD, probably because not all cells transduced with miR-silencing sequences were also 
transduced with GFP-Rab target protein. Determination of endogenous levels of Rab 
proteins’ expression after cell transduction with adenoviruses could overcome this 
limitation, and improve achievement of higher KD of target protein.  
To summarize, our results indicate that the adenoviral molecular tools for Rab 
proteins’ KD that were tested proved to be efficient in silencing GFP-tagged versions of 
corresponding Rab proteins, and they are now ready to be useful in further assays. 
 
3.2.6. Generation of stable cell lines 
 A stable RNAi analysis requires integration of miR-silencing sequence into the 
genome of host cell and its constant expression. Lentiviral vectors are usually used to drive 
gene integration, but few cells efficiently integrate the plasmid in the end. An antibiotic 
selection of transduced cells is required in order to eliminate non-transduced cells and 
maximize transduction efficiency.  
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The backbone of lentiviral plasmids 
antibiotic resistance to blasticidin, and cytotoxicity of b
was assessed to enable selection for transduced cells. In order to determinate 
concentration to use, non-
concentrations of blasticidin, 
assay (Figure 3.29). We verified that at day 3, 6 µg/mL b
95% cell death, while at day 5 few cells in 4 
that blasticidin concentration of 
selection of transduced cells.  
 
 
 
 
 
 
 
 
Figure 3.29 – Blasticidin induces c
treated with increasing concentrations of blasticidin for 
assessed at day 3 and day 5 
(N=3) ± SD. ***p≤0,001.  
 
miR sequence-containing 
lentiviral vector. In this work lentiviruses were not used in further experiments, however 
they are ready to be use in any context later. 
 
 
 
used in this work includes the DNA sequenc
lasticidin treatment on B6
transduced B6-RPE07 cells were treated wit
and cell survival was evaluated at day 3 and day 5 using a
lasticidin was sufficient to cause over 
µg/mL blasticidin remain. These results indicate
6 µg/mL for 3 days was a suitable dose for antibiotic 
 
ytotoxicity on B6-RPE07 cell line. B6
3 and 5 days. The cytotoxic effect was 
using MTT assay. Results are presented as mean average value 
constructs were designed and cloned into the destination 
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3.3. Screening of Rab proteins involved in VEGF secretion by mouse RPE cells 
3.3.1. Development and optimization of a protocol for screening Rab proteins 
involved in VEGF secretion by mouse RPE cells 
RPE cells have long been studied for secretion of growth factors and cytokines, and 
assays are performed according to each cell type and specific aims. In some cases, stimuli are 
used for cellular secretory machine, aiming to increase or decrease secreted molecules’ 
levels. Such variations can be caused by chemicals, hypoxia or hyperoxia, co-culture with 
other cell types, addition of pathogens, and others. For VEGF the most common stimulus is 
hypoxia, as VEGF gene regulation depends on HIF-1α activity, which is potentiated under 
hypoxic conditions. Hypoxia can be achieved by regulating oxygen tension directly or by 
mimicking its effect, using transition metals for example. Cobalt and nickel can activate 
hypoxia-mediated signaling pathways aberrantly during normoxia, and are currently used as 
hypoxia-mimicking agents (Vengellur & LaPres, 2004). Here, we first investigated whether 
cobalt could potentiate sVEGF secretion by B6-RPE07 cells, and therefore could be used as a 
stimulus.   
Following the choice of a stimulus, it is important to determine the time course of the 
assay that will allow detecting variations in secreted molecules’ levels. Regarding sVEGF 
secretion, different timepoints have been reported for RPE cells, ranging from some minutes 
to 2 days (Bian, Elner, & Elner, 2007; Slomiany & Rosenzweig, 2006). In our system, we have 
showed above that sVEGF levels were measurable at 48 hours after an overnight serum 
starvation-period (Figure 3.23). From here we looked for a protocol that allowed us to detect 
differences in sVEGF secretion levels by B6-RPE07 cells when Rab proteins’ KD was at a 
maximum level.   
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3.3.1.1. Stimulation of VEGF secretion by CoCl
Cobalt chloride has been described as a hypoxia
hydroxylases enzymes, therefore allowing HIF
transcription factor in Vegfa gene. We first tested a range of CoCl
cytotoxicity in B6-RPE07 cells overtime. B6
100 µM of CoCl2 for 24, 48 and 72 hours and a
CoCl2 toxicity (Figure 3.30). B6
periods longer than 24 hours. 
concentration increases, cell survival decreases. The same is true for 72 hours incubation 
time. Therefore 100 µM of CoCl
cytotoxic effects. We further tested effect of 25, 50 and 75 µM concentrations of CoCl
sVEGF secretion.  
 
 
 
 
 
 
 
 
 
Figure 3.30 – CoCl2 cytotoxic effect on 
increasing amounts of CoCl2 
cell viability was assessed by MTT assay. At 24 hours none
with cell viability. At 48 and 72 hours, increasing amounts of CoCl
cell survival. Results are presented as mean average value 
**0,01≤p<0,001.  
 
2  
-mimicking agent, as cobalt inhibits 
-1α translocation to the nucleus where it acts a 
2 concentrat
-RPE07 cells were incubated with 25, 50, 75 and 
 MTT viability assay was performed to evaluate 
-RPE07 incubation with CoCl2 proved cytotoxicity of 100 µM in 
We have also observed that after 48 hours, as CoCl
2 was discarded as a stimulus for sVEGF secretion due its 
B6-RPE07 cell line. B6-RPE07 cells
(25, 50, 75 and 100 µM) for 24, 48 and 72 hours. Toxic effect on 
 of the concentration
2 correlate with decreasing 
(N=3) ± SD.
ions and their 
2 
2 on 
 were exposed to 
s interfered 
 *0,05≤p<0,01; 
 
Previous data pointed to 48 hours as a potential timepoin
measurement (unstimulatory condition). We then tested whether CoCl
sVEGF secretion levels by B6
conditions tested for basal levels 
starvation). B6-RPE07 cells were incubated 
ELISA was performed using supernatants’ samples
relative to Control (unstimulated cells) (Figure 3.31). Simi
models, CoCl2 induced a significant increase of sVEGF secretion by B6
Román, Ibarra-Sánchez, Lamas, & González Espinosa, 2010; Liu et al., 1999; Slomiany & 
Rosenzweig, 2006). At 48 hour
when compared to unstimulated cells; 50 µM of CoCl
sVEGF secretion in 3,5-fold. 
 
 
 
 
 
 
 
 
 
Figure 3.31 – B6-RPE07 cells secrete 
incubated with 25, 50 and 75 µM of CoCl
starvation period. Conditioned media and cell pellets were collected and supernatants’ level
of sVEGF were quantified by ELISA, showing a correlation between CoCl
sVEGF levels. Results are presented as mean average value 
 
 
t for sVEGF basal levels 
-RPE07 cells after 48 hours incubation time
(1% FBS-medium, after an overnight period of serum 
with 25, 50 and 75 µM of CoCl2 and a
. Results are presented as sVEGF levels 
larly to reports from other cell 
-RPE07 cells
-time, 25 µM of CoCl2 increased sVEGF 
2, almost 3-fold, and 75 µM, increased 
sVEGF in response to CoCl2. B6-RPE07 cell line was 
2 for 48 hour, preceded by an overnight serum
2 concentration and 
(N=3) ± SD. *0,05≤p<0,01.
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 Putting all data together, we verified that CoCl2 is indeed an adequate hypoxia-
mimicking agent for B6-RPE07 cells, as sVEGF secretion levels increase when cells are 
incubated with a CoCl2-containing solution. Higher concentrations tested (75 and 100 µM) of 
CoCl2 induced cell death at 48 hours and were discarded. The lowest amount tested (25 µM) 
did not affect cell viability and showed a 2-fold induction of sVEGF secretion. At last, 50 µM 
of CoCl2 caused higher induction of sVEGF secretion (compared to 25 µM) at 48 hours 
without a lot of cell death (only 10%), and therefore we selected it as an inducer of sVEGF 
secretion by B6-RPE07 cells in further experiments.  
 
3.3.1.2. Endogenous Rab proteins’ KD by miR-containing adenoviruses 
miR-silencing adenoviruses’ efficiency was tested by simultaneous transduction of 
B6-RPE07 cells with the corresponding GFP-tagged adenovirus of each target protein. 
However, timing of endogenous levels of Rab proteins’ silencing also needed to be assessed. 
We decided to evaluate endogenous Rab proteins KD at day 3 after transduction, because 
the transduction step requires a serum starvation period, and quantification of sVEGF levels 
works fine at 48 hours time. Some reports show maximum expression of adenoviral vectors 
at day 3 after transduction of RPE cells (Ramo et al., 2008; Wittchen & Hartnett, 2011). In 
our case, longer periods would be unsuitable for sVEGF secretion measurements, because 
cell biology of B6-RPE07 would be affected by prolonged growing in 1% FBS-medium. We 
tested Rab proteins’ KD at day 5 after adenoviral transduction anyway, to assess adenoviral-
silencing performance in this system.  
Six Rab proteins were selected for this assay: Rab3a, Rab6a, Rab6b, Rab14, Rab15 
and Rab22a (1/4 of total Rab proteins under study). B6-RPE07 cells were transduced with 
MOI 5,000 of each adenoviral construct, since this MOI was enough to efficiently KD 
overexpressed Rab proteins (Figure 3.28). Cells were fed with fresh medium after 5 to 6 
hours, and left overnight to recover from transduction. Next morning, cell medium was 
replaced by serum free-medium, and cells were incubated for approximately 10 to 12 hours 
(day 1 post-transduction). Following serum starvation, cells were fed with 1% FBS-medium. 
On day 3 (48 hours later) and day 5 (96 hours later) cell pellets were preparared for RNA 
 
isolation and cDNA preparation.
depicted at Figure 3.32. 
  
 
 
 
 
Figure 3.32 – Schematic representation of experimental procedure for screening Rab 
proteins involved in VEGF secretion by B6
adenoviruses were added. Transduction was left to occur for 5 to 6 hours, and fresh medium 
was added. Next day cells were serum
replaced for 1% FBS-medium
pellets were collected and processed. 
 
qRT-PCR analysis was performed, us
presented as relative quantification (RQ) to 
condition (Figure 3.33). qRT-
adenoviruses in silencing endogenous levels of selected target Rab proteins. 
show that endogenous levels of 
sequences. On average we have obtained 58% of KD (range from 40
transduction for all Rab proteins tested. We have also observed that, for
except Rab14, the silencing effect was
by day 5, there was 10% more KD of the protein levels than by day 3. Rab15’s example 
confirms that day 3 is a better timepoint when considering silencing of target proteins driven 
by adenoviruses in B6-RPE07 cells
and day 5 we verified that by day 5 m
at day 3. 
 Schematic representation of this experimental procedure is 
-RPE07 cells. B6-RPE07 cells
-starved for 10 to 12 hours, and then medium was 
. At day 3 and day 5 post-transduction supernatants and cell 
 
ing actin as endogenous control and r
levels of target Rab proteins at 
PCR analysis confirmed efficacy of generated miR sequence 
Rab GTPases were efficiently reduced by miR
-90%) on day 3 post
 attenuated by day 5, compared to day 3. For Rab14, 
. In general, when we compared KD levels between day 3 
ost of them had already recover from level of KD seen 
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Figure 3.33 – Endogenous Rab proteins are efficiently KD by 
delivered by adenoviruses.
miR-silencing sequences for target Rab proteins
Rab22a). After 5 to 6 hours, virus
were left to recover overnight. On day 1 
hours preceded incubation with 1% FBS
were processed for qRT-PCR analysis. Endogenous Rab protein
relative to miR-Neg condition, and for most of them, KD levels were higher by day 3 than by 
day 5 post-transduction. Results are presented as mean average value 
considered as endogenous control. *0,05
 
 Taking together our data regarding finding the best timepoint to evaluate VEGF 
secretion, establishing best CoCl
determining the proper transduction conditions (MOI, timepoints, serum percentage) to 
achieve an efficient KD of endogenous levels of 
first time a protocol to investigate Rab proteins’ role in 
 
 
 
miRNA sequences 
 B6-RPE07 cells were transduced with adenoviruses containing 
 (Rab3a, Rab6a, Rab6b, Rab14, Rab15 and 
es were removed and fresh medium was added, and cells 
post-transduction, a serum starvation time of 10 to 12 
-medium. At day 3 and 5 post-transduction
s’ levels were d
(N=3) 
≤p<0,01; **0,01≤p<0,001; ***p≤0,001. 
2 concentrations to stimulate sVEGF secretion
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3.3.2. Screening of Rab proteins’ silencing effect on VEGF secretion 
Screening of Rab proteins’ involvement on VEGF secretion by B6-RPE07 cells was 
performed using the protocol previously established and adenoviral miR sequences-
containing preparations. B6-RPE07 cells were transduced with appropriate MOI of 
adenoviral particles for 5 to 6 hours. Cells were fed with fresh medium and left overnight to 
recover. On day 1 after transduction, cells were serum-starved for 10 to 12 hours and then 
fed with 1% FBS medium. On day 3 post-transduction cell supernatants were collected as 
well as cell pellets, and total cellular protein was determined. sVEGF secreted levels were 
quantified by ELISA and normalized to total amount of protein. We proved that presence of 
miR-Neg control adenovirus did not interfere with sVEGF secretion when compared to NT 
cells, both at unstimulatory and stimulatory conditions (Figure 3.34). We therefore 
considered miR-Neg condition as the control regarding the effect of Rab proteins-silencing 
on sVEGF secretion.   
 
 
 
 
 
 
 
 
 
Figure 3.34 – Presence of miR-Neg adenovirus did not influence sVEGF secretion by B6-
RPE07 cells. B6-RPE07 cells were transduced with miR-Neg adenovirus at MOI 10,000, both at 
basal conditions (unstimulated cells) and in the presence of 50µM of CoCl2. Conditioned media 
and cell pellets were collected after 48 hours and supernatants’ levels of sVEGF were 
quantified by ELISA. miR-Neg adenovirus did not influence sVEGF secretion levels compared to 
NT cells. Results are presented as mean average value (N=22, unstimulatory; N=25, 
stimulatory) ± SD.  
 
138 
 
We further assessed if
cells were transduced with miR
Neg adenovirus, sVEGF secreted levels were upregulated by CoCl
happened for unstimulated cells (Figure 3.31), confirming th
sVEGF secretion was not affected by 
 
 
 
 
 
 
 
 
 
Figure 3.35 – CoCl2 induces upregulation of sVEGF secretion
presence of miR-Neg adenovirus. 
at MOI 10,000, with and without
48 hours and supernatants’ level
induced a 3-fold increase in VEGF secreted levels
(N=15) ± SD. ***p≤0,001.  
 
3.3.2.1. Effect on VEGF secretion 
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construct for 5 to 6 hours. On day 3 after 
were collected, and supernatants’ level of sVEGF was quantified by ELISA and normalized to 
total amount of protein.  
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to try to understand their role on VEGF secretion taking in account their cellular location 
(Figure 3.36). We observed that among the secretory Rab proteins, KD of Rab6b, Rab10 and 
Rab14 significantly upregulated sVEGF secretion by B6-RPE07 cells in at least 1,5-fold. In the 
case of Rab14 there was a higher increase on sVEGF secretion, around 2-fold. Our results 
also showed that for Rab8a and Rab27b KD there was only a slightly upregulation of sVEGF. 
For all the others secretory Rab proteins (Rab3a, Rab3b, Rab3d, Rab6a, Rab8b and Rab27a) 
individually KD we did not found alterations on sVEGF levels. These results suggest that 
either these Rab proteins are not involved in secretion of VEGF by RPE cells, or that there 
might exist a compensatory mechanism for VEGF transport outside the cell when one Rab is 
silenced.   
On the contrary, when endocytic and recycling Rab proteins were individually 
silenced we observed that, in all cases, sVEGF levels were altered (Figure 3.36). This result 
proposes an important role for endocytic and recycling Rab proteins on the regulation of 
VEGF secretion by RPE cells. We verified that Rab4a and Rab4b KD increased VEGF secreted 
levels in 1,5-fold. In general, Rab5 isoforms behaved similarly: Rab5a and Rab5b KD 
upregulated sVEGF secretion by around 2-fold, while Rab5c KD induced an upregulation of 
almost 3-fold in sVEGF secretion. Rab7a and Rab11a KD upregulated sVEGF secretion by 
1,25-fold, and Rab11b KD induced a 2,5-fold increase of sVEGF secreted levels. Rab15 KD 
increased sVEGF secretion only slightly and Rab21 and Rab22b KD also showed to upregulate 
sVEGF secretion. Rab22a was the only endocytic protein which KD showed to downregulate 
sVEGF secretion, although only in 10%.  
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Figure 3.36 – miR-silencing adenoviruses of individual 
influence sVEGF secretion by B6
cells were transduced with miR
(A) and endocytic/recycling Rab
at day 3 post-transduction and supernatants’ level
are presented as mean average value 
***p≤0,001. 
 
 
Rab proteins differently 
-RPE07 cells under unstimulatory conditions. 
-containing adenoviruses at MOI 5,000/each for secretory Rabs 
 proteins (B). Conditioned media and cell pellets were collected 
s of sVEGF were quantified by ELISA. 
(5≤N≤12) ± SD. *0,05≤p<0,01; **0,01≤p<0,001; 
 
B6-RPE07 
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We further investigated the effect of individual Rab proteins’ silencing on sVEGF 
secretion by B6-RPE07 cells in the presence of CoCl2, using the same protocol as before. In 
general, we verified that sVEGF levels fold increase obtained under stimulatory conditions in 
comparison to control (miR-Neg) were lower than the ones obtained under unstimulatory 
conditions (Figure 3.37). Moreover, the effect on sVEGF secretion by Rab proteins KD 
followed the same trend on stimulatory and unstimulatory conditions. In particular, for 
secretory Rab proteins we also observed an effect on sVEGF levels when Rab6b, Rab10 and 
Rab14 were KD, although in a lower extent than in unstimulatory conditions. Regarding 
endocytic and recycling Rab proteins’ group, there were also few differences. KD of Rab5a, 
Rab7a, Rab11a, Rab15, and Rab22b previously shown to upregulate sVEGF secretion under 
unstimulatory conditions; now KD of the same proteins did not exert a significant effect on 
sVEGF levels. All other Rab proteins tested behaved the same when hypoxia-mimicking 
stimulus for sVEGF secretion was used. Rab4a and Rab4b KD increase sVEGF secreted levels 
by 2-fold, as well as Rab11b. Rab5b and Rab5c KD effect was now lower than in unstimulated 
conditions, with an increase of only 1,25-fold and 1,5-fold, respectively. Rab21 KD induced a 
slight increase of sVEGF secretion levels, whereas Rab22a KD kept to downregulate sVEGF 
levels as before. 
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Figure 3.37 – miR-silencing adenoviruses 
influence sVEGF secretion by B6
were transduced with miR-containing adenovirus
proteins (A) and endocytic/recycling Rabs 
collected at day 3 post-transduction
ELISA. Results are presented as mean average value 
**0,01≤p<0,001; ***p≤0,001.
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Regarding absolute values of secreted sVEGF, we observed that they are higher in cells 
stimulated with CoCl2 than in unstimulated cells, but the relative difference to each 
corresponding miR-Neg condition is lower in CoCl2-stimulated cells. This fact might be 
explained by upregulation of Flt1 gene in hypoxia: in endothelial cells, Flt1 gene promoter is 
strongly activated via hypoxia-inducible enhancer element. In our RPE cells, Flt1 
transcription might be enhanced too, increasing the number of both full length and soluble 
isoforms of the receptor available for sVEGF to bind to and despite the existence of more 
sVEGF molecules in cell media, differences relative to control condition are not so striking. 
Data regarding Flt1 mRNA levels in both control and experimental conditions is needed to 
confirm such hypothesis.  
 
3.3.2.2. Effect on VEGF secretion by multiple Rab proteins’ KD 
The first screening to individual Rab proteins gave us some possible targets involved 
in VEGF secretion by B6-RPE07 cells. We decided to further evaluated KD of multiple Rab 
proteins together, according to their known function in cell biology, to investigate potential 
intracellular pathways. Due to volume restrictions at the cell transduction’s step, we 
selected only one adenoviral clone for each target protein, based on its efficiency as 
determined by previous Western Blot analysis (Figure 3.25), and we used MOI 5,000/virus as 
before. However, for larger groups considered (secretory, endocytic and endosomal Rab 
proteins) MOI of each adenovirus was diminished to 2,000.  
For these experiments we have KD some pools of Rab proteins: all secretory Rabs 
together (Rab3a+Rab3b+Rab3d+Rab6a+Rab6b+Rab8a+Rab8b+Rab10+Rab14+Rab27a+  
Rab27b), Rab8(a+b) isoforms together, Rab8+Rab10, Rab8+Rab14, and Rab8+Rab10+Rab14, 
since Rab8, Rab10 and Rab14 are described to be involved in the transport from TGN to the 
plasma membrane (Ang, Fölsch, Koivisto, Pypaert, & Mellman, 2003; Junutula et al., 2004; 
Schuck et al., 2007). Respecting endocytic and recycling Rab proteins, we tested KD of all 
Rab5(a+b+c) isoforms and Rab5+Rab21 (Rab5a+Rab5b+Rab5c+Rab21) effects on sVEGF 
secretion levels. Both Rab5 and Rab21 are involved in the early steps of endocytic pathway 
(Simpson et al., 2004; Zerial & McBride, 2001). Unstimulatory and stimulatory conditions 
were tested and results are presented at Figure 3.38.  
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Figure 3.38 – miR-silencing adenoviruses to multiple Rab proteins differently influence 
VEGF secretion by B6-RPE07 cells in both unstimulatory 
conditions. B6-RPE07 cells wer
5,000/each for considered combinations. For combinations of secretory, endocytic and 
endosomal Rab proteins, MOI 2
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value (6≤N≤12) ± SD. *0,05≤p<0,01; **0,01≤p<0,001; ***p≤0,001.
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 Again, when we compared results obtained on unstimulatory versus stimulatory 
conditions we verified that sVEGF secretion was higher in the absence of CoCl2. Moreover, 
under unstimulatory conditions we observed that simultaneous KD of all secretory Rab 
proteins induced a slight but significant increased of sVEGF secretion. This effect was lost 
when CoCl2 was used. Regarding KD of all endocytic Rab proteins (Rab4a+ 
Rab4b+Rab5a+Rab5b+Rab5c+Rab7a+Rab11a+Rab11b+Rab15+Rab21+Rab22a+Rab22b) we 
found that sVEGF secreted levels were upregulated by 2,5-fold in unstimulated cells. 
However, this increasing effect was reverted by the presence of CoCl2, in which only a small 
increase of sVEGF took place. Endosomal Rabs’ KD combined effects of individual Rab4a, 
Rab4b, Rab5a, Rab5b, Rab5c, Rab10, Rab14, Rab15, Rab21, Rab22a and Rab22b KD, 
excluding Rab7a (marker for late endosomes and lysosomes) and Rab11(a+b), involved in the 
recycling pathway to the plasma membrane. Overall, endosomal Rabs’ KD induced a 2-fold 
increase in sVEGF secreted levels in unstimulatory conditions, but this effect was again 
reverted by hypoxia-mimicking conditions (1,5-fold). KD of Rab8 isoforms had no effect on 
sVEGF secretion in either condition tested. Combination of Rab8+Rab10 KD had no effect too 
in unstimulated cells; however, in stimulatory conditions, sVEGF secretion increased a little. 
KD of Rab8+Rab14 induced an upregulation of sVEGF secreted levels in both unstimulatory 
and stimulatory conditions, despite at a lower extent in the last one. The striking effect of 
Rab proteins KD on sVEGF levels came up with KD of Rab10+Rab14. Individually these Rabs 
showed to induce an upregulation of sVEGF secretion levels, but double KD potentiated 
these effect, upregulating sVEGF levels by 3-fold in unstimulated cells. In the presence of 
CoCl2, this effect diminished to only 2-fold increase, though. When Rab8+Rab10+Rab14 were 
KD, there was no effect on sVEGF secretion levels, in neither condition. Comparison between 
sVEGF secreted levels when Rab10+Rab14 and Rab8+Rab10+Rab14 were KD, revealed a 
highly significant decrease, at both unstimulated and stimulated cells. At last, KD of all 
Rab5(a+b+c) isoforms induced an almost 2-fold increase of sVEGF in unstimulatory 
conditions, but this was not verified in stimulated cells. Joint KD of Rab5 and Rab21 
increased sVEGF levels at both conditions tested, but in stimulatory cells, the effect was not 
so clean, with only a slight increase. Here, like in the previous experiments, effect of Rab 
proteins’ KD is similar in both unstimulatory and stimulatory conditions. However the range 
of fold increase is lower and, in some cases, it even disappears in the presence of CoCl2, 
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suggesting an extra regulatory mechanism of sVEGF secretion in hypoxia-mimicking 
conditions.   
 In summary, our results show for the first time that Rab proteins are involved in VEGF 
secretion by RPE cells. We found out a regulatory role for Rab6b, Rab8, Rab10 and Rab14, 
and further characterization of secretory pathway will follow, namely possible interactions 
of these proteins with VEGF receptors biology. Rab4, Rab5, Rab7 and Rab11 have already 
been implicated in VEGFR2 trafficking and recycling in endothelial cells (Ballmer-Hofer, 
Andersson, Ratcliffe, & Berger, 2011; Jopling et al., 2009), but there is no data so far 
regarding involvement of secretory Rab proteins. The novel roles we described for Rab 
GTPases will be crucial for understanding intracellular pathways of VEGF secretion by RPE 
cells, and how their deregulation could promote neovascularization, a common feature of 
many intraocular syndromes. From this starting point, future studies will be performed to 
unravel interacting partners of VEGF secretory molecular machinery in RPE.  
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It is well known that VEGF plays a key role in retinal homeostasis and that 
deregulation of VEGF biology is the cause of several eye diseases (Penn et al., 2008). In this 
work we showed, for the first time, the involvement of Rab GTPases in VEGF secretion by 
RPE cells in vitro. Our findings set us one step forward in understanding of the RPE molecular 
machinery responsible for the delicate balance between health and disease.   
 RPE cells constitute the blood-retinal barrier and they integrate essential functions 
for maintenance of visual homeostasis. A failure on any of these functions can lead to retinal 
degeneration, and subsequently to blindness. VEGF signaling is impaired in most eye 
diseases, and therefore their treatment strategies involve mainly targeting of VEGF biology. 
The search for molecules involved in VEGF signaling pathways drives research of several 
groups worldwide with the purpose of finding potential therapeutic targets.  
 The complex signaling network that responds to sVEGF binding to its main receptor, 
VEGFR2, in RPE cells activates several responses including cell survival and proliferation, and 
cell permeability and migration. RPE cells secrete sVEGF by its basolateral side which faces 
the fenestrated endothelium of choriocapillaries. The tiny regulation of secreted VEGF levels 
points out the difference between stabilization of choroidal endothelium and uncontrolled 
growth of blood vessels into the retina, which is the main cause of intraocular syndromes (X. 
Ding et al., 2009; Penn et al., 2008). There are quite a lot molecular players known to model 
intracellular pathways of VEGF signaling, but a vast part remains to be identified.  
Rab GTPase family of molecular switches is present in every compartment of the 
endomembrane system and is acknowledged to regulate membrane trafficking and other 
cellular processes. Rab5a and Rab7a were the first Rab proteins to be directly implicated in 
VEGF biology, by modulating both VEGFR2 trafficking and signaling in endothelial cells 
(Jopling et al., 2009). Later Rab11 along with Arf1 and Arf6 were shown to regulate sFlt1 
trafficking through the secretory pathway in endothelial cells (Jung et al., 2012). Moreover, 
Rab25 was described as a tumor suppressor protein in breast cancer cells, where it regulates 
VEGF and VEGFR1 expressions’ (Cheng et al., 2010). But until now, no information was 
known regarding sVEGF modulation by epithelial cells, in particular by RPE cells.  
 In RPE cells several Rab proteins have been studied and implicated in genetic 
diseases. However, RPE is a difficult model to work with due to its special cell features. Every 
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known and described model of RPE cells has its own limitations. The RPE model that better 
mirrors RPE in vivo biology is human fetal RPE, impracticable in Portugal due to ethical 
concerns. Alternative use of mouse cells overcomes this limitation but the problem of 
getting enough material to work with arises. RPE primary cells from several mice are needed 
for an experiment to be performed. Animal’s individuality is then lost, as variability inside 
samples increases. In this work we characterized both mouse RPE primary cells and the 
recently described mouse RPE cell line, B6-RPE07, concerning RPE features as summarized 
below. 
Establishment of mouse RPE primary cultures involved isolation of RPE cells from 21 
days-old mice and usage of primary cells until passage 3. Culture of these primary cells 
showed that they display most of epithelial features as in vivo, like growing in a monolayer 
clearly defined by cellular tight junctions. Expression of epithelial markers was evaluated and 
ZO1 and Na
+
/K
+
 ATPase proteins were beautifully localized in RPE cells in culture. The 
measurement of transepithelial resistance on cell cultures in Transwell® inserts proved how 
difficult is to establish a highly polarized monolayer of mouse RPE primary cells in vitro.  
Importantly, mouse RPE primary cells express VEGF and its receptors VEGFR1 and VEGFR2, 
and show measurable levels of secreted sVEGF. These parameters are commonly used for 
RPE cells characterization and thus our RPE primary cultures matched. Recent description of 
a mouse RPE cell line, B6-RPE07, brought a different cell model to this work. B6-RPE07 cells 
were subjected to the same analysis as RPE primary cells, and we concluded that they were 
very similar in terms of RPE features. Moreover, B6-RPE07 cells were not limited in number 
or dependent on animals’ accessibility. Reproducibility of results is the major advantage of 
using a cell line, despite its inherent limitations for being considered immortalized cells. We 
selected B6-RPE07 cells as our in vitro cell model based on the fact that we would need 
many cells to perform our screenings, and also a reliable model, where inherent variations of 
primary cell cultures would not contribute to the final results. 
Since the finding of RNAi by Craig Mello and Andrew Fire, this tool has been widely 
used to trigger gene silencing. miRNAs were only reported later on, but their house-keeping 
regulatory principles were rapidly adapted to DNA recombinant systems. Use of adenoviral 
and lentiviral particles to introduce foreign DNA sequences into a host cell is the fastest and 
efficient way to do it, despite the boundaries in using them in clinical trials. Therefore, viral 
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gene transfer is used regularly nowadays for scientific research purposes, as it was the case 
of this work. We designed miRNA silencing-sequences for mouse Rab proteins and cloned 
them in an expression vector that allows expression of miRNA-based KD cassettes in 
mammalian cells. Co-cistronic expression of EmGFP and miR silencing sequence revealed to 
be a valuable resource for titration and cell transduction procedures. We generated and 
validated a collection of molecular tools to study Rab proteins’ functions by targeting their 
cellular expression levels. Despite the use of specialized web tools with optimized 
algorithmics to generate miR-silencing sequences, it was not possible to design miR-silencing 
sequences for all desired targets. Rab1a, Rab1b, Rab33a, Rab39b and Rab44 were excluded 
from our library due to inefficient silencing by different miR sequences tested. We must do 
not forget, however, that the fact that their role in VEGF secretion was not studied here, it 
does not mean that they cannot be involved on the regulation of sVEGF by the RPE. There 
are reports implicating Rab1 in Legionella pneumophila and Shigella flexneri host defences 
(Dong et al., 2012; Neunuebel et al., 2011; Tan & Luo, 2011). In both these 2 infections 
caused by vacuole-living pathogens, bacteria exploit host cell vesicle transport for 
appropriate trafficking of the vacuole. Proteins Rab33a and Rab39b were described to 
localize to Golgi, while Rab44 localization and function remain unknown. Until now, from 
these 3 proteins, only Rab33a is described to be involved in the autophagosome maturation 
(Hutagalung & Novick, 2011). Little is known about these Rab proteins, and future work on 
VEGF secretion by RPE cells must definitely address their function. 
We performed a novel study on Rab proteins’ expression in in vitro mouse models of 
RPE (B6-RPE07 and primary cells), the first one to include a total of 59 proteins. We verified 
that most of Rab proteins evaluated were expressed in both RPE cell types. However, we 
stated that Rab3c, Rab17, Rab19, Rab25, Rab26, Rab37, Rab40b and Rab44 were not present 
in either cell type. Therefore Rab3c, Rab26 and Rab37 are absent from secretory vesicles and 
granules of our RPE cells, and Rab17 and Rab19 are not present in RE and Golgi complex, 
respectively. Rab40b is not involved in endosome transport in our models too. Epithelial 
Rab25 is not expressed, but the question remains if this is a RPE cell intrinsic feature, or an 
acquired feature due to in vitro cell culture. To clarify this question we could isolate mouse 
RPE cells and directly evaluate the expression of Rab25 on these cells, without culturing 
them. The role of these 8 Rab proteins was not further addressed in RPE cells, but they 
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should not be excluded from future studies on sVEGF secretion, especially the epithelial 
Rab25 whose expression is upregulated in breast cancer (Cheng et al., 2010). 
We selected key Rab proteins from both secretory and endocytic/recycling 
intracellular pathways to understand their role on VEGF secretion. Three Rab3 isoforms 
(Rab3a, Rab3b and Rab3d), Rab6a and Rab6b, Rab8a and Rab8b, Rab10, Rab14, Rab27a and 
Rab27b were selected as secretion-related Rab proteins. From endocytic and recycling 
pathways we chose Rab4a, Rab4b, all Rab5 isoforms (Rab5a, Rab5b and Rab5c), Rab7a, 
Rab11a, Rab11b, Rab15, Rab21, Rab22a and Rab22b. We decided to start studying sVEGF 
secretion by RPE cells by choosing key Rab proteins described in intracellular pathways, but 
we are aware though that a complete screen on Rab proteins’ involvement in sVEGF 
secretion by RPE cells should include the remaining Rab GTPases’ family members.  
We have developed, optimized and established a novel protocol to evaluate the 
effect of Rab proteins’ KD on sVEGF secretion levels by B6-RPE07 cells. Adenoviral 
constructs’ titers were determined using EmGFP co-cistronic expression. Transient KD 
efficiency of miR-silencing sequences was evaluated and we verified that it ranged from 30% 
to 90% of protein KD. Appropriate MOI to induce B6-RPE07 Rab proteins’ KD was also 
calculated, and its effect on cell survival was assessed. Adenoviruses showed to have no 
significant influence on cell survival and proliferation rates. Regarding the corresponding 
lentiviral vectors that we have produced we did not deeply characterized them. We have 
tested cytotoxicity of blasticidin in B6-RPE07 cells, and we accomplished a suitable 
concentration needed to perform stable cell lines’ selection. Further experimental conditions 
using lentiviral particles and stable expression of miR-silencing cassettes would have to be 
delineated.  
We have performed this screening under both unstimulatory and stimulatory 
conditions. Hypoxia is the most common stimulus used for VEGF upregulation, and here we 
tested whether CoCl2 could be used as a hypoxia-mimicking agent. We proved that B6-RPE07 
secrete higher levels of sVEGF in response to presence of CoCl2, compared to unstimulatory 
conditions, after 48 hours. This timepoint was considered for achievement of protocol’s 
timeline, which also took in account the timeline of different Rab proteins’ KD achieved by 
adenoviruses. At the end, we decided to perform screening trials of sVEGF secretion at day 3 
153 
 
post-transduction with adenoviral miR-silencing sequences. Cell media samples from 
unstimulatory and stimulatory conditions were analyzed for secreted sVEGF by ELISA. 
Results were normalized per total cell lysate, and presented relative to miR-Neg condition 
levels.  
The effect of Rab proteins’ KD on sVEGF secretion by B6-RPE07 cells was tested 
targeting Rab proteins individually and in multiple combinations. Our study allowed us to 
draw several conclusions. First, we observed that in none of the conditions tested levels of 
sVEGF secretion decreased highly significantly. This fact might be innate to our system: RPE 
cells have a constitutive pathway of sVEGF secretion, and decreasing levels may not be 
detected using our protocol. Moreover, it is possible that an unconventional secretory 
pathway exists, therefore compensating deregulation of the conventional one. Second, we 
verified that KD of some Rab proteins involved in secretory and endocytic/recycling 
machinery caused an upregulation of sVEGF secretion levels by RPE cells, namely for Rab6b, 
Rab10, Rab14, Rab5 and Rab11. Taking together all the findings in this work we will propose 
a model in which Rab proteins regulate sVEGF secretion and endocytosis in RPE cells. In the 
next section, we will go through the potential targets and try to explain their role in model’s 
synchronization.  
 
4.1. Proposed model for regulation of VEGF secretion by mouse RPE cells  
 We verified RPE cells secrete sVEGF in a constitutive way. Moreover, we also proved 
that the system is induced to secrete more sVEGF in the presence of a hypoxia-mimicking 
agent, cobalt chloride. The model we are proposing considers both basal and stimulatory 
conditions (Figure 4.1).  
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Figure 4.1 – Schematic illustration of the model proposed for 
involvement in regulation of VEGF secretion by RPE cells.
possible interactions and regulatory pathways for Rab proteins in VEGF secretion by RPE cells 
in both unstimulatory (A) and stimulatory 
 The proposed model depicts 
(B) conditions. See text for further details.
Rab GTPases’ 
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Under unstimulatory or basal conditions, RPE cells express VEGF which is 
incorporated into Golgi-derived vesicles. Such vesicles are transported through cytoplasm 
until they reach plasma membrane, where their contents are released. Besides Golgi-derived 
vesicles, an unconventional secretion pathway may exist, where vesicles originating from 
endoplasmic reticulum, lysosomes or autophagosomes may exist to mediate VEGF transport 
to plasma membrane (Y. Ding et al., 2012). The conventional secretory pathway is likely to 
be regulated by Rab proteins and additional molecular adaptors, as it happens for other 
molecules. Our results implicate Rab8 in this step of VEGF secretory pathway in RPE cells. 
Rab6b, Rab10 and Rab14 were the only secretory Rab proteins whose individually KD 
showed to have a highly significant effect on sVEGF secretion. These Rab proteins are 
described to localize to Golgi apparatus. Rab6b regulates intra-Golgi transport, while Rab10 
and Rab14 have been implicated in GLUT4-vesicles’ secretion. In addition, Rab10 and Rab14 
also localize to early endosomes, mediating their sorting. KD of Rab6b and Rab10 showed an 
increase of sVEGF secretion in about 1,5-fold, and Rab14 KD induced a even higher increase 
(2-fold). Rab6b
+
 vesicles move along Golgi and ER membranes as Rab6b mediates retrograde 
transport (Opdam et al., 2000). Rab6b is expressed in a tissue and cell-type specific manner, 
and in RPE might control the number of new VEGF-containing vesicles available to be 
secreted. As Rab6b KD induces upregulation of sVEGF levels, we might consider that Rab6b 
controls VEGF-vesicles retention at the Golgi apparatus while waiting for a signal to let 
vesicles go through the secretory pathway (Figure 4.1, A).  
We surprisingly found out that Rab10 and Rab14 may cooperate in sVEGF secretion 
along with Rab8. Rab8a and Rab8b are both involved in exocytosis, either from TGN or RE to 
plasma membrane, namely in polarized cells like intestinal cells (Sato et al., 2007). Our 
results show that individual KD of Rab10 and Rab14 upregulate sVEGF secreted levels, but 
this effect is potentiated when double KD of Rab10+Rab14 is performed (3-fold increase). 
However, simultaneous KD of Rab8 can revert this result: sVEGF secreted levels are similar to 
control when these 3 Rab proteins are silenced. This fact suggests that Rab10 and Rab14 
somehow influence Rab8-mediated secretion of VEGF-vesicles, possibly by a negative 
feedback loop mechanism (Figure 4.1, A). When Rab8a, Rab8b and both are silenced, VEGF 
secretion levels are not significantly altered, meaning that other effector and adaptor 
proteins should be involved in VEGF secretion. In double Rab8+Rab10 KD, no effect in sVEGF 
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secretion was seen, suggesting that Rab14 is a major player in this regulation. In double 
Rab8+Rab14 KD, sVEGF secretion levels increase 1,5-fold, reinforcing the idea that Rab14 is 
important for controlling of sVEGF secretion process, probably by regulating Rab8. 
Rab10+Rab14 combined regulation of VEGF signaling may be initiated from early endosome 
formed upon internalization of VEGF-VEGFR2 (Figure 4.1, A). Sorting of EE either for 
degradation and/or recycling pathways, with subsequent activation of feedback loops, can 
be an indicator for reducing sVEGF secretion, once signaling pathways are already active and 
biological responses on their way. Moreover, Rab10 and Rab14 may also mediate transport 
of EE-derived VEGF containing-vesicles back to TGN. In summary, Rab10 and Rab14 may 
exert an inhibitory regulation on Rab8, which in turn controls sVEGF secretion. We must 
have in mind that basal secretion of sVEGF must involve unknown molecules other than 
these Rab proteins that keep secretory pathway working, because sVEGF levels do not 
significant decrease below control in any condition tested, neither when all secretory Rab 
proteins considered were simultaneously silenced (Figures 3.36 and 3.38).    
Among endocytic and recycling Rab proteins’ groups we clearly observed an effect on 
VEGF secretion when these proteins were KD. We can therefore postulate that, in this study, 
increase of sVEGF secretion levels occurs mainly through accumulation of extracellular 
molecules of sVEGF, rather than de novo synthesis, because endocytosis of VEGF-VEGFR2 
and its recycling pathways were inhibited. KD of Rab4a and Rab4b resulted in 1,5-fold 
increase of secreted sVEGF, therefore ablating fast recycling pathway. Early endosomes are 
then re-directioned to slow recycling pathway, via recycling endosomes that will promote 
later delivery of VEGFR2 back to plasma membrane. This will potentially slow down sVEGF 
binding to receptor, increasing sVEGF levels in supernatant. When we interfere with the 
major players on slow recycling pathway (Rab11a, Rab11b and Rab15) VEGF secretion is 
differently affected. KD of Rab15 only slightly influenced sVEGF secretion levels, while KD of 
both Rab11a and Rab11b promoted their upregulation. This fact suggests that VEGFR2 are 
recycled back to plasma membrane mainly via recycling endosomes, in which Rab11b plays a 
key role. When Rab11b is ablated, secreted sVEGF accumulates in cell media as there are 
less receptors to bind to, and only Rab4-mediated recycling is delivering VEGFR2 back to 
plasma membrane. Therefore VEGF-VEGFR2 internalization and signaling may still occur but 
at a slower rate.  
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VEGF-VEGFR2 process of endocytosis is orchestrated mainly by Rab5 proteins, and 
individual KD of Rab5 isoforms reflected their relative importance. Likewise, sVEGF 
molecules accumulate in the supernatant when Rab5 isoforms are KD. Rab21 is also a 
modulator of endocytosis and early endocytic pathway, and Rab21 KD in B6-RPE07 cells 
showed sVEGF secreted levels increased by 1,5-fold. Multiple KD of Rab5a+Rab5b+Rab5c 
and double KD of Rab5+Rab21 had a similar effect on sVEGF, reinforcing the idea that Rab5 
and Rab21 are important for VEGFR2 endocytosis, as already stated by previous studies in 
endothelial cells (Jopling et al., 2009). We also evaluated what happened to sVEGF levels 
when all endocytic Rab proteins in study were silenced. As a result sVEGF was upregulated of 
by 2-fold, maybe due to a cumulative effect of individual Rab proteins. KD of all endosomal 
Rab proteins had a similar result, reinforcing the idea that endocytic pathway is crucial for 
regulation of sVEGF levels.  
Our RPE model is induced to secrete more sVEGF in the presence of hypoxia-
mimicking agent CoCl2. CoCl2 stabilizes HIF1α and stimulates VEGF transcription, increasing 
the number of VEGF molecules available to be secreted (Figure 4.1, B). Globally, the effect of 
Rab proteins’ KD is similar in stimulatory conditions compared to unstimulated cells, but the 
amplitude of fold increase is lower, although absolute values of secreted sVEGF are higher in 
cells stimulated with CoCl2 than in cells in basal conditions. However, the relative difference 
to each respective control condition (miR-Neg) is lower in stimulated cells. This fact might be 
explained by 2 features related to hypoxia-mediated responses described in endothelial cells 
(Gampel et al., 2006; Gerber, Condorelli, Park, & Ferrara, 1997). First, Flt1 and Flk1 genes are 
differently regulated by hypoxia: hypoxia leads to strong transcription activation of Flt1 
promoter via a hypoxia-inducible enhancer element, whereas Flk1 is essentially unchanged 
(Gerber et al., 1997). Second, endothelial cells are able to held VEFGR2 in endosomal storage 
pools, which are recycled back to plasma membrane in response to VEGF stimulation. By 
controlling trafficking of VEGFR2, VEGF has power over the sensitivity of endothelial cells to 
proangiogenic signals (Gampel et al., 2006). In our RPE model, both situations may occur, 
therefore helping to explain the results regarding VEGF secreted levels. Presence of VEGFR1 
in RPE cells, both full length and soluble forms, will retain some sVEGF, because it will bind 
to VEGFR1 with higher affinity than to VEGFR2. Furthermore, reinforcement of the number 
of VEGFR2 at plasma membrane from storage pools will decrease sVEGF levels. Overall, if 
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these regulatory mechanisms are activated, differences in number of sVEGF molecules 
relative to control will not be so striking, despite the existence of more sVEGF molecules. 
Moreover, we do not have any information whether Rab proteins themselves can regulate 
both transport of VEGFR1 and VEGFR2 to plasma membrane, and whether Rab proteins KD 
could influence these pathways. Rab proteins regulation of VEGFRs should be further 
addressed in future experiments. 
Under unstimulatory conditions Rab6b, Rab10 and Rab14 were, once more, the only 
secretory Rab proteins to have effect on VEGF secretion. KD of Rab6b and Rab10 induced 
1,25-fold increase, and KD of Rab14, 1,5-fold increase in VEGF secretion. Rab6b might again 
be controlling the traffic of VEGF-vesicles towards plasma membrane by holding them at 
Golgi. The cooperative role that we are proposing for Rab10 and Rab14 on sVEGF secretion 
can also be seen in hypoxia-mimicking conditions (Figure 4.1, B). Double KD of Rab10+Rab14 
potentiates effect of individual KD of each Rab protein, and this result is again highly 
significantly reverted when Rab8 is simultaneously silenced. Multiple combinations of Rab8, 
Rab10 and Rab14 KD also suggest a key role for Rab14 in this process, despite the fact that 
fold increase in hypoxia-mimicking conditions is lower than in unstimulated cells. The notion 
that Rab10 and Rab14 may influence Rab8-mediated secretion of VEGF containing-vesicles is 
therefore reinforced.  
The effect of endocytic Rab proteins’ KD was more obvious than secretory Rab 
proteins’ KD such as it happened for unstimulatory conditions. Effect of Rab4a and Rab4b KD 
remains the same, as interference on fast recycling pathway increased sVEGF levels in cell 
media. However, regarding slow endocytic pathway and Rab11 and Rab15, there are 
differences. Rab11a and Rab15 KD had no effect in VEGF secreted levels in hypoxia-
mimicking conditions, and Rab11b KD effect was much less obvious now (50% less of 
increase than in unstimulatory conditions). This result can be explained considering the 
existence of more VEGFR2 at plasma membrane from the storage pools, and more VEGFR1: 
fewer molecules are detected in the supernatant, even if conventional recycling pathway of 
VEGFR2 is ablated. Fast endocytic recycling pathway via Rab4 then contributes for it too 
(Figure 4.1, B).  
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The fact that there are other receptors for VEGF to bind to may be the reason why 
targeting of Rab5-mediated endocytosis does not highly increases sVEGF levels. Rab5b and 
Rab5c KD interfered with endocytosis rate, but VEGF that remains soluble may be clustered 
by the higher number of available receptors. Therefore, KD of these proteins only slightly 
increases VEGF secretion. The same was true for Rab21 KD, which affected only a little 
sVEGF secretion in the presence of CoCl2, either alone or combined with Rab5 KD. When we 
performed KD of endocytic Rabs together we saw little differences of sVEGF levels compared 
to control conditions. However, when we KD endosomal Rab proteins, letting Rab11a, 
Rab11b and Rab7a perform their normal function, we observed a higher increase in sVEGF 
levels.  
 
4.2. Future directions 
RPE homeostasis is highly dependent on a tight regulation of VEGF biology, and it 
starts as early as E9.5 in mice and prolongs through adulthood. In vivo studies using mouse 
models showed how important VEGF is for development and maintenance of 
choriocapillaries. Excision of Vegfa gene in VEGF
rpe-/-
 results in RPE-specific deficiency of 
Vegfa expression from the onset of RPE differentiation (Marneros et al., 2005). This 
conditional inactivation of Vegfa results in absence of choriocapillaries, occurrence of 
microphthalmia and loss of visual function. Moreover Vegfa loss cannot be compensated for 
by expression of other angiogenic growth factors. VEGF
rpe+/- 
mice display low levels of Vegfa 
transcription, and mice present severe abnormalities of RPE cells, despite formation of 
choroidal vessels. This observation suggests an autocrine role for VEGF in maintaining RPE 
function (Marneros et al., 2005). A more recent report used the same VEGF
rpe-/- 
mouse 
model and concluded that Vegfa deletion also causes rapid dysfunction of photoreceptors, 
reinforcing the idea that endogenous VEGF provides critical trophic support necessary for 
proper retinal function (Kurihara et al., 2012). Neutralization studies targeting VEGF support 
its autocrine role in RPE and paracrine function for the choriocapillaries. Adenoviral delivery 
of short-hairpin RNA (shRNA) sequences, a different method to target gene silencing,  for 
Vegfa attenuated its transcription and prevented CNV in mice (Cashman, Bowman, 
Christofferson, & Kumar-Singh, 2006). Recently, the same principle was reported in BALB/c 
160 
 
mice using shRNA and a nonviral approach. Nanoparticle-mediated delivery of shRNA.Vegfa 
plasmids proved to regress CNV, showing a sustainable form of gene therapy (Qazi et al., 
2012). Use of sFlt1 has also been reported as neutralizing agent for sVEGF in mouse. After 4 
weeks of sVEGF neutralization, inner and outer nuclear layers of the retina were thinner and 
retinal function was compromised. These in vivo results showed that VEGF acts also in non-
vascular cells of retina, strengthening the fact that systemic and intraocular anti-VEGF 
therapies for treatment of angiogenesis associated with eye disease need to be controlled 
(Saint-Geniez et al., 2008).  
Additionally to target VEGF itself, alternatively spliced isoform of VEGF165, VEGF165b, 
has been described as antiangiogenic and as a potential target. VEGF165b is downregulated in 
DR, and intraocular delivery of VEGF165b in a mouse model of retinal neovascularization 
confirmed it can be a therapeutic agent in ischemia-induced angiogenesis, as well as a 
cytoprotective agent for RPE cells (Magnussen et al., 2010). A different report also showed 
that regulation of alternative splicing of VEGF165 by inhibiting related kinases could be a 
potential therapeutic strategy in angiogenic pathologies (Nowak et al., 2010). Use of a VEGF 
chimeric toxin to selectively kill RPE cells demonstrated for the first time the possibility to 
target a normal non-endothelial cell type through VEGFR expression (Hoffmann et al., 2000). 
Internalization of a chimeric protein by receptor-mediated endocytosis occurs only in cells 
expressing high levels of receptor. Therefore killing of RPE cells using a VEGF-toxin provided 
support for presence of functional VEGFRs on these cells (Hoffmann et al., 2000). A more 
recent study implicated PEDF, RPE-secreted antiangiogenic factor, in VEGFR2’s processing. 
When sVEGF levels are increased apically, PEDF induces proteolysis of VEGFR2 and other 
membrane proteins, reducing activation of signaling cascades and allowing normal RPE 
barrier function (Ablonczy et al., 2009). Lastly, therapeutic potential of VEGFR1 and VEGFR2 
was evaluated in mouse models of ROP and AMD (Huang, Shen, & Vinores, 2011). This 
report shows that VEGFR1 and VEGFR2 were upregulated during CNV pathogenesis and both 
mediate the angiogenic process, although through different mechanisms. Use of neutralizing 
antibodies for VEGFR1 and VEGFR2 suppressed retinal neovascularization in these models of 
ocular disease, suggesting them as potential therapeutic agents (Huang et al., 2011).  
The early success of anti-VEGF therapies for neovascular AMD is certainly 
encouraging, but given VEGF’s complex role in ocular homeostasis and integrity, effects of 
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long-term inhibition of VEGF in the eye will require close monitoring. Search for different 
potential targets had begun, and interesting results start to pop out. Vesicular trafficking in 
epithelial cells have been intensity scrutinized and new elements of signaling pathways 
revealed. The use of mammalian epithelial cell lines, mainly MDCK model, has identified 
components that guide apical and basolateral proteins along biosynthetic and recycling 
pathways (Rodriguez-Boulan, Kreitzer, & Müsch, 2005). However, when considering RPE cells 
as a polarized epithelial cell model, findings are not “quick and clear”. This is partly because 
immortalized RPE cell lines and isolated RPE cells in culture do not readily maintain their 
pigmentation or their extensive apical processes, and aspects of their in vivo regulation by 
interaction with photoreceptors and Bruch’s membrane, are lost (Futter, 2006). Mouse 
models have allowed delineation of some proteins’ roles in RPE intracellular transport, like 
myosin VIIa and Rab27a (Pereira-Leal et al., 2001). But in humans these roles are not easily 
determined because of human beings’ longevity. Retinal architecture and longevity are the 
main differences between mice and human that difficult acknowledgment of human retinal 
degenerative diseases. But still, mouse models are valuable tools for scientific research in 
RPE field. Moreover, in the context of eye diseases, research mainly looks for a therapeutic 
target for VEGF deregulation, and often forgets to seek for basic molecular mechanisms of 
such deregulation.  
The model we propose for secretion of VEGF further needs to be validated in vivo. 
Subretinal injections of miR-containing adenoviral particles to target key Rab proteins may 
be performed in wt mice. Mice exposed to prolonged individual Rab10- and Rab14-silencing, 
and both, can be examined in vivo using ophthalmologic procedures for phenotypical 
characterization. Based in our cell culture results, one could expect that mice would show 
high sVEGF levels. However, we do not know if such increased levels are enough to induce 
CNV, nor if and when it would develop. Phenotype rescue could be assessed by 
overexpressing Rab8, Rab10 and Rab14 constructs. Additionally, role of Rab8 can be further 
investigated using the described knock-out (KO) mouse model. Rab8-deficient mice proved 
that Rab8 is necessary for proper localization of apical proteins in intestinal epithelial cells 
(Sato et al., 2007). Primary RPE cells from Rab8
-/-
 mice can be cultivated in vitro and assessed 
for sVEGF secretion levels, which we expect to be similar to wt mice. Nevertheless, overtime 
studies would be limited to 12 weeks as Rab8-deficient mice do not last longer. Besides Rab8 
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KO mice, there are constructs expressing mutant forms of Rab8 that could be also tested in 
vivo in RPE cells to evaluate its effect on sVEGF secretion (Grigoriev et al., 2011). 
The model we propose for VEGF secretion by RPE cells can also be validated using 
available AMD, DR and ROP mice models. Adenoviral particles of overexpressing Rab8, 
Rab10 and Rab14 can be subretinally injected in mice, and the resulting phenotype, 
characterized. Within time we would expect to see, if not reversion, deaceleration of CNV 
symptoms. Mice models of CNV would be the best test for Rab proteins’ function. We can 
conjugate results obtained with cell culture experiments on VEGFR signaling and maximize 
the efficacy of treatment. Indeed, there are several molecules under study and on clinical 
trials for targeting components of signaling cascade downstream of VEGFR (Syed, Evans, & 
Bielory, 2012). Ultimately we will validate Rab proteins as key regulators of VEGF secretion 
by RPE and eventually find other Rabs and interacting-molecular adaptors to be therapeutic 
targets for eye diseases.  
Complementary in vitro experiments can also be performed to better characterize 
our proposed model. First, we can study VEGFR2 endocytic pathway in RPE using a tracer, a 
single-chain(sc)VEGF molecule developed for monitoring VEGFR responses to antiangiogenic 
treatment in mammary tumors (Levashova et al., 2010). We can follow intracellular route of 
scVEGF-VEGFR2 vesicles when our key Rab proteins, Rab8, Rab10 and Rab14 are silenced or 
overexpressed. Second, we can interfere with VEGF de novo synthesis by using chemical 
compounds for protein synthesis machinery, and try to correlate its outcome with Rab 
proteins’ KD. Third, we can target VEGFR too. We should test if the hypothesis of increasing 
sFlt1 production in hypoxic conditions for endothelial cells is also true for B6-RPE07 cells. 
Moreover existence of storage pools of VEGFR2 in RPE has never been addressed and must 
be clarified. These experiments would certainly help to highlight regulation of sVEGF levels 
by RPE cells in hypoxia-mimicking conditions, and subsequent role of Rab proteins. Fourth, 
we can look for interacting partners in the secretory pathway, namely motor adaptors. 
Myosin VI has been shown to facilitate secretory traffic in non-polarized cells, and to be 
involved in a sorting pathway to the basolateral surface of polarized MDCK cells (Au, Puri, 
Ihrke, Kendrick-Jones, & Buss, 2007). Regarding VEGFR signaling, VEGFR2 activation and 
downstream signaling are decreased in MyosinVI
-/-
 endothelial cells in response to VEGFA, 
revealing a regulatory role for this motor protein in arterial morphogenesis (Lanahan et al., 
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2010). More recently a report using prostate cancer cells revealed that siRNA-mediated KD 
of MyosinVI expression results in a significant reduction of VEGF secretion (Puri et al., 2010). 
These results involving Myosin VI in VEGF secretion by cancer cells are a promising starting 
point for us to look for Myosin VI role in RPE cells, and possible interactions with Rab 
proteins in VEGF secretion.  
Our achievement’s unravel Rab proteins’ role in VEGF secretion by RPE cells and are 
the basis for future studies to better understand RPE molecular secretory machinery. Anti-
VEGF therapy is nowadays the treatment of choice for wet AMD and CNV-involving eye 
diseases but is constrained by frequent need of intravitreal re-injections and their associated 
risks (Syed et al., 2012). Additionally, a substantial number of patients do not respond to the 
treatment, therefore existing high potential for alternative cost-effective therapies. 
Ultimately, a better knowledge of molecular mechanisms of VEGF secretion in the eye could 
help in finding a therapeutic target to control VEGF secretion in RPE cells.  
Acknowledgment of Rab proteins involvement in VEGF secretion by RPE cells could 
be a starting point for study Rab proteins’ function in other pathologies. Data regarding Rab 
proteins’ expression in other disease models pop up when high-throughput screenings are 
performed. In diabetes mellitus several projects found out differences in Rab proteins’ 
expression (Gene Expression Omnibus GSE33440 and GSE29142). Thus, it would be 
interesting to search for a correlation between Rab proteins’ expression in RPE cells of 
diabetic retinopathy patients, and their diseased-retina symptoms. Such an approach should 
be considered for other eye diseases, as retinopathy of prematurity, proliferative 
vitreoretinopathy and AMD. Differences in Rab proteins’ expression by RPE cells might be 
related to deregulation of VEGF secretion, implicating such basic molecular players of cell 
biology in diseases affecting thousands of people worldwide, and opening new perspectives 
for target VEGF secretion.  
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Figure 6.1 – B6-RPE07 cells and mouse RPE primary cells express Rab proteins
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Figure 6.2 – miRNA sequences delivered
proteins. B6-RPE07 cells were transduced with GFP
(positive control) and corresponding adenoviruses containing miR sequences, plus 
GFP-tagged Rab protein. Cells were fed with fresh medium 5 to 6 hours after 
transduction, and harvested for Western Blot analysis 24 hours later. Anti
revealed KD levels of target protein by comparison of staining intensities: positive 
control (+) versus GFP-tagged Rab plus miR sequences 
loading control.  
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Resumo alargado 
O olho é o elemento do sistema visual responsável por captar e direcionar a luz para 
a retina, a qual é composta pela neuroretina, pelo epitélio pigmentar da retina (EPR) e pela 
coróide. 
O EPR é constituído por uma monocamada de células polarizadas e constitui a 
barreira hemato-retiniana, uma barreira imunológica responsável pela homeostasia do 
ambiente iónico no EPR e à volta deste. A face apical do EPR está em estreita relação com as 
projeções dos fotorreceptores, que contêm os discos membranares onde se processa o ciclo 
visual. A face basolateral do EPR repousa sobre a membrana de Bruch, que separa o EPR do 
endotélio fenestrado dos capilares da coroide. O EPR regula o tráfego de nutrientes entre os 
fotorreceptores e a coroide, uma vez que estes não possuem acesso direto aos nutrientes 
transportados pelo sangue. Para além desta função essencial, o EPR desempenha muitas 
outras, como a absorção de luz e a participação no ciclo visual, a fagocitose dos discos 
membranares desgastados dos fotorreceptores e a secreção de fatores de crescimento, 
onde se inclui o fator de crescimento vascular endotelial (VEGF). Todas estas propriedades 
do EPR evidenciam o seu papel na manutenção da visão, e deixam antever que qualquer 
falha ou desregulação de apenas uma destas funções poderá pôr em causa o funcionamento 
adequado do olho, conduzindo à degenerescência da retina, e subsequentemente à 
cegueira.   
A degenerescência do EPR é comum em várias patologias do olho, nomeadamente na 
degenerescência macular relacionada com a idade (DMRI), a principal causa de perda severa 
de visão em países industrializados. A idade avançada, o tabaco e a dieta estão estabelecidos 
como fatores de risco para a DMRI, e todos contribuem para a alteração da homeostasia do 
EPR. A DMRI é, portanto, uma doença multifatorial, que envolve a degenerescência da 
retina, principalmente do complexo formado pelo EPR, fotorreceptores e membrana de 
Bruch. Alterações ao nível dos capilares da coroide estão também inerentes, e o crescimento 
anormal de vasos sanguíneos em direção à retina é uma das características desta doença. Os 
tratamentos existentes para a DMRI têm como primordial objetivo retardar ou prevenir este 
crescimento descontrolado, cujo maior responsável e mediador é o VEGF. As principais 
terapias têm como alvo o VEGF e os seus recetores, mas o seu papel crucial na biologia dos 
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vasos sanguíneos em geral torna-os suscetíveis a terapias prolongadas que visem a sua 
regulação. Deste modo, continuam a procurar-se diferentes moléculas intervenientes na 
biologia do VEGF que possam ser consideradas como agentes terapêuticos.  
A sinalização celular induzida pelo VEGF é estritamente regulada, nomeadamente ao 
nível da interação ligando-recetor e da sua endocitose e reciclagem de volta à membrana 
plasmática. As diferentes isoformas do VEGF interagem com recetores tirosina cinase, 
responsáveis pelos processos de sobrevivência, proliferação e migração celulares. Estas 
respostas intracelulares requerem uma complexa rede de sinalização na qual estão 
envolvidas diversas moléculas. Entre elas encontra-se a família de proteínas Rab GTPases, 
que regula as vias intracelulares de sinalização e tráfego membranares, essenciais na 
transdução de sinais extracelulares em respostas biológicas. A sua crucial importância nestes 
mecanismos levou-nos a considerar o seu envolvimento nas vias de secreção do VEGF, e a 
questionar-mo-nos se teriam algum papel regulador sobre as mesmas. O principal objetivo 
deste trabalho é identificar proteínas Rab GTPases-chave nas vias de secreção e endocitose 
do VEGF no EPR, e perceber de que modo a alteração da sua função contribui para a 
patogénese da DMRI. Tal identificação poderá também servir de base a uma procura mais 
direcionada de novos agentes terapêuticos. 
A primeira tarefa levada a cabo no âmbito deste trabalho foi a caracterização dos 
modelos de EPR in vitro disponíveis para a realização dos estudos sobre a função das 
proteínas Rab. O murganho foi o modelo animal selecionado, e foram estabelecidas culturas 
primárias de EPR a partir de animais com idades compreendidas entre 21 e 24 dias. Estas 
células primárias foram submetidas a testes para provar a sua validade enquanto células 
epiteliais do EPR. Verificámos que, de facto, estávamos perante células epiteliais, ao 
observar a expressão de proteínas marcadoras de atividade epitelial, como a proteína ZO1, 
envolvida na formação de junções de oclusão entre as células epiteliais, e a existência de 
resistência transepitelial. O facto de oferecerem resistência à passagem de corrente elétrica 
é uma característica das células epiteliais polarizadas in vivo, que pode ser mimetizada in 
vitro através do seu crescimento em suportes próprios. Confirmámos igualmente que as 
células primárias de EPR expressavam e secretavam o fator de crescimento VEGF para o 
meio de cultura. Os receptores tirosina cinase envolvidos na sinalização do VEGF estavam 
também presentes nas células ao nível do ácido ribonucleico (ARN) mensageiro, o que nos 
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leva a concluir que as células podem responder ao VEGF tanto de forma autócrina como 
parácrina. Contudo, e apesar de ser possível subcultivar e utilizar as células primárias de EPR 
até à passagem 3, o seu número era bastante inferior ao necessário para realizar 
experiências que envolvessem um elevado número de condicionantes e variáveis, pelo que 
se tornou crucial utilizar um outro modelo de EPR de murganho que suprimisse essa 
limitação. A linha celular B6-RPE07 foi recentemente descrita como tendo sido obtida a 
partir de culturas primárias de murganho imortalizadas, mantendo as características 
epiteliais. Os nossos estudos confirmaram a sua semelhança com as culturas primárias 
previamente obtidas e caracterizadas, com a vantagem acrescida de reprodutibilidade de 
resultados entre experiências. A linha celular de EPR de murganho B6-RPE07 foi então 
escolhida como modelo de EPR in vitro. 
O passo seguinte foi o desenvolvimento de ferramentas moleculares que nos 
permitissem avaliar o efeito das proteínas Rab na secreção do VEGF. A primeira abordagem 
consistiu em estudar a expressão das proteínas Rab nas células do EPR. Efetuámos uma 
análise extensiva da expressão de 59 isoformas de proteínas Rab, e concluímos que a 
maioria é expressa nas células do EPR, quer primárias, quer na linha celular. No entanto, as 
proteínas Rab3c, Rab17, Rab19, Rab25, Rab26, Rab37, Rab40b e Rab44 não são expressas 
em nenhum dos tipos de células de EPR analisados, tendo sido excluídas como proteínas-
alvo de experiências posteriores. De seguida, os princípios de funcionamento in vivo das 
sequências de micro ARN (miARN) e a tecnologia de ácido desoxirribonucleico (ADN) 
recombinante foram aplicados na geração de vetores virais. Estas ferramentas moleculares 
permitiram-nos inserir no interior das células do EPR sequências de miARN que silenciaram 
as proteínas Rab GTPases. Deste modo, foi possível avaliar o efeito do seu silenciamento na 
secreção do VEGF. De entre as proteínas Rab expressas nas células do EPR, foram escolhidas 
algumas proteínas-chave das vias secretora (Rab3a, Rab3b, Rab3d, Rab6a, Rab6b, Rab8a, 
Rab8b, Rab10, Rab14, Rab27a e Rab27b) e da via endocítica e de reciclagem celulares 
(Rab4a, Rab4b, Rab5a, Rab5b, Rab5c, Rab7a, Rab11a, Rab11b, Rab15, Rab21, Rab22a e 
Rab22b) e foram desenhadas as respetivas sequências de miARN para as silenciar. As 
sequências foram consideradas válidas para o silenciamento quando demonstraram uma 
eficiência igual ou superior a 50% na diminuição dos níveis proteicos das proteínas-alvo e, 
para cada uma, foram selecionadas entre uma e 3 sequências de miARN diferentes. As 
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sequências de miARN foram subsequentemente introduzidas em adenovírus e lentivírus, 
usados para expressão das mesmas de forma transitória e constitutitva, respetivamente, nas 
células do EPR. No âmbito deste trabalho, foram consideradas as preparações de 
adenovírus, cujo título foi determinado, para uma homogeneização das condições 
experimentais. Avaliámos igualmente o efeito dos adenovírus na sobrevivência das células 
B6-RPE07, e concluímos que este parâmetro não é significativamente afetado. Assim, 
construímos e validámos importantes ferramentas moleculares para o estudo das proteínas 
Rab, úteis também para outros estudos na área da biologia destas proteínas.  
A última tarefa no âmbito deste trabalho foi a criação e aperfeiçoamento de um 
protocolo in vitro onde fosse possível avaliar o efeito do silenciamento das proteínas Rab 
consideradas na secreção do VEGF pelas células do EPR. O meio de cultura e o tempo de 
incubação apropriados a este rastreio foram determinados em experiências preliminares de 
secreção do VEGF. No final, verificámos que 10 horas de incubação em meio sem soro, 
seguidas de 48 horas de incubação em meio com baixa percentagem de soro (1%), seria a 
condição que melhor traduziria os níveis do VEGF secretados pelas células. Para a realização 
deste estudo considerámos então a avaliação dos níveis do VEGF ao fim de 3 dias, 
coincidindo com a altura em que o silenciamento das proteínas-alvo induzido pela presença 
de adenovírus é máximo. Outros tempos de incubação mais prolongados foram excluídos 
por porem em causa a sobrevivência e viabilidade celulares. Para além das condições basais 
de secreção do VEGF, em que nenhum estímulo foi adicionado às células, foi incluída neste 
trabalho uma condição de estímulo de secreção do VEGF através do uso de cloreto de 
cobalto no meio de cultura das células. O cloreto de cobalto é um agente químico que 
mimetiza as condições de hipoxia in vivo, ao estimular a expressão do VEGF pelas células. No 
nosso sistema o cloreto de cobalto induziu um aumento de secreção do VEGF de cerca de 
300% nas células B6-RPE07. O efeito do silenciamento das proteínas Rab na secreção do 
VEGF foi avaliado para cada uma individualmente, e em grupos, tendo em conta a 
localização e função destas proteínas na célula. A quantidade de VEGF secretada para o meio 
de cultura pelas células foi calculada através de um ensaio imunológico bastante sensível, e 
normalizada para a quantidade de proteína total existente em cada condição. 
O nosso trabalho permitiu-nos tirar duas conclusões principais. Primeiro, em 
nenhuma das condições testadas no nosso sistema foi possível detetar um decréscimo 
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significativo nos níveis de VEGF secretados pelas células do EPR, relativamente à situação-
controlo, quer em condições estimulatórias e não estimulatórias. Este fato pode ser inato ao 
sistema utilizado, uma vez que o estudo do efeito do silenciamento das Rab GTPases não 
incluiu todas as proteínas Rab expressas pelo EPR, ou pode também ficar a dever-se à 
existência de uma via secretora não convencional, que de certa forma compensa a 
tradicional que foi afetada. Segundo, verificámos que o silenciamento das proteínas Rab 
envolvidas nas vias endocítica e de reciclagem provocou um aumento significativo da 
secreção do VEGF pelas células do EPR. Este facto demonstra a importância das proteínas 
Rab na regulação dos níveis de VEGF secretados pelas células do EPR, permitindo-nos propor 
um modelo deste processo. Em condições normais, as proteínas Rab6b, Rab10 e Rab14 
estão localizadas ao nível do complexo de Golgi, encontrando-se também a Rab10 e a Rab14 
nas membranas dos endossomas. Quando os níveis proteicos de Rab6b são diminuídos, 
verificámos que a secreção de VEGF aumenta, indicando que esta proteína poderá exercer 
uma função reguladora ao nível do complexo de Golgi. O silenciamento da Rab10 e da Rab14 
individualmente aumenta muito significativamente os níveis de VEGF secretados, sendo este 
efeito potenciado pelo silenciamento em simultâneo das duas proteínas (Rab10+Rab14), 
implicando-as na regulação da secreção do VEGF. O aumento de 300% na secreção do VEGF 
quando ambas Rab10+Rab14 são silenciadas é revertido quando a Rab8 é também 
silenciada, sugerindo que o efeito das proteínas Rab10 e Rab14 na secreção de VEGF é 
regulada pela Rab8. Observámos também que na ausência de Rab10+Rab14, o transporte de 
vesículas secretoras de VEGF a partir do complexo de Golgi para a membrana plasmática fica 
desregulado, aumentando bastante. A proteína Rab8, juntamente com outros fatores não 
considerados no âmbito deste trabalho, estão envolvidos neste processo, e os nossos dados 
indicam sofrerem uma ação inibitória por parte das proteínas Rab10 e Rab14. O 
silenciamento individual das proteínas Rab envolvidas na via endocítica e da reciclagem 
causou um aumento da secreção de VEGF, exceto no caso da Rab22a, em que houve uma 
diminuição ligeira. Os nossos dados corroboram assim resultados de outros grupos que 
descreveram o papel das proteínas Rab na endocitose do complexo VEGF-VEGFR2, 
nomeadamente da Rab5 e Rab7, e na reciclagem de vesículas endocíticas em geral. O 
silenciamento das proteínas Rab envolvidas nestas vias provoca a sua desregulação, e 
consequentemente uma acumulação de VEGF no meio extracelular. Nas condições em que a 
hipoxia foi mimetizada, e a secreção de VEGF estimulada, por cloreto de cobalto, obtivemos 
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os mesmos resultados que em condições normais. No entanto, a amplitude do aumento da 
secreção do VEGF foi em geral mais baixa. Este facto pode ser explicado pelo aumento de 
expressão de recetores de VEGF que se verifica noutros modelos animais e celulares de 
hipoxia, diminuindo o número de moléculas de VEGF disponíveis no meio. A hipótese de 
alteração da expressão das proteínas Rab em condições de hipoxia deve ser também 
considerada, e avaliada em experiências futuras.  
Os resultados obtidos no âmbito deste trabalho contribuem assim para o 
esclarecimento do papel das proteínas Rab GTPases na regulação da secreção do VEGF pelas 
células do EPR, e servem de base para estudos futuros que visem compreender melhor este 
mecanismo. Experiências futuras deverão incluir a avaliação dos níveis proteicos e a 
localização dos recetores de VEGF nas células do EPR, e de que modo estes parâmetros são 
afetados pelo silenciamento das proteínas Rab. Será igualmente importante avaliar o efeito 
das restantes proteínas Rab que não foram consideradas neste trabalho, e validar in vivo o 
efeito de todas, através de injeções subretinianas de adenovírus contendo sequências de 
miARN em murganhos. Estes estudos complementares permitirão um conhecimento mais 
aprofundado dos mecanismos moleculares de secreção de VEGF pelas células do EPR, e 
também perceber como a sua desregulação está envolvida em patologias da visão. Em 
última análise, os nossos resultados poderão contribuir para a descoberta de um novo 
agente terapêutico capaz de controlar a secreção de VEGF pelas células do EPR.  
 
 
 
 
 
 
 
 
Target miR Sequence 5'-3' (sense) miR Sequence 5'-3' (antisense) Adenovirus Lentivirus 
Rab2a 
355 TGCTGACGATTTACCAACACCTGTGTGTTTTGGCCACTGACTGACACACAGGTTGGTAAATCGT 356 CCTGACGATTTACCAACCTGTGTGTCAGTCAGTGGCCAAAACACACAGGTGTTGGTAAATCGTC #2298 C25 #2288C28 
357 TGCTGAACATTAGGTAACCACAGGTGGTTTTGGCCACTGACTGACCACCTGTGTACCTAATGTT 358 CCTGAACATTAGGTACACAGGTGGTCAGTCAGTGGCCAAAACCACCTGTGGTTACCTAATGTTC #2299 C29 #2289 C32 
577 TGCTGACATTAGGTAACCACAGGTGTGTTTTGGCCACTGACTGACACACCTGTTTACCTAATGT 578 CCTGACATTAGGTAAACAGGTGTGTCAGTCAGTGGCCAAAACACACCTGTGGTTACCTAATGTC #2630C8 #2624 C16 
Rab2b 
359 TGCTGTTTCCATCGATGTTGACCATAGTTTTGGCCACTGACTGACTATGGTCAATCGATGGAAA 360 CCTGTTTCCATCGATTGACCATAGTCAGTCAGTGGCCAAAACTATGGTCAACATCGATGGAAAC #2481 C22 #2470 C4 
361 TGCTGTTCTAGATCACTCTTATTCCCGTTTTGGCCACTGACTGACGGGAATAAGTGATCTAGAA 362 CCTGTTCTAGATCACTTATTCCCGTCAGTCAGTGGCCAAAACGGGAATAAGAGTGATCTAGAAC #2480 C19 #2469 C1 
Rab3a 
371 TGCTGAACATATAGTCGAAGTTCTGGGTTTTGGCCACTGACTGACCCAGAACTGACTATATGTT 372 CCTGAACATATAGTCAGTTCTGGGTCAGTCAGTGGCCAAAACCCAGAACTTCGACTATATGTTC #1829 C7 #1536 C2 
373 TGCTGTGACCTTGAAGTCTATGCCAAGTTTTGGCCACTGACTGACTTGGCATACTTCAAGGTCA 374 CCTGTGACCTTGAAGTATGCCAAGTCAGTCAGTGGCCAAAACTTGGCATAGACTTCAAGGTCAC #1568 C2 #1592 C9 
Rab3b 
375 TGCTGTTTGATTCCAGTCTTACCATCGTTTTGGCCACTGACTGACGATGGTAACTGGAATCAAA 376 CCTGTTTGATTCCAGTTACCATCGTCAGTCAGTGGCCAAAACGATGGTAAGACTGGAATCAAAC #2292 C1 #2282 C10 
377 TGCTGTATCGCAGATGGCATCCACCAGTTTTGGCCACTGACTGACTGGTGGATCATCTGCGATA 378 CCTGTATCGCAGATGATCCACCAGTCAGTCAGTGGCCAAAACTGGTGGATGCCATCTGCGATAC #2293 C82 #2283 C1 
Rab3c 
379 TGCTGAAACCTGGCATCTTGTGCAGAGTTTTGGCCACTGACTGACTCTGCACAATGCCAGGTTT 380 CCTGAAACCTGGCATTGTGCAGAGTCAGTCAGTGGCCAAAACTCTGCACAAGATGCCAGGTTTC #2294 C85 #2284 C16 
381 TGCTGTGTAAAGGAATCGTCGGCATAGTTTTGGCCACTGACTGACTATGCCGAATTCCTTTACA 382 CCTGTGTAAAGGAATTCGGCATAGTCAGTCAGTGGCCAAAACTATGCCGACGATTCCTTTACAC #2295 C87 #2285 C19 
Rab3d 
383 TGCTGATCAAGAGCAGTTTGAACATGGTTTTGGCCACTGACTGACCATGTTCACTGCTCTTGAT 384 CCTGATCAAGAGCAGTGAACATGGTCAGTCAGTGGCCAAAACCATGTTCAAACTGCTCTTGATC #2296 C90 #2286 C22 
385 TGCTGAAACCAAGATCATCGGCGAGCGTTTTGGCCACTGACTGACGCTCGCCGGATCTTGGTTT 386 CCTGAAACCAAGATCCGGCGAGCGTCAGTCAGTGGCCAAAACGCTCGCCGATGATCTTGGTTTC #2297 C92 #2287 C87 
Rab4a 
387 TGCTGTTAGTAAGCGCATTGTAGGTTGTTTTGGCCACTGACTGACAACCTACAGCGCTTACTAA 388 CCTGTTAGTAAGCGCTGTAGGTTGTCAGTCAGTGGCCAAAACAACCTACAATGCGCTTACTAAC #2423 C24 #2403 C26 
389 TGCTGAACATCAGCTCATTCTCTTGTGTTTTGGCCACTGACTGACACAAGAGAGAGCTGATGTT 390 CCTGAACATCAGCTCTCTCTTGTGTCAGTCAGTGGCCAAAACACAAGAGAATGAGCTGATGTTC #2424 C28 #2404 C9 
Rab4b 
391 TGCTGAACCCATCCTCTCTGGGTCTAGTTTTGGCCACTGACTGACTAGACCCAGAGGATGGGTT 392 CCTGAACCCATCCTCTGGGTCTAGTCAGTCAGTGGCCAAAACTAGACCCAGAGAGGATGGGTTC #2425 C16 #2405 C32 
393 TGCTGAATGCCTGAACCCATCCTCTCGTTTTGGCCACTGACTGACGAGAGGATGTTCAGGCATT 394 CCTGAATGCCTGAACATCCTCTCGTCAGTCAGTGGCCAAAACGAGAGGATGGGTTCAGGCATTC #2426 C35 #2406 C36 
Rab5a 
305 TGCTGTTTATTTCCAGTATTTGGCCCGTTTTGGCCACTGACTGACGGGCCAAACTGGAAATAAA 306 CCTGTTTATTTCCAGTTTGGCCCGTCAGTCAGTGGCCAAAACGGGCCAAATACTGGAAATAAAC #2215 C6 #2208 C25 
307 TGCTGTTGATTTGCCAACAGCAGACTGTTTTGGCCACTGACTGACAGTCTGCTTGGCAAATCAA 308 CCTGTTGATTTGCCAAGCAGACTGTCAGTCAGTGGCCAAAACAGTCTGCTGTTGGCAAATCAAC #2216 C60 #2209 C31 
309 TGCTGTTCACAAAGCGAAGAACCAGGGTTTTGGCCACTGACTGACCCTGGTTCCGCTTTGTGAA 310 CCTGTTCACAAAGCGGAACCAGGGTCAGTCAGTGGCCAAAACCCTGGTTCTTCGCTTTGTGAAC #2217 C66 #2210 C38 
Rab5b 
347 TGCTGTGCCCATTGGGCCTGGCTGTAGTTTTGGCCACTGACTGACTACAGCCACCCAATGGGCA 348 CCTGTGCCCATTGGGTGGCTGTAGTCAGTCAGTGGCCAAAACTACAGCCAGGCCCAATGGGCAC #2312 C33 #2300 C35 
349 TGCTGTTGCCCATTGGGCCTGGCTGTGTTTTGGCCACTGACTGACACAGCCAGCCAATGGGCAA 350 CCTGTTGCCCATTGGCTGGCTGTGTCAGTCAGTGGCCAAAACACAGCCAGGCCCAATGGGCAAC #2313 C38 #2301 C37 
Rab5c 
351 TGCTGTGCAAATGTATCTGTGTTGGTGTTTTGGCCACTGACTGACACCAACACATACATTTGCA 352 CCTGTGCAAATGTATGTGTTGGTGTCAGTCAGTGGCCAAAACACCAACACAGATACATTTGCAC #2314 C41 #2302 C40 
353 TGCTGTTCTTAGCCCGTGCAAATGTAGTTTTGGCCACTGACTGACTACATTTGCGGGCTAAGAA 354 CCTGTTCTTAGCCCGCAAATGTAGTCAGTCAGTGGCCAAAACTACATTTGCACGGGCTAAGAAC #2315 C46 #2303 C43 
Rab6a 
625 TGCTGATCACGAGTATGCTGGAATTGGTTTTGGCCACTGACTGACCAATTCCAATACTCGTGAT 626 CCTGATCACGAGTATTGGAATTGGTCAGTCAGTGGCCAAAACCAATTCCAGCATACTCGTGATC #2955 C2 #2972 C15 
627 TGCTGTAATAGATCACCTCCACGAAAGTTTTGGCCACTGACTGACTTTCGTGGGTGATCTATTA 628 CCTGTAATAGATCACCCACGAAAGTCAGTCAGTGGCCAAAACTTTCGTGGAGGTGATCTATTAC #2956 C63 #2973 C20 
723 TGCTGATAACATTCAGCTCTTTGGCTGTTTTGGCCACTGACTGACAGCCAAAGCTGAATGTTAT 724 CCTGATAACATTCAGCTTTGGCTGTCAGTCAGTGGCCAAAACAGCCAAAGAGCTGAATGTTATC #3199 C29 #3170 C63 
Rab6b 
521 TGCTGTTTAGAAGTCTGCTGGAAGGAGTTTTGGCCACTGACTGACTCCTTCCAAGACTTCTAAA 522 CCTGTTTAGAAGTCTTGGAAGGAGTCAGTCAGTGGCCAAAACTCCTTCCAGCAGACTTCTAAAC #2606 C12 #2591 C6 
523 TGCTGTTATCTGCCTCTTATCAGCCAGTTTTGGCCACTGACTGACTGGCTGATGAGGCAGATAA 524 CCTGTTATCTGCCTCATCAGCCAGTCAGTCAGTGGCCAAAACTGGCTGATAAGAGGCAGATAAC #2607 C17 #2592 C12 
Rab7a 
363 TGCTGTTCACATACTGGTTCATGAGAGTTTTGGCCACTGACTGACTCTCATGACAGTATGTGAA 364 CCTGTTCACATACTGTCATGAGAGTCAGTCAGTGGCCAAAACTCTCATGAACCAGTATGTGAAC #2316 C49 #2304 C46 
365 TGCTGTCAGAAAGTCCGCTCCTATTGGTTTTGGCCACTGACTGACCAATAGGAGGACTTTCTGA 366 CCTGTCAGAAAGTCCTCCTATTGGTCAGTCAGTGGCCAAAACCAATAGGAGCGGACTTTCTGAC #2317 C53 #2305 C49 
Rab8a 
749 TGCTGTAATGTCGTAGACCAGCATGAGTTTTGGCCACTGACTGACTCATGCTGCTACGACATTA 750 CCTGTAATGTCGTAGCAGCATGAGTCAGTCAGTGGCCAAAACTCATGCTGGTCTACGACATTAC #3201 C63 #3172 C40 
751 TGCTGTGCAGAGGCATGCTCTTCAATGTTTTGGCCACTGACTGACATTGAAGAATGCCTCTGCA 752 CCTGTGCAGAGGCATTCTTCAATGTCAGTCAGTGGCCAAAACATTGAAGAGCATGCCTCTGCAC #3202 C115 #3173 C173 
Rab8b 
693 TGCTGTCCCATAGTCAATTGCTAACTGTTTTGGCCACTGACTGACAGTTAGCATGACTATGGGA 694 CCTGTCCCATAGTCATGCTAACTGTCAGTCAGTGGCCAAAACAGTTAGCAATTGACTATGGGAC #2963 C93 #2979 C187 
757 TGCTGAAGAGTCTAAGATTACGCTGTGTTTTGGCCACTGACTGACACAGCGTACTTAGACTCTT 758 CCTGAAGAGTCTAAGTACGCTGTGTCAGTCAGTGGCCAAAACACAGCGTAATCTTAGACTCTTC #3204 C86 #3175 C48 
Rab9a 
525 TGCTGTTCAAAGTAAGGATAGTCGCCGTTTTGGCCACTGACTGACGGCGACTACTTACTTTGAA 526 CCTGTTCAAAGTAAGTAGTCGCCGTCAGTCAGTGGCCAAAACGGCGACTATCCTTACTTTGAAC #2608 C24 #2593 C17 
527 TGCTGATCAGGTGTTCTGACCTATCTGTTTTGGCCACTGACTGACAGATAGGTGAACACCTGAT 528 CCTGATCAGGTGTTCACCTATCTGTCAGTCAGTGGCCAAAACAGATAGGTCAGAACACCTGATC #2609 C27 #2594 C21 
Rab9b 
529 TGCTGCAAAGCGTCCATCTACCTCCAGTTTTGGCCACTGACTGACTGGAGGTATGGACGCTTTG 530 CCTGCAAAGCGTCCATACCTCCAGTCAGTCAGTGGCCAAAACTGGAGGTAGATGGACGCTTTGC #2634 C24 #2628 C26 
531 TGCTGTTACCAAGGTTCTCAAAGCTCGTTTTGGCCACTGACTGACGAGCTTTGAACCTTGGTAA 532 CCTGTTACCAAGGTTCAAAGCTCGTCAGTCAGTGGCCAAAACGAGCTTTGAGAACCTTGGTAAC #2635 C28 #2629 C29 
Rab10 
267 TGCTGTTCATTGGCATGCTCATCTATGTTTTGGCCACTGACTGACATAGATGAATGCCAATGAA 268 CCTGTTCATTGGCATTCATCTATGTCAGTCAGTGGCCAAAACATAGATGAGCATGCCAATGAAC #2211 C2 #2204 C1 
269 TGCTGCTCCCTTGCAATCTGTTCTCCGTTTTGGCCACTGACTGACGGAGAACATTGCAAGGGAG 270 CCTGCTCCCTTGCAATGTTCTCCGTCAGTCAGTGGCCAAAACGGAGAACAGATTGCAAGGGAGC #2212 C43 #2205 C7 
271 TGCTGATACCATGCTCCCTTGCAATCGTTTTGGCCACTGACTGACGATTGCAAGAGCATGGTAT 272 CCTGATACCATGCTCTTGCAATCGTCAGTCAGTGGCCAAAACGATTGCAAGGGAGCATGGTATC #2213 C51 #2206 C13 
273 TGCTGTACAACTGAAGTGCAGGGCTGGTTTTGGCCACTGACTGACCAGCCCTGCTTCAGTTGTA 274 CCTGTACAACTGAAGCAGGGCTGGTCAGTCAGTGGCCAAAACCAGCCCTGCACTTCAGTTGTAC #2214 C54 #2207 C19 
Rab11a 
399 TGCTGAGTAAATCGAGACAGGAGGTTGTTTTGGCCACTGACTGACAACCTCCTCTCGATTTACT 400 CCTGAGTAAATCGAGAGGAGGTTGTCAGTCAGTGGCCAAAACAACCTCCTGTCTCGATTTACTC #2290 C74 #2280 C4 
401 TGCTGTTCATATGTGAGATGCTTAGCGTTTTGGCCACTGACTGACGCTAAGCATCACATATGAA 402 CCTGTTCATATGTGATGCTTAGCGTCAGTCAGTGGCCAAAACGCTAAGCATCTCACATATGAAC #2291 C76 #2281 C7 
Rab11b 
395 TGCTGAGCAGGTTGCTCTTACCTACAGTTTTGGCCACTGACTGACTGTAGGTAAGCAACCTGCT 396 CCTGAGCAGGTTGCTTACCTACAGTCAGTCAGTGGCCAAAACTGTAGGTAAGAGCAACCTGCTC #2421 C19 #2401 C18 
397 TGCTGTGAGGATGTTCTTGAATGCTTGTTTTGGCCACTGACTGACAAGCATTCGAACATCCTCA 398 CCTGTGAGGATGTTCGAATGCTTGTCAGTCAGTGGCCAAAACAAGCATTCAAGAACATCCTCAC #2422 C31 #2402 C22 
567 TGCTGTAGGTAATCGTACTCGTCGTCGTTTTGGCCACTGACTGACGACGACGAACGATTACCTA 568 CCTGTAGGTAATCGTTCGTCGTCGTCAGTCAGTGGCCAAAACGACGACGAGTACGATTACCTAC #2632 C15 #2626 C20 
Rab12 
411 TGCTGAAGTCATCGAACGTCTCCTTCGTTTTGGCCACTGACTGACGAAGGAGATTCGATGACTT 412 CCTGAAGTCATCGAATCTCCTTCGTCAGTCAGTGGCCAAAACGAAGGAGACGTTCGATGACTTC #2479 C38 #2468 C23 
413 TGCTGTCTTCATCCACTTTGGCAAGTGTTTTGGCCACTGACTGACACTTGCCAGTGGATGAAGA 414 CCTGTCTTCATCCACTGGCAAGTGTCAGTCAGTGGCCAAAACACTTGCCAAAGTGGATGAAGAC #2478 C35 #2467 C20 
Rab13 287 TGCTGTGAATAGGAGGCAAGAAATGCGTTTTGGCCACTGACTGACGCATTTCTCCTCCTATTCA 288 CCTGTGAATAGGAGGAGAAATGCGTCAGTCAGTGGCCAAAACGCATTTCTTGCCTCCTATTCAC #1570 C3 #1826 C9 
Target miR Sequence 5'-3' (sense) miR Sequence 5'-3' (antisense) Adenovirus Lentivirus 
Rab13 289 TGCTGTTGAGGTGCCACCACAGTTCTGTTTTGGCCACTGACTGACAGAACTGTTGGCACCTCAA 290 CCTGTTGAGGTGCCAACAGTTCTGTCAGTCAGTGGCCAAAACAGAACTGTGGTGGCACCTCAAC #1571 C4 #1827 C15 
291 TGCTGTCACCTTTCACATCCTTGGTTGTTTTGGCCACTGACTGACAACCAAGGGTGAAAGGTGA 292 CCTGTCACCTTTCACCCTTGGTTGTCAGTCAGTGGCCAAAACAACCAAGGATGTGAAAGGTGAC #1572 C8 #1828 C2 
Rab14 
367 TGCTGTATAGTAGCTCCGTGTAACCGGTTTTGGCCACTGACTGACCGGTTACAGAGCTACTATA 368 CCTGTATAGTAGCTCTGTAACCGGTCAGTCAGTGGCCAAAACCGGTTACACGGAGCTACTATAC #2318 C56 #2306 C52 
369 TGCTGTACAGTGTTTGGATTGGTGAGGTTTTGGCCACTGACTGACCTCACCAACAAACACTGTA 370 CCTGTACAGTGTTTGTTGGTGAGGTCAGTCAGTGGCCAAAACCTCACCAATCCAAACACTGTAC #2319 C61 #2307 C55 
Rab15 
579 TGCTGTACTCATCCACGTCACTGACCGTTTTGGCCACTGACTGACGGTCAGTGGTGGATGAGTA 580 CCTGTACTCATCCACCACTGACCGTCAGTCAGTGGCCAAAACGGTCAGTGACGTGGATGAGTAC #2675 C36 #2672 C26 
581 TGCTGTTTCGTAGAAGTCCATGCCGTGTTTTGGCCACTGACTGACACGGCATGCTTCTACGAAA 582 CCTGTTTCGTAGAAGCATGCCGTGTCAGTCAGTGGCCAAAACACGGCATGGACTTCTACGAAAC #2631 C14 #2625 C18 
Rab17 
293 TGCTGTAAGGTAGGGCTGACAGTCTTGTTTTGGCCACTGACTGACAAGACTGTGCCCTACCTTA 294 CCTGTAAGGTAGGGCACAGTCTTGTCAGTCAGTGGCCAAAACAAGACTGTCAGCCCTACCTTAC #2610 C34 #2595 C27 
295 TGCTGAACGAAAGTGGTCCAGTTATGGTTTTGGCCACTGACTGACCATAACTGCCACTTTCGTT 296 CCTGAACGAAAGTGGCAGTTATGGTCAGTCAGTGGCCAAAACCATAACTGGACCACTTTCGTTC #2611 C39 #2596 C82 
Rab18 
419 TGCTGTTCACCTTAAAGTCAACACCTGTTTTGGCCACTGACTGACAGGTGTTGTTTAAGGTGAA 420 CCTGTTCACCTTAAACAACACCTGTCAGTCAGTGGCCAAAACAGGTGTTGACTTTAAGGTGAAC #2427 C40 #2407 C39 
421 TGCTGTATAGCACAGAGCAGTAACCGGTTTTGGCCACTGACTGACCGGTTACTTCTGTGCTATA 422 CCTGTATAGCACAGAAGTAACCGGTCAGTCAGTGGCCAAAACCGGTTACTGCTCTGTGCTATAC #2428 C40 #2408 C40 
Rab19 
423 TGCTGATCATAAGCGATGATAGCTGCGTTTTGGCCACTGACTGACGCAGCTATTCGCTTATGAT 424 CCTGATCATAAGCGAATAGCTGCGTCAGTCAGTGGCCAAAACGCAGCTATCATCGCTTATGATC #2429 C43 #2409 C11 
425 TGCTGTGTTGCGGGCAATTAACTCCTGTTTTGGCCACTGACTGACAGGAGTTATGCCCGCAACA 426 CCTGTGTTGCGGGCATAACTCCTGTCAGTCAGTGGCCAAAACAGGAGTTAATTGCCCGCAACAC #2430 C9 #2410 C29 
Rab20 
429 TGCTGTATATCCACAGTCTGATCTGAGTTTTGGCCACTGACTGACTCAGATCACTGTGGATATA 430 CCTGTATATCCACAGTGATCTGAGTCAGTCAGTGGCCAAAACTCAGATCAGACTGTGGATATAC #2612 C43 #2597 C31 
587 TGCTGTCAAAGAGGAGGTCCACATTGGTTTTGGCCACTGACTGACCAATGTGGCTCCTCTTTGA 588 CCTGTCAAAGAGGAGCCACATTGGTCAGTCAGTGGCCAAAACCAATGTGGACCTCCTCTTTGAC #2633 C20 #2627 C23 
Rab21 
431 TGCTGTTTAGCGGAAGTATGGTAATGGTTTTGGCCACTGACTGACCATTACCACTTCCGCTAAA 432 CCTGTTTAGCGGAAGTGGTAATGGTCAGTCAGTGGCCAAAACCATTACCATACTTCCGCTAAAC #2433 C26 #2413 C53 
433 TGCTGTACAAAGGTCGAGAAAGAGCTGTTTTGGCCACTGACTGACAGCTCTTTCGACCTTTGTA 434 CCTGTACAAAGGTCGAAAGAGCTGTCAGTCAGTGGCCAAAACAGCTCTTTCTCGACCTTTGTAC #2434 C27 #2414 C57 
Rab22a 
615 TGCTGTCTACTTGTGATCATTTCCCAGTTTTGGCCACTGACTGACTGGGAAATTCACAAGTAGA 616 CCTGTCTACTTGTGAATTTCCCAGTCAGTCAGTGGCCAAAACTGGGAAATGATCACAAGTAGAC #2849 C17 #2852 C150 
621 TGCTGTTTAGACACATGCAACTCAACGTTTTGGCCACTGACTGACGTTGAGTTATGTGTCTAAA 622 CCTGTTTAGACACATAACTCAACGTCAGTCAGTGGCCAAAACGTTGAGTTGCATGTGTCTAAAC #2986 C159 #2991 C31 
Rab22b 639 TGCTGTTACCTAGCAAGTACAAGCCTGTTTTGGCCACTGACTGACAGGCTTGTTTGCTAGGTAA 640 CCTGTTACCTAGCAAACAAGCCTGTCAGTCAGTGGCCAAAACAGGCTTGTACTTGCTAGGTAAC #2964 C102 #2980 C61 
Rab23 
439 TGCTGTATATCTCCAACCTCCGCTACGTTTTGGCCACTGACTGACGTAGCGGATTGGAGATATA 440 CCTGTATATCTCCAATCCGCTACGTCAGTCAGTGGCCAAAACGTAGCGGAGGTTGGAGATATAC #2482 C25 #2471 C7 
441 TGCTGTTCTCTTGGTCCTTTGTTTGTGTTTTGGCCACTGACTGACACAAACAAGACCAAGAGAA 442 CCTGTTCTCTTGGTCTTGTTTGTGTCAGTCAGTGGCCAAAACACAAACAAAGGACCAAGAGAAC #2483 C28 #2472 C10 
Rab24 
443 TGCTGCACACAGGTAGATTTGACAGCGTTTTGGCCACTGACTGACGCTGTCAACTACCTGTGTG 444 CCTGCACACAGGTAGTTGACAGCGTCAGTCAGTGGCCAAAACGCTGTCAAATCTACCTGTGTGC #2520 C1 #2506 C2 
445 TGCTGAAAGCAGCCACACTGACGTAAGTTTTGGCCACTGACTGACTTACGTCAGTGGCTGCTTT 446 CCTGAAAGCAGCCACTGACGTAAGTCAGTCAGTGGCCAAAACTTACGTCAGTGTGGCTGCTTTC #2521 C4 #2507 C5 
Rab25 
447 TGCTGTGTCGTGGCTGAACTCATTGCGTTTTGGCCACTGACTGACGCAATGAGCAGCCACGACA 448 CCTGTGTCGTGGCTGCTCATTGCGTCAGTCAGTGGCCAAAACGCAATGAGTTCAGCCACGACAC #2673 C29 #2670 C21 
449 TGCTGAAACATGCAGGCCTCCTCAGTGTTTTGGCCACTGACTGACACTGAGGACCTGCATGTTT 450 CCTGAAACATGCAGGTCCTCAGTGTCAGTCAGTGGCCAAAACACTGAGGAGGCCTGCATGTTTC #2674 C34 #2671 C23 
Rab26 
533 TGCTGTTGAAAGCAACATCGTAGAAGGTTTTGGCCACTGACTGACCTTCTACGGTTGCTTTCAA 534 CCTGTTGAAAGCAACCGTAGAAGGTCAGTCAGTGGCCAAAACCTTCTACGATGTTGCTTTCAAC #2884 C32 #2889 C27 
535 TGCTGATGACCTTGAAAGCAACATCGGTTTTGGCCACTGACTGACCGATGTTGTTCAAGGTCAT 536 CCTGATGACCTTGAACAACATCGGTCAGTCAGTGGCCAAAACCGATGTTGCTTTCAAGGTCATC #2885 C42 #2890 C101 
777 TGCTGTGTTTCAGCTCCTTTGCTATGGTTTTGGCCACTGACTGACCATAGCAAGAGCTGAAACA 778 CCTGTGTTTCAGCTCTTGCTATGGTCAGTCAGTGGCCAAAACCATAGCAAAGGAGCTGAAACAC #3206 C95 #3177 C192 
Rab27a 
459 TGCTGTGAAGAATGCAGTGGTTAAGCGTTTTGGCCACTGACTGACGCTTAACCTGCATTCTTCA 460 CCTGTGAAGAATGCAGGTTAAGCGTCAGTCAGTGGCCAAAACGCTTAACCACTGCATTCTTCAC #2522 C5 #2508 C7 
461 TGCTGTATGTTTGTCCCGTTGGCAGCGTTTTGGCCACTGACTGACGCTGCCAAGGACAAACATA 462 CCTGTATGTTTGTCCTTGGCAGCGTCAGTCAGTGGCCAAAACGCTGCCAACGGGACAAACATAC #2523 C8 #2509 C10 
Rab27b 
743 TGCTGTCAAACATCAGTAAGAAGCCCGTTTTGGCCACTGACTGACGGGCTTCTCTGATGTTTGA 744 CCTGTCAAACATCAGAGAAGCCCGTCAGTCAGTGGCCAAAACGGGCTTCTTACTGATGTTTGAC #3209 C10 #3180 C84 
745 TGCTGTTTCCACTGACTTCTCTACATGTTTTGGCCACTGACTGACATGTAGAGGTCAGTGGAAA 746 CCTGTTTCCACTGACCTCTACATGTCAGTCAGTGGCCAAAACATGTAGAGAAGTCAGTGGAAAC #3210 C55 #3181 C87 
Rab28 
537 TGCTGACATCTTGCCACCTATTGTCTGTTTTGGCCACTGACTGACAGACAATATGGCAAGATGT 538 CCTGACATCTTGCCATATTGTCTGTCAGTCAGTGGCCAAAACAGACAATAGGTGGCAAGATGTC #2570 C15 #2568 C21 
539 TGCTGTAACAGTTCTTGACAAGGGCTGTTTTGGCCACTGACTGACAGCCCTTGAAGAACTGTTA 540 CCTGTAACAGTTCTTCAAGGGCTGTCAGTCAGTGGCCAAAACAGCCCTTGTCAAGAACTGTTAC #2571 C21 #2569 C29 
Rab29 
553 TGCTGAGAACAACGCAGATGCACATGGTTTTGGCCACTGACTGACCATGTGCATGCGTTGTTCT 554 CCTGAGAACAACGCATGCACATGGTCAGTCAGTGGCCAAAACCATGTGCATCTGCGTTGTTCTC #2613 C47 #2598 C39 
555 TGCTGAGAACTAGCAGCATGTCCAGCGTTTTGGCCACTGACTGACGCTGGACACTGCTAGTTCT 556 CCTGAGAACTAGCAGTGTCCAGCGTCAGTCAGTGGCCAAAACGCTGGACATGCTGCTAGTTCTC #2614 C54 #2599 C41 
Rab30 
451 TGCTGAATCAACTCCAATTGTGGCTCGTTTTGGCCACTGACTGACGAGCCACATGGAGTTGATT 452 CCTGAATCAACTCCATGTGGCTCGTCAGTCAGTGGCCAAAACGAGCCACAATTGGAGTTGATTC #2484 C31 #2473 C13 
453 TGCTGTGAAGTCTCCAGGTAATACATGTTTTGGCCACTGACTGACATGTATTATGGAGACTTCA 454 CCTGTGAAGTCTCCATAATACATGTCAGTCAGTGGCCAAAACATGTATTACCTGGAGACTTCAC #2485 C35 #2474 C16 
Rab32 
779 TGCTGTAAAGAGGTGCTCTCGGGTCTGTTTTGGCCACTGACTGACAGACCCGAGCACCTCTTTA 780 CCTGTAAAGAGGTGCTCGGGTCTGTCAGTCAGTGGCCAAAACAGACCCGAGAGCACCTCTTTAC #3211 C24 #3182 C133 
783 TGCTGAAACCATCCAGTGAAGCCATGGTTTTGGCCACTGACTGACCATGGCTTCTGGATGGTTT 784 CCTGAAACCATCCAGAAGCCATGGTCAGTCAGTGGCCAAAACCATGGCTTCACTGGATGGTTTC #3213 C58 #3184 C99 
Rab33b 
463 TGCTGTACTGTGTGTGTCAGCAAACTGTTTTGGCCACTGACTGACAGTTTGCTCACACACAGTA 464 CCTGTACTGTGTGTGAGCAAACTGTCAGTCAGTGGCCAAAACAGTTTGCTGACACACACAGTAC #2524 C11 #2510 C13 
465 TGCTGTTATCAGGCAGCTGGCTAAGCGTTTTGGCCACTGACTGACGCTTAGCCCTGCCTGATAA 466 CCTGTTATCAGGCAGGGCTAAGCGTCAGTCAGTGGCCAAAACGCTTAGCCAGCTGCCTGATAAC #2525 C13 #2511 C17 
Rab34 
471 TGCTGATAGGTCTCCCACAACGATGAGTTTTGGCCACTGACTGACTCATCGTTGGGAGACCTAT 472 CCTGATAGGTCTCCCAACGATGAGTCAGTCAGTGGCCAAAACTCATCGTTGTGGGAGACCTATC #2615 C58 #2600 C48 
473 TGCTGTATCGAAGGTGTCTTTGCAGAGTTTTGGCCACTGACTGACTCTGCAAACACCTTCGATA 474 CCTGTATCGAAGGTGTTTGCAGAGTCAGTCAGTGGCCAAAACTCTGCAAAGACACCTTCGATAC #2616 C63 #2601 C52 
Rab35 
475 TGCTGATCGCTTGACGTTGACAAAGGGTTTTGGCCACTGACTGACCCTTTGTCCGTCAAGCGAT 476 CCTGATCGCTTGACGGACAAAGGGTCAGTCAGTGGCCAAAACCCTTTGTCAACGTCAAGCGATC #2526 C16 #2512 C20 
477 TGCTGTTTCTTTGCTCGCAGAACCAGGTTTTGGCCACTGACTGACCTGGTTCTGAGCAAAGAAA 478 CCTGTTTCTTTGCTCAGAACCAGGTCAGTCAGTGGCCAAAACCTGGTTCTGCGAGCAAAGAAAC #2527 C20 #2513 C23 
Rab36 
479 TGCTGAATCCCTGCGATCTCAAAGCGGTTTTGGCCACTGACTGACCGCTTTGATCGCAGGGATT 480 CCTGAATCCCTGCGATCAAAGCGGTCAGTCAGTGGCCAAAACCGCTTTGAGATCGCAGGGATTC #2617 C68 #2602 C56 
481 TGCTGTGAAGAATGCCTTCACATTCTGTTTTGGCCACTGACTGACAGAATGTGGGCATTCTTCA 482 CCTGTGAAGAATGCCCACATTCTGTCAGTCAGTGGCCAAAACAGAATGTGAAGGCATTCTTCAC #2618 C75 #2603C64 
Rab37 
407 TGCTGTTCAGAACGGATCACCCTTTCGTTTTGGCCACTGACTGACGAAAGGGTTCCGTTCTGAA 408 CCTGTTCAGAACGGAACCCTTTCGTCAGTCAGTGGCCAAAACGAAAGGGTGATCCGTTCTGAAC #2431 C34 #2411 C50 
409 TGCTGCAGAAAGGCCAACTCCACGTTGTTTTGGCCACTGACTGACAACGTGGATGGCCTTTCTG 410 CCTGCAGAAAGGCCATCCACGTTGTCAGTCAGTGGCCAAAACAACGTGGAGTTGGCCTTTCTGC #2432 C14 #2412 C4 
Rab38 403 TGCTGTGCACATAGCGCTTGATAATGGTTTTGGCCACTGACTGACCATTATCACGCTATGTGCA 404 CCTGTGCACATAGCGTGATAATGGTCAGTCAGTGGCCAAAACCATTATCAAGCGCTATGTGCAC #2320 C63 #2308 C60 
Target miR Sequence 5'-3' (sense) miR Sequence 5'-3' (antisense) Adenovirus Lentivirus 
Rab38 405 TGCTGTTGACCAGCAATGTCCCAGAGGTTTTGGCCACTGACTGACCTCTGGGATTGCTGGTCAA 406 CCTGTTGACCAGCAATCCCAGAGGTCAGTCAGTGGCCAAAACCTCTGGGACATTGCTGGTCAAC #2321 C70 #2309 C61 
Rab39a 
731 TGCTGTTGACAGTCTTTCAGCTTCTTGTTTTGGCCACTGACTGACAAGAAGCTAAGACTGTCAA 732 CCTGTTGACAGTCTTAGCTTCTTGTCAGTCAGTGGCCAAAACAAGAAGCTGAAAGACTGTCAAC #3215 C62 #3186 C1 
733 TGCTGTGAATGTTGACATCTATCCAGGTTTTGGCCACTGACTGACCTGGATAGGTCAACATTCA 734 CCTGTGAATGTTGACCTATCCAGGTCAGTCAGTGGCCAAAACCTGGATAGATGTCAACATTCAC #3216 C190 #3187 C11 
Rab40b 
491 TGCTGTCGTCTTGTGATCAATTCCCGGTTTTGGCCACTGACTGACCGGGAATTTCACAAGACGA 492 CCTGTCGTCTTGTGAAATTCCCGGTCAGTCAGTGGCCAAAACCGGGAATTGATCACAAGACGAC #2528 C4 #2514 C25 
493 TGCTGAGCTCTTGCAAACTCAGTACCGTTTTGGCCACTGACTGACGGTACTGATTGCAAGAGCT 494 CCTGAGCTCTTGCAATCAGTACCGTCAGTCAGTGGCCAAAACGGTACTGAGTTTGCAAGAGCTC #2529 C24 #2515 C28 
Rab40c 
787 TGCTGATACTGATCACCTTTGTCAGAGTTTTGGCCACTGACTGACTCTGACAAGTGATCAGTAT 788 CCTGATACTGATCACTTGTCAGAGTCAGTCAGTGGCCAAAACTCTGACAAAGGTGATCAGTATC #3219 C72 #3190 C21 
791 TGCTGCTTAGGAGCTGAAACCTTGCCGTTTTGGCCACTGACTGACGGCAAGGTCAGCTCCTAAG 792 CCTGCTTAGGAGCTGACCTTGCCGTCAGTCAGTGGCCAAAACGGCAAGGTTTCAGCTCCTAAGC #3220 C79 #3191 C31 
Rab42 
499 TGCTGATGTTGATACCATTGAGCGGAGTTTTGGCCACTGACTGACTCCGCTCAGGTATCAACAT 500 CCTGATGTTGATACCTGAGCGGAGTCAGTCAGTGGCCAAAACTCCGCTCAATGGTATCAACATC #2530 C27 #2516 C31 
501 TGCTGACATCATCCCTCCAGATATCCGTTTTGGCCACTGACTGACGGATATCTAGGGATGATGT 502 CCTGACATCATCCCTAGATATCCGTCAGTCAGTGGCCAAAACGGATATCTGGAGGGATGATGTC #2531 C32 #2517 C35 
Rab43 
503 TGCTGCAAGAAGGTGCTCCTCTTGCTGTTTTGGCCACTGACTGACAGCAAGAGGCACCTTCTTG 504 CCTGCAAGAAGGTGCCTCTTGCTGTCAGTCAGTGGCCAAAACAGCAAGAGGAGCACCTTCTTGC #2322 C4 #2310 C66 
505 TGCTGCAGTGAGGCACTGACAAGAAGGTTTTGGCCACTGACTGACCTTCTTGTGTGCCTCACTG 506 CCTGCAGTGAGGCACACAAGAAGGTCAGTCAGTGGCCAAAACCTTCTTGTCAGTGCCTCACTGC #2323 C73 #2311 C69 
 
